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ANKYRIN-B AND mTOR COMPLEX 1 IN THE REGULATION OF ELECTRICAL
ACTIVITIES IN THE HEART

Henry Wu, B.A.

Supervisory Professor: Shane Cunha, Ph.D.

The mammalian target of rapamycin complex 1 (mTORC1) activity is paramount
in the regulation of electrical activities in the brain and the heart. In the brain, the tumor
suppressor gene TSC2 encodes the protein product tuberin that interacts with hamartin to
form a heterodimer Tuberous Sclerosis Complex (TSC) that regulates mTORC1. When
TSC2 is disrupted, mTORC1 activity becomes dysregulated resulting in abnormal
electrical activities in the brain manifesting in the form of epileptic seizures. In the heart,
mTORC1 activity is triggered by a sustained increase in hemodynamic pressure causing
the heart to electrically remodel. A likely candidate serving as the mediator between
mTORC1-dependent electrical remodeling in the brain and heart is the adaptor protein
ankyrin. In the heart, ankyrin-B targets and maintains the membrane expression of ion
channels and transporters that are critical for maintaining calcium ion homeostasis,
which underlies normal excitation-contraction coupling. Sustained mTORC1 activity in
the heart decreases the expression of ankyrin-B and alters the electrical conductance
between the atria and ventricles. These effects are reversed with the administration of

vi

the mTORC1 inhibitor rapamycin. In addition, we identified and characterized two
functionally and spatially distinct full-length ankyrin-B isoforms – AnkB-188 and
AnkB-212. AnkB-188 selectively interacts with the sodium-calcium exchanger (NCX1)
increasing its membrane expression, overall current, and targeting to the sarcoplasmic
reticulum/transverse-tubule of neonatal cardiomyocytes. Whereas AnkB-212 does not
increase NCX1 membrane expression or current, but uniquely localizes to the
sarcomeric M-line. Knockdown of either isoform results in abnormal contraction
rhythms in vitro, but only the M-line population appears to be regulated by mTORC1.
Collectively, the data support the hypothesis that mTORC1 regulates electrical
remodeling of the stressed heart by decreasing the expression of the ankyrin-B
population at the M-line.
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CHAPTER 1: INTRODUCTION

1

1.1 Scope of the Dissertation
This thesis addresses molecular mechanisms of heart failure and arrhythmia. The
topic is important because of the two following reasons:
First, heart failure is a leading cause of death and disability in the United States
[10]. Over the past several decades, advances in pharmaceutical therapies and acute
interventions have decreased the incidence of coronary artery disease and myocardial
infarction, yet the prevalence of heart failure has steadily risen. Currently, around 5
million Americans suffer from heart failure, over a million patients are hospitalized
because of it, and 300,000 die from consequences of heart failure, with fatal cardiac
arrhythmias being a major consequence [11-13]. To put the numbers in perspective,
death from heart failure exceeds deaths from all forms of cancer combined [14], and that
number is expected to double in the next decade [10].
Second, despite many advances in different areas of cardiovascular medicine and
heart disease management shifts from an acute to a chronic setting, symptomatic
treatment via inotropic and neurohumoral axis interventions remain the only modalities
to face such clinical challenge and the onset of fatal arrhythmias remain unpredictable
[15]. With the rising prevalence, there has been a dearth of novel treatment strategies for
heart failure and the prevention of the subsequent arrhythmia. This suggests that a
different focus in the study of heart failure pathogenesis is necessary for the
development of novel therapies.
The development of heart failure is often preceded by cardiac growth manifested
as an increase in cardiac mass, or cardiomyocyte hypertrophy. This structural
2

remodeling temporarily allows for the preservation of cardiac function in response to
hypertension, valvular heart disease, or anemia. Over time, the hypertrophied heart no
longer compensates against the stressors and the heart progresses into decompensated
systolic heart failure, characterized by a loss of functional heart muscle. It is during this
stage of the pathology that hearts typically begin to lose their sinus rhythm and progress
to arrhythmias. However, the molecular mechanisms that drive the stressed heart to
initially hypertrophy and ultimately lose its function and the coordinated contraction
remain incompletely understood.
Prior to the progression into heart failure, the stressed heart undergoes a series of
characteristic changes. Structurally, hearts hypertrophy and are capable of nearly
doubling the mass through hypertrophic remodeling [16]. Modulation of the structural
remodeling process therefore is recognized as a potentially novel therapeutic approach
for the prevention and treatment of heart failure.
Much effort has been put forth toward the understanding of the structural
remodeling process. Studies using microarrary gene expression profiling have identified
expression changes in calcium handling proteins, sarcomeric proteins, mitochondrial,
apoptotic, inflammatory, and extracellular matrix gene clusters [17, 18]. Unfortunately,
treatment strategies aimed at normalizing inflammatory reactions and preventing
extracellular matrix modifications have not been found to be beneficial [19, 20].
Therefore, a better understanding of the remodeling processes involved in heart failure
are necessary to develop a novel targeted approach to reduce the morbidity and mortality
associated with heart failure.

3

The structural remodeling process, specifically hypertrophy of the myocardium,
in response to stress dramatically increases the pro-arrhythmic potential. In fact, an
important cause of the high mortality and sudden death in heart failure is the insidious
onset of potentially fatal cardiac arrhythmias [13]. Therefore, a direct focus on the
mechanisms governing the electrical remodeling process is mandatory. Thus, we set out
to investigate the molecular and cellular events that regulate the electrical properties of
the heart accompanying cardiac hypertrophy and whether there is a point of intervention.
Furthermore, we also explored the mechanism by which the prolonged hypertrophic
response to stress affects the expression and function of ions handling proteins that
establish normal sinus rhythm.
This dissertation provides the evidence in support of the hypothesis that changes
in cardiac cellular signaling are required for structural and functional changes in the
stressed heart, and sustained pathologic hypertrophic response alters normal rhythm of
the heart. The rationale is based on the established and highly conserved pathway – the
mammalian target of rapamycin (mTOR) – that integrates the environmental signals
such as oxygen availability, energy status of the cell, and nutrient metabolism with
cellular growth [21, 22] and its sustained activity promotes the development of abnormal
heart rhythms [23, 24]. Specifically, I identified dysregulation of the adaptor protein
ankyrin-B – a key protein in proper subcellular targeting and retention of ion channels,
transporters, and receptors that regulate the ionic movement – as a novel molecular
target under mTOR regulation, and that sustained mTOR activity downregulates
expression of ankyrins causing altered expression of ion handling channels and

4

transporters. The study presents downregulation of ankyrin by mTOR activity as the key
linking the chronically stressed myocardium and arrhythmogenesis.

1.2 Hemodynamic Load-Induced Structural and Functional Remodeling
Cardiac hypertrophy is a response to a wide variety of external stimuli. In
general there are two types of cardiac hypertrophy: physiologic and pathologic.
Physiologic cardiac hypertrophy (i.e. normal growth without structural or functional
compromise) occurs in the postnatal period, during pregnancy, or with exercise [25, 26].
On the other hand, pathologic cardiac hypertrophy occurs in response to hypertension,
neurohumoral stimulation, or myocardial infarction (Figure 1.1) [16].

5

Figure 1.1. Conditions leading to physiologic versus pathologic cardiac growth.
Depending on the stimulus, cardiac structural remodeling can be physiologic or
pathologic. Physiologic remodeling can be beneficial while pathologic remodeling is
associated with decompensated heart failure, ventricular dilation, and electrophysiologic
changes leading to malignant arrhythmias. Reproduced with permission from Hill, J.A.
and E.N. Olson, Cardiac plasticity. N Engl J Med, 2008. 358(13): p. 1370-80, Copyright
Massachusetts Medical Society [16].

The process of pathologic cardiac hypertrophy was first identified as a step
toward the development of heart failure in the earlier part of the last century [27]. Later,
it was recognized that the initial hypertrophy in response to pathologic stressors was first
adaptive, but led to systolic dysfunction when the compensation became “inadequate”
6

[28-30]. The initial adaptive state was in line with Laplace’s law which dictated that
[wall tension = pressure x radius / (2 x wall thickness)] [26] such that load-induced
increases in systolic wall stress was offset by increase in wall thickness [20, 31]. In
contrast, the Framingham Heart Study established that left ventricular hypertrophy alone
was an independent risk factor for adverse cardiovascular outcomes such as heart failure
and arrhythmias. This finding from The Framingham Heart Study suggested the
maladaptive role of cardiac hypertrophy that was vastly different from the adaptive
nature as suggested by Laplace’s law [32, 33]. This begs the question whether cardiac
growth is necessary to compensate for the increased cardiac work.
At the cellular level, the heart responds to an increase in workload by posttranslational modification of proteins. For example, acute mechanical stress directly
activates angiotensin II type 1 receptor and G-protein coupled receptors leading to
phosphorylation changes of downstream growth signaling proteins [34-36]. When
subjected to an increase in workload chronically, sustained activation of intracellular
signaling cascades not only activates cellular growth pathways and leads to hypertrophy,
it also changes gene expression, most notably the reactivation of the fetal gene program
(e.g. α- to β-myosin heavy chain expression) [16, 37]. In several small animal studies
where cardiac hypertrophy was attenuated by inhibition of calcineurin-mediated
intracellular growth pathway with cyclosporine showed preservation of systolic function
when challenged with hemodynamic stress [38-40]. Similar studies where suppression
of other intracellular growth pathways such as GSK-3β pathway or calcium/calmodulin
kinase II have all demonstrated reduced cardiac hypertrophic and preservation of cardiac
function in response to pressure overload or β-adrenergic stimulation [41-43]. Inhibition
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of pathologic hypertrophic response therefore presents a potential therapeutic avenue for
the preservation of cardiac functions.
Since left ventricular hypertrophy is established as an independent risk factor for
development of heart failure and arrhythmias, attenuating cardiac hypertrophic response
while preserving the contractile performance is a logical approach to prevention and
treatment of heart failure. As aforementioned, a number of signaling events take place
in the stressed heart to regulate cardiac growth. Thus, a better understanding of how the
intracellular signaling events as it relates to changes in electric properties of the heart is
essential. Of all the signaling events, the mammalian target of rapamycin (mTOR)
pathway is one of the best well-characterized growth signaling cascade to be active in
the stressed heart [44-46]. Therefore, a major focus of this thesis is on mTOR activity
and proteins responsible for maintaining regular rhythm in the heart.

1.3 mTOR Signaling in the Heart
The evolutionarily-conserved mTOR pathway is part of the insulin signaling that
regulate cellular growth and proliferation such as ribosomal biogenesis, protein
translation, autophagy, and nutrient metabolism.
mTOR (mammalian target of rapamycin) biology was elucidated through the use
of the macrolide rapamycin, an antifungal composed of a large macrocyclic lactone ring
with deoxy sugars attached that was isolated from a yeast strain Streptomyces
hygroscopius found on Easter Island of Rapa-Nui [47]. Rapamycin inhibits cellular
growth and proliferation and is now an FDA-approved drug for use as an
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immunosuppressant for kidney transplant and prevention of post-angioplasty restenosis
[48-50]. Rapamycin has a high affinity for FK506-binding protein 12
(FKBP12) that subsequently inactivates the mTORC1 complex [51] or mTORC2
complex with chronic rapamycin administration [52]. Using rapamycin, mTOR’s
sensitivity to nutrient availability and ability to mediate protein synthesis was first
identified in yeast [53, 54]. Studies in which withdrawal of amino acid from Drosophila
and mammalian cells with rapamycin administration resulted in decreased mTORC1
activity were demonstrated and the mechanisms by which inhibition occurred were
elicited [21]. Nutrient availability, specifically branched-chain amino acids, binds to
Rag-Ragulator complex to recruit and directly stimulate mTOR activity [44-46]. In
contrast, rapamycin inhibits mTOR activity by complexing with FK506 binding protein
12 (FKBP12), which in turn binds to mTOR’s FKBP12-rapamycin binding domain to
inhibit its ability to phosphorylate the downstream effectors [55, 56].
mTOR regulates protein translation through phosphorylation of proteins in the
translational machinery, and the two most well-characterized downstream targets of
mTOR are ribosomal protein p70 S6 kinase-1 (p70S6K1) and eukaryotic initiation factor
4E-binding protein (4E-BP1) [57]. p70S6K1 regulates cell size via phosphorylation of
40S ribosomal protein S6 that is important in translational control of mRNAs containing
5’-terminal oligopyrimidine tract. 4E-BP1 normally binds and inhibits eukaryotic
initiation factor 4E (eIF-4E), but the inhibition is relieved with 4E-BP1 phosphorylation
by mTOR. eIF-4E then recruits 40S ribosomal subunit to the 5’ end of mRNAs [58].
Collectively, mTOR activation results in increased cap-dependent protein translation
[59-61].
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Further studies on mTOR found that mTOR nucleates two major complexes –
mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) [62]. mTORC1 is
composed of mTOR, regulatory-associated protein of mTOR (RAPTOR), mammalian
lethal with Sec13 protein 8 (mLST8), the proline-rich Akt substrate 40 kDa (PRAS40),
and DEP domain-containing mTOR-interacting protein (DEPTOR). mTORC2 is
composed of mTOR, rapamycin-insensitive companion of mTOR (RICTOR), protein
observed with RICTOR (PROTOR), mLST8, mammalian stress-activated protein
kinase-interacting protein 1 (mSin1) [63, 64]. The different components of the two
complexes yield distinctly different downstream functions and upstream regulations.
mTORC1 activity primarily drives protein translation, cell growth, and cell proliferation
whereas mTORC2 regulates cytoskeletal organization via actin reorganization [65].
Another notable difference between the two is that mTORC1 is sensitive to acute
rapamycin inhibition and does not change with chronic administration, whereas
mTORC2 is not acutely sensitive to rapamycin but is inhibited with chronic rapamycin
treatment [66]. The question remains, what roles do the two complexes have in heart
growth?
In the unstressed heart, mTORC1 is normally inhibited by its upstream regulator,
the tuberous sclerosis complex (TSC) composed of TSC1 (hamartin) and TSC2 (tuberin)
[67]. In the unstimulated state, N-terminus of tuberin binds hamartin to form a
heterodimer coiled-coil complex and the C-terminus of tuberin, the GTPase-activating
protein domain, actively inhibits Ras homolog enriched in brain (Rheb) by hydrolyzing
Rheb-GTP (active form capable of activating mTORC1) to Rheb-GDP (inactive form)
[68-70]. Growth factors (e.g. insulin or insulin-like growth factor 1) or mechanical
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stress activates mTORC1 in the insulin signaling pathway by phosphorylating and
dissociating the TSC complex in a phosphatidyl inositol-3 kinase (PI3K)-dependent
manner [71]. Dissociation of tuberin and hamartin suppresses GTPase-activity of
tuberin and promotes Rheb-GTP that recruits and activates mTORC1 on the lysosomal
surface [72-74].
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Figure 1.2. The mTOR signaling network. A, mTOR kinase nucleates both the mTOR
complex 1 and complex 2. mTOR complex 1 contains RAPTOR, mLST8, PRAS40, and
RAGulator complex (not shown in the diagram). mTORC1 drives cellular growth by
increasing protein translation and decreasing degradation. B, When Akt is in active, TSC
complex inhibits Rheb and PRAS40 inhibits mTORC1. Upon activation, Akt promotes
mTORC1 activity by inhibiting the TSC complex and PRAS40. When TSC complex
becomes genetically inactivated, strongly elevated Rheb activity greatly increases mTORC1
activity despite negative feedback inhibition by Akt and PRAS40. Reproduced with
permission from Guertin, D.A. and D.M. Sabatini, Defining the role of mTOR in cancer.
Cancer Cell, 2007. 12(1): p. 9-22 [9]. Permission number: 3673841346160.

Collectively, given the sensitivity of insulin signaling to environmental cues and
its role in cell growth and proliferation, mTORC1 activity intimately provides and plays
a major role in the cardiac hypertrophic response to hemodynamic stress.

1.4 Overactive mTORC1 Underlies Electrical Changes in the Brain
Chronically stressed heart with hypertrophic phenotype exhibits changes in
electrocardiogram (EKG) recording [75]. But prior to changes in the EKG, the
hypertrophic phase is characterized by numerous signaling pathway changes [76-82].
Prior to the investigation of mTORC1 pathway regulating the electrical changes in the
heart, it is prudent to start by exploring the relationship between mTORC1 in the brain,
another electrically active organ.
The activation of the mTORC1 pathway in the central nervous system is highly
associated with the recurrence of seizures [83]. Genetic mutations of the mTOR
pathway components such as phosphatidyl-inositol-3 kinase (PI3K), phosphatase and
tensin homologue (PTEN), Akt/PKB, and mTOR all display unprovoked seizures in
animal models [84-88]. But the involvement of mTORC1 in seizure development goes
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beyond genetic manipulation of the pathway. Chemical or electrical stimulation and
post-traumatic brain injury in rodent models have all elicited recurrent seizures marked
by increased mTORC1 activity, and treatment with rapamycin either attenuated the
severity or the frequency of seizure activities [89-93]. Furthermore, early data using
rapamycin for medically intractable seizures have had promising results leading to
current larger scale clinical trials [94].
A notable disease that typifies hyperactive mTORC1 in the brain is tuberous
sclerosis complex (TSC). TSC is an autosomal dominant disease caused by germline
mutations in either of the tumor suppressor genes, TSC1 or TSC2. As shown in figure
1.2B, inactivation of either gene leads to the inactivation of the TSC complex and
hyperactivation of the mTORC1 pathway that promotes the neuropathological changes
in the central nervous system characterized by the formation of tubers [95-97]. Tuber
formation is a result of abnormal neuronal migration and cellular hypertrophy [98, 99]
and has been shown to be the likely origin of recurrent seizures [100, 101], a process
whereby the brain is functionally altered and generates abnormal electrical signals. The
presence and the number of cortical tubers highly correlate to the degree of seizure
severity and number of occurrences, which are one of the most defining and devastating
neurologic consequences manifesting in many of the patients afflicted with TSC [102105].
The mechanism by which overactive mTORC1 remodels electrical properties of
neurons that cause recurrent seizures remains perplexing. Much attention has been
focused on the inappropriate neuronal migration and synaptogenesis in unprovoked
epilepsy [98, 106-108]. But recently, changes in ion handling proteins secondary to
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mTORC1 overactivation are beginning to be identified. Functional and expression
changes of ion channels and receptors at the cellular level such as voltage-gated
potassium channels, glutamate and GABA receptors that result in spontaneous abnormal
neuronal firing have been characterized [109-111]. Specifically, neurons with
overactive mTORC1 exhibit decreased expression and currents in two inward-rectifier
potassium channels (Kir2.1 and Kir6.1) – ATP-sensitive channels that play a role in
neuronal repolarization – and an increased expression and currents through the
excitatory GluN2C NMDA receptors [109, 112]. Altogether, the net results are lowered
threshold for neuronal firing and increased frequency of action potential firing. The
expression and current changes are reversible by either inhibiting mTORC1 directly or
by modulating downstream effectors of mTORC1 in vivo and in vitro. These same
neurons also exhibit increased spontaneous firing as a result of decreased repolarizing
current [109, 112].
The effects of mTORC1 on ion channels, and therefore the electrical properties
of the neurons, are clear, but the mechanistic regulation of the channels remains elusive.

1.5 Ion Channels and the Adaptor Protein Ankyrin
Ion channels and transporters require proper interaction with adaptor protein such
as ankyrin to facilitate their proper membrane localization and functioning. Ankryins
are a family of intracellular adaptor proteins that interact, transport, and (implicit in the
name) anchor membrane proteins at their proper subcellular domains to the underlying
cytoskeletal structure [8]. Three independent ANK genes (ANK1, ANK2, and ANK3)
14

make up the ankyrin family and each has a unique function and subcellular localization
to facilitate the proper formation of the cellular architecture and biogenesis of distinct
membrane domains [113].
The ankyrin proteins vary vastly in size, but a canonical ankyrin protein has four
domains: 1.) membrane-binding domain, 2.) spectrin-binding domain, 3.) death domain,
and 4.) C-terminal domain (Figure 1.3). Contrary to the naming scheme, the membranebinding domain does not directly bind to the plasma membrane, but instead binds to a
variety of membrane-bound proteins such as ion channels, transporters, and cell
adhesion molecules [114-116]. The spectrin-binding domain is where interaction with
the underlying cytoskeletal structure occurs. The death domain and the C-terminal
domain together are thought to comprise the “regulatory domain” because of their
intramolecular association with the membrane binding domain that likely specifies
ankyrin’s affinity for different binding partners.
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Figure 1.3. Organization of domains of a prototypical ankyrin. 24 ANK repeats
comprise the membrane-binding domain that is responsible for interactions with other
proteins. Each ANK repeat is composed of an α-helix-β-hairpin loop-α-helix and the
exposed tip of β-hairpin loop is where protein binding takes place. The spectrin-binding
domain is where ankyrin binds to the underlying cytoskeleton spectrin, thereby
“anchoring” the interacting membrane protein. The regulatory domain modulates
ankyrin’s intramolecular association and targets ankyrin to specific subcellular domains.
Reproduced with permission from Cunha, S.R. and P.J. Mohler, Cardiac ankyrins:
Essential components for development and maintenance of excitable membrane domains
in heart. Cardiovasc Res, 2006. 71(1): p. 22-9 [8]. Permission number: 3673851380495.

Because of ankyrin’s ability to bind with multiple partners simultaneously, it is
therefore within the ankyrin’s capability to facilitate the formation of large membrane
protein complexes to create specialized membrane domains and tether them to the
underlying cytoskeleton. An example of the protein complex formed by an ankyrin
protein is the interactions between neuronal ankyrin-G with voltage-gated ion channels,
cell adhesion molecules (neurofascin-186 or L1-CAM), and the underlying cytoskeleton
βIV-spectrin at the axon initial segment (AIS) and nodes of Ranvier [117, 118].
The divergence of the regulatory domain within the same and between different
ankyrin products confers different functions of ankyrins by specifying their subcellular
localizations and interactions with different binding partners [119, 120]. The
functionally distinct and different spatially-localized ankyrins are central in the
establishment of neuronal polarity and ion channel clustering at the axon initial segments,
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nodes of Ranvier, and paranodes that work in concert to establish membrane excitability
and saltatory conduction [121-123].
Neuronal excitability begins at the axon initial segment (AIS), a site of
integration from many dendritic signals that result in the initiation of action potentials.
Action potentials are generated by clusters of voltage-gated sodium channels and
repolarized by voltage-gated potassium channels that are concentrated at the AIS and
nodes of Ranvier [118, 124]. Studies have attributed the clustering of the voltage-gated
ion channels at the AIS to their interactions with ankyrin-G. Furthermore, in an ankyrinG null murine model, not only is the clustering of voltage-gated sodium channels at the
AIS is disturbed, deficits in action potential initiation and rate of firing are observed [117,
118, 125-127]. Although these studies showed decreased action potential generation and
frequency when the binding sites are disrupted by knockdown or point mutations, a
recent report showed that lithium-pilocarpine-induced epilepsy in a murine model
caused ankyrin-G-dependent changes in the expression of voltage-gated sodium
channels [128]. The role ankyrin plays in modulating neuronal excitability by way of
their interactions with the ion channels is evident.
Likewise, in the context of the recurrent seizures and decreased voltage-gated
potassium channels and currents observed in animal models of TSC, the potential
changes in ankyrin expression or localization secondary to dysregulated mTORC1
activity may underlie the molecular pathway leading to increased excitability in the
central nervous system of Tsc2-hGFAP described in chapter 2 (Figure 1.4).
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Figure 1.4. Proposed model of mTORC1 regulation of neuronal excitability. Action potential is
generated at the axon initial segment (intersection between the soma and the axon) and propagated
through the nodes of Raniver (denoted by the areas in between the myelin sheaths) by the voltagegated sodium channels (Nav1.6). Repolarization of the action potential is mediated by the voltagegated potassium channels (Kv7.2/7.3). Maintenance of Nav1.6 and Kv7.2/7.3 at their proper
subcellular domains is mediated by the adaptor protein ankyrin-G and its expression is likely
regulated by mTORC1. Rectangular boxes along the axon represent the myelin sheaths.

1.6 Ankyrin and the Heart
Like the neurons, cardiomyocytes are intrinsically electrically active. Whereas
neuronal activity is measured by generation and firing frequencies of action potentials,
cardiomyocyte performance is measured by the generation of action potentials,
contraction strength and rhythm. These properties of the cardiomyocytes are related as
every beat of the heart begins with the generation of an action potential that travels down
the sarcoplasmic reticulum/transverse-tubule (SR/T-tubule) to depolarize the voltagegated calcium channels (or dihydropyridine receptor) causing a calcium-induced calcium
release via the ryanodine receptor [129]. This calcium release in turn causes a
mechanical contraction by the cardiomyocyte, and, by cell-to-cell electrical coupling at
intercalated discs, leads to the contraction of the entire myocardium. Collectively, this is
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termed “excitation-contraction coupling” and links the electrical stimulus to a
mechanical response [130, 131].
Normal excitation-contraction coupling, similar to neuronal depolarization and
repolarization, requires the precise targeting and maintenance of integral membrane
proteins at specialized membrane domains. While adaptor proteins such as ankyrin help
establish important subcellular domains for action potential generation and propagation
in neurons, ankyrin coordinates and establishes identity and functions of SR/T-tubule
junction and intercalated discs - important subcellular domains of cardiomyocytes – for
the proper conversion of electrical signal to mechanical force. Specifically, ankyrin-B in
the heart functions at the SR/T-tubule by targeting and retaining the sodium-calcium
exchanger (NCX) and sodium potassium ATPase (NKA) [2, 4]. Loss-of-function
ankyrin-B mutations at the cellular level that disrupt interactions with its binding
partners lead to decreased NCX and NKA membrane expression and reduced half-life,
elevated sarcoplasmic reticulum calcium content, and increased duration of calcium
sparks [2, 4, 5, 132, 133]. At the clinical level, the missense mutations have been linked
to various arrhythmias – or abnormal rhythms of contraction - that include but not
limited to bradycardia, atrial fibrillation, idiopathic ventricular fibrillation,
catecholminergic polymorphic ventricular tachycardia, prolonged ventricular
repolarization (type IV long QT syndrome), and sudden cardiac death [3-5, 134, 135].
QT interval is the time it takes for the heart to depolarize then subsequently repolarize
fully and correlates directly with the increase in the duration of calcium transients
observed at the cellular level.
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Interestingly, ankyrin-B populations are observed at two distinctly different
functional subcellular domains of the cardiomyocyte: one at the SR/T-tubule and the
other at the M-line. While many studies have focused on the function of ankyrin-B at
the SR/T-tubule, very little is known about the function of ankyrin-B population at the
M-line, a site where myosin heavy chain is organized [136]. However, the existence of
two ankyrin-B populations at two functionally divergent subcellular domains cannot be
attributed to a single isoform despite the multivalent properties of ankyrin proteins. Also,
the majority of the studies dealing with ankyrin-B are focused on its binding partners
exclusively localized at the SR/T-tubule (e.g. NCX, NKA, and IP3R) that are completely
absent at the M-line. Given that ankyrin-B is expressed at the SR/T-tubule and the Mline, we speculate that there exists more than one ankyrin-B isoform in cardiomyocytes
that contribute to the maintenance of the excitation-contraction integrity.
Cardiac expression of multiple ankyrin-B isoforms is a likely hypothesis since
alternative-splicing of ankyrin genes has been well-documented. For example, multiple
isoforms of ankyrin-G has been identified in the brain [137, 138], muscles [139-141],
and heart [142-144]. Multiple isoforms of ankyrin-B have also already been identified
in the brain that play a role in neurite outgrowth and control growth cone navigation
[145-149]. Yet neurologic clinical manifestation of loss-of-function ankyrin-B remains
unreported at this time.
Multiple mutations in ankyrin-B have been associated with cardiac arrhythmias.
Interestingly, individual mutations have been linked to diverse groups of arrhythmias.
Previous studies examining the molecular basis of ankyrin-B dysfunction have been
unable to account for how a single mutation could manifest as atrial fibrillation,
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bradycardia, and idiopathic ventricular fibrillation. Findings from these studies were
interpreted with the false assumption that the heart expresses one isoform of ankyrin-B.
Our hypothesis that the heart expresses multiple ankyrin-B isoforms provides a more
fitting explanation for the diversity of arrhythmias resulting from ankyrin-B dysfunction.
In Chapter 4, I describe the identification and functional characterization of two novel
ankyrin-B isoforms in mammalian heart. This work provides the foundation for future
experiments to re-evaluate arrhythmia-associated mutations in the context of
endogenously expressed ankyrin-B isoforms.
Different sets of arrhythmias also manifests throughout different stages of heart
failure [13]. Multiple, signaling, functional, structural remodeling occur simultaneously
in the hypertrophic heart [16]. From Chapter 4, we identify and characterize multiple
ankyrin-B isoform expressions and localization in cases of primary cardiac arrhythmias.
Using that as platform to interrogate electrical changes in secondary cardiac hypertrophy
in Chapter 3, I demonstrate that ankyrin-B expression decreases in a murine model of
cardiac hypertrophy via overactivation of the mTORC1 pathway by increased
hemodynamic load. Furthermore, I demonstrate a link between mTORC1 activation and
reduced ankyrin-B expression at the sarcomeric M-line. Changes in ankyrin-B
expression may induce arrhythmia in the hypertrophic heart by disrupting the proper
subcellular localization and function of the sodium calcium exchanger and/or other
calcium ion handling proteins. In sum, this chapter lays out a molecular path that may in
part account for arrhythmogenesis associated with secondary cardiac hypertrophy.
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CHAPTER 2: THE DIFFERENTIAL EFFECTS OF PRENATAL AND/OR
POSTNATAL RAPAMYCIN ON NEURODEVELOPMENTAL DEFECTS AND
COGNITION IN A NEUROGLIAL MOUSE MODEL OF TUBEROUS
SCLEROSIS COMPLEX
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2.1 Introduction
Tuberous sclerosis complex (TSC) is a tumor suppressor disorder caused by
heterozygous mutations in either the TSC1 (hamartin) or the TSC2 (tuberin) genes [150,
151]. Loss of heterozygosity of either gene [152, 153] and activation of the mTORC1
kinase [152, 154] are important molecular features associated with TSC pathology.
Although TSC affects multiple organs, neurodevelopmental defects result in the most
substantial morbidity and mortality. Tubers, subependymal nodules and subependymal
giant cell astrocytomas (SEGAs) represent common TSC neurodevelopmental
abnormalities [155, 156] and are associated with intellectual disability, autism and
epilepsy. The prevention and management of these developmental brain lesions are
major challenges in caring for patients.
The hamartin and tuberin heterodimer inhibit the rapamycin-sensitive mTORC1
signal transduction pathway that controls translation, proliferation and cell growth [57,
157, 158]. Preclinical trials have demonstrated significant rescue of many neurologic
defects using rapamycin [95-97, 159, 160], a macrolide that, upon binding to the
intracellular binding protein FKBP12, inhibits the ability of the mTORC1 kinase to
signal to its downstream effectors. These studies have paved the way for several human
clinical trials that have recently resulted in the approval of everolimus, a rapamycin
derivative, for the treatment of SEGAs [161, 162]. Nonetheless, the ability of rapamycin
to rescue perinatal defects remains largely untested. A recent report demonstrated a
promising effect of one dose of prenatally-administered rapamycin on the longevity of a
Tsc1-Nestin mouse model of TSC [159]. Here, we substantially extend those studies by
comparing and contrasting the histological and behavioral effects of different perinatal
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rapamycin treatment regimens in the previously reported Tsc2-hGFAP neuroglial mouse
model of TSC [98]. Using the Tsc2-hGFAP mouse model, we have shown that the loss
of Tsc2 in radial glial progenitor cells recapitulates many brain manifestations of TSC.
Tsc2-hGFAP animals have cortical and cellular hypertrophy, heterotopias, defects in
lamination and myelination, astrogliosis and die at about one month of age [98]. These
defects are a combination of prenatal and postnatal neurodevelopmental abnormalities
and thus provide a good model for the study of perinatal treatment of TSC. Using the
Tsc2-hGFAP model, we sought to systematically determine the most effective treatment
regimens to rescue neurodevelopmental defects. We show that combined rapamycin
treatment resulted in almost complete rescue of neuronal and glial pathologies, while
prenatal or postnatal treatment alone yielded less complete but significant improvements
in brain histology. Surprisingly, the animals treated with combined therapy did not
perform as well as postnatally treated animals on learning and memory tasks. mTORC1
activity is critical for dictating the overall growth of differentiating neuronal stem cells
and postmitotic neurons [163, 164], axon guidance [165] and dendritic arborization
[166]. Therefore, overt inhibition of mTORC1 during neurodevelopment may disrupt
proper axon guidance and dendritic arborization leading to subsequent deficit in learning
and memory in adulthood. These results show that rapamycin can rescue perinatal
neurodevelopmental defects and support the cautious design of trials that will assess
early rapamycin treatment of TSC-affected children.
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2.2 Materials and Methods
2.2.1 Animals
Tsc2-hGFAP mice (Tsc2ko/flox;hGFAP-Cre) were generated and genotyped as
previously described [98]. All protocols were approved by the University of Texas
Health Science Center at Houston Animal Welfare Committee.

2.2.2 Rapamycin treatment regimen
Rapamycin (MP Biomedicals) was dissolved in 100% methanol at 1.0 mg/ml for
storage at -200C. Before use, rapamycin was diluted with PBS and administered
intraperitoneally at 0.1 mg/kg daily. Prenatal treatment was conducted by administering
rapamycin to pregnant dams from embryonic day 12.5 (E12.5), the approximate day of
hGFAP-Cre expression in radial glial progenitors, until delivery (prenatal group).
Postnatal treatment started at birth (P0) and ended at weaning (P21) (postnatal group). A
third group was treated prenatally from E12.5 and then after birth until weaning
(pre+post = combined group). One group of treated animals was used for histologic
analysis, and another group was observed for longevity.
For behavior testing, animals were switched from 0.1 mg/kg rapamycin daily to 2
mg/kg rapamycin three times a week between P35 and P44 as daily 0.1 mg/kg was no
longer sufficient to suppress seizure activities of the Tsc2-hGFAP mice two weeks past
weaning. We used 2 mg/kg because this dose was able to extend the lives and maintain
the health of the Tsc2-hGFAP mice without runting them (Figure 2.5). Rapamycin has a
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half-life of 4.5 hours in blood [167] so that it is virtually eliminated completely from the
body at the end of every 24-hours post injection, the alternate inhibition and activation of
mTORC1 every other day appears to achieve therapeutic effects.

2.2.3 Western analysis, histology and immunohistochemistry
Brain lysates were made from P21 animals and analyzed as previously described
[98]. Briefly, P21 mice were anesthetized with 2.5% avertin and transcardially perfused
with cold PBS followed by 4% paraformaldehyde. Hematoxylin and eosin staining and
immunohistochemistry were performed as previously reported [98]. Antibodies used
were: phosphorylated (Ser 240/244) S6 (1:100, Cell Signaling), Cux1 (1:50, Santa Cruz),
BrdU (1:50, Becton Dickinson), GFAP (1:400, Sigma), NeuN (1:100), MBP (1:200)
(Millipore), Olig2 (1:200) (Millipore) and CC1 (1:100, Calbiochem). Antibodies used
for western analysis were: tuberin (1:500), hamartin (1:500), a-tubulin (1:2000), S6
(1:500), pS6 (S240/244) (1:500), pS6 (S235/236) (1:500) from Cell Signaling.

2.2.4 Quantitative analysis
Three sections from three mice of each group were used for all quantitation.
Sections were matched and a standard area was used for counting. ANOVA was used
for analysis of data. The log-rank test was used to compare survival curves. For BrdU
analysis, the cortex was divided equally into 10 bins, and a standardized width was used
for counts. Learning and memory testing experimenters were blind to the treatment
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groups. Animals were trained in two variations of the hidden platform version of the
Morris water-maze task: 1-day version and a 7-day version [168-171]. For 1-day
training protocol, animals were given 12 consecutive trials (4 min inter-trial interval) in
1 day and a probe test 24 h later. For the 7-day protocol, animals were given four
training trials a day (4 min inter-trial interval) for six consecutive days. A probe trial
was given 48 h later. Movement within the maze was monitored by a video camera
linked to tracking software. Analysis of data was done with unpaired, two-tailed
Student’s t-test (number of platform crossings and path length) and repeated-measure
ANOVAs (learning curves and quadrant preference). Context discrimination testing was
done as previously described [172]. Briefly, animals were pre-exposed (no shock) to
two contexts that shared certain features (horizontal grid floor, background noise, animal
handling to and from the room) while differing in others (differently spaced grids, scent,
distal cues, floor shape and color). Animals were given one trial a day of 3 minutes in
each chamber with a minimum of 3.5 h between trials. In the shock chamber, animals
were given a 2 s, 0.75 mA shock given at 148 s, while no shock was given in the safe
chamber. Discrimination of the two contexts was assessed by comparing the time spent
freezing (monitored in 2 s intervals) in each chamber during a test trial done on day 4
during which no shock was given. Analysis of the data was done with paired, two-tailed
Student’s t-test. Data were considered significant at P<0.05.

2.3 Results
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To examine whether rapamycin could rescue some or all defects in Tsc2-hGFAP
mice, we designed three rapamycin treatment regimens to target prenatal and/or
postnatal developmental abnormalities (Figure 2.1A). We optimized a rapamycin dosage
(0.1 mg/kg i.p. daily) that suppressed mTORC1 activity as measured by levels of
phosphorylated ribosomal protein S6 (Figure 2.1B and C), but did not kill embryos or
retard postnatal growth. This dose is 10–50-fold lower than that used in other studies
involving TSC mouse models [95-97, 159]. Rapamycin treatment was stopped at birth
in the prenatal group or at postnatal day 21 (P21) in the combined and postnatal groups.
Animals were either sacrificed for brain histology or observed for longevity.
In all treatment groups, rapamycin improved the health of Tsc2-hGFAP mice
(Figure 2.1D, E, F). The postnatal and combined treatment groups were healthy and
appeared indistinguishable from controls at P21, but began to die from seizures at about
P40 (Figure 2.1F). These results along with our longevity study presented in Figure 2.5
further demonstrated that rapamycin treatment must be continued to prevent death in
mutant animals as shown in other models [96, 97]. Nonetheless, the median age of
survival of both postnatal and combined groups was significantly longer than untreated
mutants. Prenatal treatment had a modest effect on postnatal health, and did not
significantly alter the median survival. These attenuated effects of prenatal treatment are
likely due to the reactivation of mTORC1 after the cessation of treatment at P0 as
demonstrated by increased phosphorylated S6 (pS6) immunostaining (Figure 2.2A).
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Figure 2.1. Prenatal, postnatal and combined rapamycin treatments improved health, weight gain
and longevity. A, Rapamycin treatment regimens and their relationship to brain development.
Prenatal treatment was from E12.5-birth (P0); postnatal treatment from P0 to weaning (P21);
combined treatment from E12.5 to P21. In the cohorts used for histology and longevity studies,
prenatal treatment stopped at birth (open circle), postnatal and combined treatments were stopped
at P21 (open circle). B, Brain lysates from newborn animals after 0.1 mg/kg prenatal rapamycin
treatment from E12.5 to birth were analyzed by immunoblotting. The levels of phosphorylated S6
(pS6), an indicator of mTORC1 activation, were decreased in the lysates of the rapamycin-treated
Tsc2-hGFAP (mutant) animals, although not to control levels. Total S6 was unaffected. C,
Immunoblots of cortical and hippocampal lysates from P21 mice treated with 0.1 mg/kg i.p.
rapamycin from P0 to P21. Levels of pS6 in the untreated Tsc2-hGFAP cortex and hippocampus
were increased. Treatment reduced mutant pS6 levels to approximately untreated control levels.
Total levels of S6 remained unchanged. Based on these results, daily 0.1 mg/kg i.p. was used for
further experiments. D, Control and Tsc2-hGFAP mutant mice at P21 after the different
rapamycin treatment regimens. E, Graph demonstrating an improvement in weight gain for all
rapamycin regimens compared with untreated Tsc2-hGFAP mice (solid black line). Rapamycin
treatment regimens had no effect on weight gain in control animals. F, The Kaplan–Meier
survival plots of untreated and all treatment regimens after the cessation of rapamycin. Colored
arrows correspond to day of rapamycin cessation for specific groups. Median age of death: MUTuntreated P23 (n = 20); MUT-prenatal P31 (n = 12; P = 0.08); MUT-postnatal P45 (n = 6; P <
0.001); MUT-combined P41 (n = 5; P = 0.0001).

Phosphorylation of S6 in the brains of the postnatal and combined treatment
groups at P21 (Figure 2.2A) was decreased compared with untreated mutants, consistent
with the immunoblot analysis used to optimize the dose of 0.1 mg/kg (Figure 2.1C).
Further histologic analysis demonstrated significant reduction in cortical enlargement
and cellular hypertrophy in all three treatment groups (Figure 2.2B, D, F, G). The
effects of combined treatment on cortical and hippocampal organization were most
striking (Figure 2.2B, C, E). Prenatal and combined treatment restored the cell sparse
marginal zone (MZ) that was thinner and less defined in the untreated and postnatal
treated brains (Figure 2.2B). The hippocampal pyramidal layer of the combined
treatment group was well organized and almost indistinguishable from control (Figure
2.2C and E). Prenatal and postnatal treatment also improved hippocampal organization,
although the CA1 and CA3 regions remained somewhat disorganized. All untreated
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Tsc2-hGFAP animals have distinctive ring heterotopias in the stratum lacunosum
moleculare (SLM) (Figure 2.2C). No heterotopia was seen in the prenatal or combined
treatment samples. Small heterotopias were seen in two out of seven postnatal-treated
animals. We then examined ectopic NeuN-positive cells in the stratum oriens (SO) to
assess how rapamycin affected the abnormal position of these cells. Postnatal and
combined treatments reduced the number of ectopic cells in the SO, but combined
treatment reduced the number of ectopic cells to almost control levels (Figure 2.2E and
H). These results demonstrate that rapamycin can correct the abnormal migration of
Tsc2-deficient neurons. The additive effect of pre- and postnatal rapamycin treatment on
hippocampal organization is consistent with the in utero and postnatal development of
this structure [173].
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Figure 2.2. Effects of daily 0.1 mg/kg rapamycin treatment regimens on cortical histology and
organization. A, Cortical and hippocampal phosphorylated S6 (pS6) immunohistochemistry. Untreated
Tsc2-hGFAP brains at postnatal day 21 demonstrated an increased pS6 signal compared with control.
Postnatal and combined treatments decreased the intensity of pS6 staining in Tsc2-hGFAP brain
consistent with suppression of mTORC1. In the prenatally-treated brains, pS6 expression was
comparable with untreated Tsc2-hGFAP levels, suggesting reactivation of mTORC1 during the period
of no treatment from P0 to P21. B, H&E staining of the cerebral cortex. Note the well-formed MZ in
the brains from prenatal and combined treated Tsc2-hGFAP mice. C, H&E staining of hippocampus.
Combined treatment resulted in a mutant hippocampus that was almost identical in organization to the
control. The CA1 and CA3 regions were indistinguishable between control and combined treatment
groups, but remain somewhat split and disorganized (arrows and asterisks) in the prenatal and postnatal
groups. The ring heterotopia in the SLM of the mutant mice (arrowheads and insets) were absent in
prenatal and combined treatments, and were occasionally seen in the postnatal group (two out of seven
animals examined; 15/15 untreated Tsc2-hGFAP mice have ring heterotopias). D, Higher
magnification of cortical layers II/III showing NeuN immunohistochemistry of enlarged neurons of the
untreated mutant and the rescue of cell size by the various treatments. E, NeuN immunohistochemistry
of the CA1 region of the hippocampus. Note the ectopic cells in the SO of untreated Tsc2-hGFAP mice
that are decreased in number in postnatal treatment, and almost disappear in combined treatment brains.
F, Bar graph showing the rescue of cortical thickness in all treatment regimens (∗∗∗P < 0.001). The
thickness of the control cortex was unaffected by the different rapamycin regimens. G, Bar graph
showing the rapamycin rescue of neuronal hypertrophy (∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001). Control
neuronal size was not significantly affected by rapamycin. H, Bar graph showing the number of
ectopic neurons in the SO of the hippocampus in different treatment groups. Combined treatment had
the greatest effect on reducing the number of ectopic neurons in the SO (∗∗P < 0.005; ∗∗∗P < 0.0005).
Data represent mean +SEM. MZ, marginal zone; SLM, stratum lacunosum-moleculare; SO, stratum
oriens; DG, dentate gyrus.

To examine the effects of rapamycin on cortical lamination, we performed
immunohistochemistry to detect the layer II– IV-specific transcription factor Cux1 [174]
(Figure 2.3A and B). Both prenatal and combined rapamycin decreased the number of
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ectopic Cux1-positive cells in cortical layers V and VI of Tsc2-hGFAP mice. Postnatal
treatment had little effect on the distribution of Cux1-positive cells. These results
suggest that in utero administration of rapamycin can rescue the abnormal migration of
cortical neurons to appropriate layers of the cortex. To further assess the effect of
rapamycin on neuronal migration, we analyzed the fate of cortical neurons born at E15.5
using BrdU birthdating (Figure 2.3C and D). In control mice, the majority of BrdU
labeled neurons at E15.5 appear in the upper cortical layers. More BrdU-labeled
neurons are present in the lower cortical layers of the untreated mutant, suggesting that
the loss of Tsc2 affects the migration of some late-born neurons. Prenatal treatment
increased the distribution of BrdU-labeled cells toward more superficial layers, whereas
postnatal and combined treatments resulted in a BrdU distribution that was most similar
to controls. These demonstrate that rapamycin can alter the abnormal migration of Tsc2deficient neurons during both prenatal and postnatal cortical development.
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Figure 2.3. . Effects of daily 0.1 mg/kg rapamycin treatment regimens on cortical lamination.
A, Cux1 immunohistochemistry. Note the ectopic Cux1-positive cells in the deep cortical layers
of the untreated Tsc2-hGFAP brain. B, Bar graph of ectopic Cux1-positive cells. Prenatal and
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reactivation of mTORC1 by P21 (Figure 2.2A). The effects of rapamycin on
oligodendrocytes and myelination were examined. Untreated Tsc2-hGFAP mice at P21
showed a decreased number of mature cortical and callosal oligodendrocytes (Figure
2.4B, C, E, and F). Prenatal rapamycin treatment had little effect on mature
oligodendrocyte number. Postnatal and combined treatments significantly restored the
number of mature oligodendrocytes in both the cortex and corpus callosum of mutant
animals. These results are consistent with the late embryonic and postnatal maturation of
oligodendroglia [175]. Cortical myelination is also a postnatal event. Accordingly, we
observed substantial rescue of myelination defects in only the postnatal and combined
treatment groups (Figure 2.4D).
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Figure 2.4. Effects of daily 0.1 mg/kg rapamycin treatment regimens on astrocytes, oligodendroglia and
myelination. A, Glial fibrillary acid protein (GFAP) immunohistochemistry. Prominent astrogliosis in
untreated mutant was defined by increased cortical GFAP expression. Postnatal and combined
rapamycin treatment normalized GFAP expression. Prenatal treatment had little effect on the
upregulation of GFAP. B and C, CC1 and Olig2 immunohistochemistry to identify mature
oligodendroglia in the midline cortex (B) and lateral corpus callosum (C). Many mature oligodendroglia
were found in the control midline cortex and corpus callosum. In the same structures of the untreated
Tsc2-hGFAP, there was a marked decrease in mature oligodendrocytes. Postnatal and combined
treatments restored the cortical oligodendrocyte distribution to control levels (∗∗∗P < 0.001), whereas
prenatal treatment had little effect. D, Myelin basic protein (MBP) immunohistochemistry. MBP
distribution in the cortex is almost absent from untreated Tsc2-hGFAP mice. Postnatal and combined
treatment demonstrated significant restoration of the normal MBP pattern. Data represent means ±SEM.
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While haploinsufficiency for Tsc1 and Tsc2 is associated with modest behavioral
deficits [95, 176, 177], the consequences of LOH on behavior have been more difficult
to assess due to the lethality associated with many of these mouse models [98, 107, 108].
We found that 2 mg/kg intraperitoneal injection of rapamycin three times a week
beginning at P10 was able to maintain the health and extend the lifespan of Tsc2-hGFAP
mice as long as treatment continued (Figure 2.5). We reported weights of the animals
for three reasons: 1.) untreated mutants or prenatal rapamycin treated mutants all appear
physically runted by postnatal day 23, 2.) it is unknown how increased mTORC1 activity
in the brain reduces body weight but it is possible that hypothalamic mTORC1 activation
suppresses appetite [178], and 3.) seizure activities may cause a reduction in weight but
it is difficult to assess subclinical seizures. Therefore, to asses if histologic rescue in the
combined and postnatal groups led to improved brain function, postnatal and combined
treatment groups were switched from 0.1 mg/ kg daily to 2 mg/kg rapamycin three times
a week between postnatal days 35 and 44 to maintain their health and permit behavioral
analysis (Figure 2.6A). Behavior testing was initiated after the first four doses of
rapamycin and spanned P42–P120 (1.5–4 months). After the completion of behavioral
testing, brains were isolated for histologic analysis.
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Figure 2.5. Effects of 2mg/kg rapamycin i.p. on longevity and weight of Tsc2-hGFAP mice. Tsc2hGFAP animals were treated with 2mg/kg rapamycin three times a week starting at postnatal day 10.
This regimen extended the life and health of the Tsc2-hGFAP mice so that they were
indistinguishable from control mice. Mutant animals began to die from seizures approximately 2
weeks after rapamycin was discontinued.

Spatial memory, which is sensitive to the manipulation of the TSC2-mTOR
cascade, was tested using a modified 1-day version of the Morris water maze task [168,
169, 179]. Consistent with this, control mice treated with 2 mg/kg rapamycin had
significantly impaired long-term memory as indicated by increased latency (P = 0.04)
and path length (P = 0.03) to cross the previous location of the hidden platform during a
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probe trial administered 24 h after training (Figure 2.6B). Untreated mutants were
unable to be tested because none survives beyond postnatal day 40. When the
performance of the postnatal and the combined Tsc2-hGFAP treatment groups were
compared, no significant difference in acquisition was observed (Figure 2.6B versus C,
left panels). Probe trials showed a decreased path length and significantly increased
number (P = 0.036) of platform crossings for the postnatal group when compared with
those observed for the combined treatment group, suggesting enhanced memory. As the
1-day paradigm does not typically give rise to strong spatial localization, these animals
were given daily training (four trials) for an additional 7 days. Consistent with our probe
trial results, the postnatal group showed improved memory for the platform location on
day 1 compared with the combined group. This difference was maintained throughout
the training (P = 0.037), with both groups acquiring the location of the hidden platform
at similar rates (Figure 2.6D). When spatial localization was assessed in a probe trial
given 48 h after the last day of training, a significant preference for the target quadrant
was observed for the postnatal (P < 0.001), but not the combined treatment groups (P =
0.204). No significant differences in either swimming speed or performance in a visible
platform task were observed between the two treatment groups (Figure 2.7).
Heterozygous Tsc2+/- mice have an impaired ability to discriminate between two similar
contexts, a deficit that could be lessened by pre-training rapamycin treatment [95].
Untreated control mice can distinguish between two similar contexts after 1 day of
training as indicated by significantly more freezing in the context in which a mild foot
shock was delivered (Figure 2.6E). In agreement with the previous results, control
animals treated with rapamycin were unable to perform this discrimination. When both
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rapamycin-treated Tsc2-hGFAP groups were tested after 3 days of training, only the
postnatal-treated group was able to distinguish between the two contexts (Figure 2.6F).
Altogether, these results show that postnatal rapamycin can enable Tsc2-hGFAP animals
to learn and remember. While combined rapamycin treatment produced a most complete
histologic rescue, these animals had impaired memory when compared with the
postnatal group.
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Figure 2.6. Effects of rapamycin treatments on learning and memory. A, Rapamycin treatment
regimens and timing for behavior testing. Animals were treated with 0.1 mg/kg rapamycin daily
starting at E12.5 (combined group) or birth (postnatal group). Between P35 and P44, rapamycin
dosing was changed to 2 mg/kg three times a week to maintain the health of the animals. Treatment
continued throughout behavior testing and ended at P120. B, Left panel: latency to platform during
a 1-day Morris watermaze training protocol (n = 10 control untreated group, n = 10 control postnatal
rapamycin group; two-way repeated-measures of ANOVA with treatment and trial number as
between-subjects factors: F(1,18) = 2.95, P = 0.103). Right panels: latency to platform and path
length traveled during probe trial 24 h after completion of training (two-tailed, unpaired Student’s ttest; latency to platform P = 0.04; path length P = 0.03). C, Left panel: latency to platform during a
1-day Morris watermaze training protocol (n = 8 for both groups; two-way repeated-measures
ANOVA with treatment and trial number as between-subjects factors: F(1,14) = 3.01, P = 0.105).
Right panels: platform crossings and path length traveled during probe trial 24 h after completion of
training (two-tailed, unpaired Student’s t-test; platform crossings P = 0.036; path length P = 0.09).
D, Left panel: latency to platform during a 7-day Morris watermaze training protocol (n = 8
MUTpostnatal rapamycin group, n = 9 MUT-combined rapamycin group, two-way repeatedmeasures ANOVA: group main effect F(1,15) = 5.271, P = 0.037). Right panel: quadrant preference
during a probe trial 48 h after training (one-way repeated-measures ANOVA (MUT-postnatal group)
and ANOVA on ranks (MUT-combined group) with quadrant as between-subjects factor: F(3,21) =
12.831, P < 0.001; Chi-square = 4.600, 3 d.f., P = 0.204). E, Percent time spent freezing in shock
cage or safe cage after 1 day of training in a context discrimination protocol (n = 10 both groups;
two-tailed, paired Student’s t-test P = 0.009 (control untreated); P = 0.085 (control postnatal
rapamycin). F, Percent time spent freezing in shock cage or safe cage after 4 days of training in a
context discrimination protocol [n = 7 MUT-postnatal rapamycin group, n = 9 MUT-combined
rapamycin group; two-tailed, paired student’s t-test P = 0.014 (MUTpostnatal rapamycin group); P =
0.37 (MUT-combined rapamycin group)]. ∗P < 0.05, ∗∗P<, 0.01, ∗∗∗P<, 0.001. Data represent
means±SEM.
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Figure 2.7. Visual and motor control tasks for Morris water maze.
A, There was no difference in latency to finding a visual platform
between the two mutant groups. B, There was no difference in the
swim speed between the two mutant groups. Data represent
means±SEM.
After the completion of behavioral testing, we analyzed the brains of the
postnatal and combined groups to assess if 2.5 months of 2 mg/kg rapamycin treatment
changed the brain histology that was observed at P21 after daily 0.1 mg/kg rapamycin.
We found increased expression of phosphorylated S6 (240/244) above control levels
(Figure 2.8A). While 2 mg/kg rapamycin three times a week was enough to maintain the
health of the animals, it was not sufficient to suppress mTORC1 to control levels as we
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observed in the P21 brains. We also noted an increase in cortical thickness in the mutant
animals compared with controls that would also be consistent with increased mTORC1
activity. The increased pS6 was accompanied by an increase in GFAP (Figure 2.8B),
indicative of astrogliosis associated with mTORC1 hyperactivity as has been reported
previously [98, 108, 180]. Hippocampal and cortical organization, lamination and
myelination were unchanged compared with the histologic analysis observed at P21 after
daily 0.1 mg/kg rapamycin in the postnatal and combined groups (Figure 2.9).
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Figure 2.8. Effects of 2 mg/kg rapamycin on cortical phosphorylated S6 levels and
GFAP expression after behavioral testing. A, There is increased expression of pS6
levels in the cortex of both the postnatal and combined groups, indicating that 2 mg/kg
of rapamycin was not sufficient to maintain the mTORC1 inhibition observed at P21
after 0.1 mg/kg from Figure 2. B, The increased pS6 expression is accompanied by
cortical astrogliosis. C, Merge of A and B.
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Figure 2.9. Brain histology after 2 mg/kg
rapamycin and behavior testing. A, H and E
staining of the cortex. The cortex is thicker in
the treated mutant animals but appears well
organized. The postnatal treated brains are
thicker than the combined group. B, Cux1
immunohistochemistry. As seen at P21 after
0.1 mg/kg rapamycin, the mutant brains show
organized cortical layers II-IV, but the
postnatal group has more ectopic Cux1
positive cells in layers V and VI. C, MBP
immunohistochemistry. Myelination is not
affected by the 2 mg/kg rapamycin treatment
and remains well established. D and E, CC1
immunohistochemistry. Oligodendrocyte
distribution does not appear to be affected by
the 2 mg/kg rapamycin treatments, though the
thickness of the corpus callosum is increased
in the mutant brains. F, H&E staining of
hippocampus. The hippocampus of the
mutant animals remains well organized after
the 2 mg.kg treatment, though some ectopic
pyramidal cells remain in the stratum oriens of
the postnatal group as seen at P21 (arrows).
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2.4 Discussion
In this study we demonstrate the prevention of Tsc2-associated
neurodevelopmental abnormalities in a neuroglial mouse model of TSC using different
perinatal rapamycin treatment regimens. Prenatal, postnatal and combined rapamycin
treatment regimens were well tolerated and improved the overall health of Tsc2-hGFAP
mice. However, discontinuation of rapamycin at postnatal period ultimately led to death,
a finding consistent with previous reports [96, 97]. Of the three regimens tested, the
combined treatment was most effective in restoring histologic development of the cortex.
However, the observed reductions in cortical and hippocampal developmental
pathologies did not correlate with memory function. The postnatal-treated animals
performed better than the combined treatment group in two hippocampus-dependent
memory tasks.
The combined treatment, which targeted both in utero and postnatal
neurodevelopment, achieved a remarkable histologic rescue that was almost
indistinguishable from untreated control animals. The results of combined treatment
were an additive effect of rapamycin on prenatal and postnatal developmental events.
For example, the migration of cortical neurons to their appropriate layer is
predominantly a prenatal event. Only prenatal and combined treatments were able to
rescue the MZ and the distribution of Cux1-positive cells. Postnatal treatment had little
effect on antenatal neuronal migration defects. Likewise, postnatal and combined
treatments mainly affected developmental defects that are predominantly postnatal or
continue through the postnatal period such as oligodendrogenesis, myelination and the
later stages of hippocampal development [173, 175]. These results suggest
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developmental windows of opportunity for the perinatal rescue of TSC pathology with
rapamycin.
The Tsc2-hGFAP mutant mice used in this study died postnatally, even if
rapamycin treatment was maintained at 0.1 mg/kg given daily (Figure 2.1F). In order to
test the consequences of rapamycin treatment on learning and memory, 2 mg/kg
rapamycin was administered three times a week during behavioral testing. Although this
dosing was not adequate to suppress mTORC1 activation to control levels, it still has a
major clinical relevance and suggests that partial mTORC1 inhibition in human TSC
patients may be adequate to improve neurologic function.
Although both combined and postnatal groups appeared to learn the 7-day Morris
watermaze task, the performance of the postnatal group was found to be significantly
improved when compared with the combined treatment group (Figure 2.6C). This
improved performance was also observed when long-term memory was assessed, as
indicated by increased search times in the immediate vicinity where the platform was
previously located. Consistent with this, combined treatment animals were incapable of
performing a context discrimination task, suggesting that prenatal rapamycin exposure
has subtle effects that significantly affect memory consolidation in this group. As the
mTORC1 pathway participates in a number of processes critical for neurodevelopment
such as neuronal growth, axon guidance, synapse formation and myelination, disruption
of these processes could contribute to the observed memory dysfunction in the combined
treatment group [181-184]. Additional ultrastructural and dose–response studies would
be needed to assess these possibilities.
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The results of these and a previous study raise the feasibility of administering
lose-dose rapamycin to women carrying a TSC-affected fetus and/or treating TSCaffected children within the first few years of life [159]. Specifically we saw that daily
0.1mg/kg rapamycin treatment had a significant impact on the prenatal mutants but that
dose has minimal effects on the adults suggesting a different dose-response curve
between fetuses and mothers. Moreover, many TSC-associated functional deficits such
as epilepsy and autism spectrum disorders often manifest within the first few years of
life [155]. In utero medical treatment has precedence. Periconceptual folic acid
prevents neural tube defects [185]. Rapamycin is classified as a class C teratogen.
Animal studies suggest adverse effects on the fetus at higher doses, but there are no
well-controlled human studies. There have been a few reports of pregnant mothers
having received rapamycin in the transplant literature [186]. Most of the infants were
phenotypically normal; however, no formal follow-up cognitive testing has been done.
In spite of these observations, the negative effects of rapamycin on the behavior of the
combined treatment group suggests that more preclinical studies need to be done to
better assess the neuroanatomic and physiologic consequence of mTORC1 inhibition on
the developing mammalian brain. Nonetheless, the postnatal studies are perhaps more
encouraging and raise the possibility of clinical trial in infants or young children.
Further studies are needed to assess dosages that would be beneficial, but not induce a
failure to thrive phenotype as we and others have observed with high doses of rapamycin.
In summary, we demonstrate several novel developmental effects of rapamycin
on a neuroglial loss of heterozygosity model of TSC. These results suggest that
rapamycin treatment during the early perinatal period might be an opportune interval to
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treat developmental disorders caused by mTORC1 dysregulation. Partial mTORC1
rescue in human TSC patients may provide significant therapeutic benefit. Our results
will help better design future preclinical and clinical trials for TSC and other
mTORopathies.
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CHAPTER 3: mTORC1 ACTIVATION INDUCED ARRHYTHMOGENESIS
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3.1 Introduction
Mammalian target of rapamycin complex 1 (mTORC1) overactivity has been
implicated in many studies to be closely involved with epileptogenesis, a manifestation
of the hyperactive electrical signals in the central nervous system [91, 93, 187].
mTORC1 is also a strong candidate for pathologic cardiac hypertrophy and arrhythmias.
Many transcriptional, cell signaling, and metabolic changes accompanying mTORC1
signaling and the pathologic remodeling have been identified [188-190]. Prolonged
pathologic cardiac hypertrophy causes the heart to eventually decompensate, thus many
studies have focused on therapeutic methods to modulate mTORC1 signaling to halt or
even reverse the cardiac remodeling process [191-193]. However, the Framingham
Heart study identified that left ventricular hypertrophy is not only associated with
increased risk of heart failure, but it is also associated with sudden cardiac death due to
fatal arrhythmias [11-13].
Mechanisms of arrhythmias in hypertrophied hearts are complex. The most
consistent observations in arrhythmias in the hypertrophic myocardium are
heterogeneous increases in ventricular contraction and relaxation duration [13]. At the
cellular level, the ionic perturbations are often a result of alterations in calcium ion
handling proteins leading to prolonged action potential duration and repolarization [194196]. This remodeling of the electrical property of the myocardium can likely induce
arrhythmogenesis by the development of early and/or delayed afterdepolarizations, or
abnormal depolarization of cardiomyocyte that affect different phases of cardiac action
potential [197]. Early afterdepolarization is depolarization that affects either stage 2 or 3
of a cardiac action potential either because of decreased potassium ion channel
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conductance or increased inward calcium current [198, 199]. In contrast, delayed
afterdepolarization arises from resting action potential after the completion of
repolarization secondary to cytosolic calcium overload [198].
The development of arrhythmias may also arise from changes in gap junction
signaling that would delay the propagation of action potentials across the myocardium.
The degree of prolonged action potential duration is not uniform throughout the
hypertrophic heart. In some animal models, the degree of action potential duration
varied between epicardium and endocardium [200, 201]. At the cellular level, action
potentials propagate between adjacent cardiomyocytes through the intercalated disc.
Connexin 43 is a gap junction protein expressed at the intercalated disc and its retention
and function are regulated by several kinases including protein kinase A, protein kinase
C, MAPK, and casein kinase [202-208]. Hypertrophic hearts show decreased
phosphorylation and localization at the intercalated disc that correlate with slowing of
action potential conduction and an increase in overall contraction time [209-212]. Such
heterogeneous increase in depolarization duration is likely arrhythmogenic with altered
electrical gradients and abnormal repolarization [201]. Indeed, animal studies have
shown that dispersed repolarization and refractoriness within the hypertrophied
myocardium is susceptible to induced polymorphic ventricular tachycardia or ventricular
fibrillation [213-215].
Despite advances in understanding mechanisms of and novel therapeutics for
cardiac hypertrophy, the mechanism by which the stressed heart progresses from
structural and functional remodeling to electrical remodeling remains elusive [216].
Calcium ion homeostasis is central to establishing normal sinus rhythm and calcium
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mishandling is increasingly viewed as central point of disease-related electrical changes
[217, 218]. In the hypertrophic heart or the failing heart, calcium-handling channels and
transporters such as sarco-endoplasmic reticulum calcium ATPase (SERCA2a) displays
reduced expression and function [219, 220] whereas expression of the sodium-calcium
exchanger (NCX1) is increased [221]. While NCX1 expression increases in this model
of cardiac hypertrophy, the overall NCX1 current density is decreased due to either
decreased channel activity or membrane expression.
Calcium transport by NCX1 is a major mechanism of establishing normal
calcium homeostasis via removal of intracellular calcium during diastole [222]. NCX1
catalyzes the bidirectional exchange of three sodium ions for one calcium ion and works
in concert with sodium-potassium ATPase (NKA) to repolarize the cell. It has been
shown in vivo and in vitro that the cytoskeletal adapter protein ankyrin-B, encoded by
the ANK2 gene, is critical for the proper membrane targeting and functioning of NCX1
and NKA [2, 5, 133]. Recently, it was shown that ankyrin-B expression is altered in
cardiomyopathy and regulated by calcium-dependent pathways in similar fashion as
SERCA2a and NCX1. Yet, the link between cellular hypertrophic growth signaling and
the changes in electrogenic protein expression remain unexplored.
Cardiac hypertrophy is closely linked with cardiac arrhythmias [213-215] and
mTORC1 signaling is central in regulating cellular hypertrophic response [193, 223].
We propose that mTORC1 activity links cardiac hypertrophy to arrhythmia via
regulation of ankyrin-B expression.
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3.2 Materials and Methods
To determine the effects of mTORC1 on cardiac rhythm, we employed both in
vivo and in vitro methods to activate mTORC1. We first used an established in vivo
model of load-induced cardiac hypertrophy and examined the effects on cardiac rhythms
with electrocardiogram (EKG) recordings. EKG recordings and heart tissues were
obtained from 3 groups of animals: (1) mice chest cavities were exposed, aorta
visualized, but was not constricted (sham); (2) mice chest cavities were exposed, aorta
visualized, and was constricted (transverse aortic constriction, or TAC). They were
allowed a 1-week recovery period prior to 2-week DMOS vehicle administration; (3)
Another group of TAC’d mice were allowed a 1-week recovery period prior to 2-week
daily intraperitoneal administration of 2mg/kg rapamycin [stock 1mg/1mL DMSO and
diluted in 1x PBS prior to injection] (MP Biomedicals). A baseline EKG recording was
obtained in all groups prior to the start of vehicle or rapamycin administration. Figure
3.1 outlines the timeline for the in vivo experimental protocol.
We also employed an in vitro model of induced mTORC1 activity in primary
neonatal rat ventricular myocyte (NRVM) culture. We chose NRVM culture because
the dispersed NRVMs spontaneously and rhythmically contract in culture starting 1 day
after plating and express cardiomyocyte structures such as transverse-tubules and
sarcomeres. Whereas adult mouse cardiomyocytes are difficult to maintain in culture,
NRVMs are easier to isolate, culture, and readily transfected. This makes them an ideal
model for exploring signaling regulation for cardiomyocytes in vitro [224, 225].
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Induced mTORC1 activity was achieved by disrupting the direct upstream
inhibitor of mTORC1 - the tuberous sclerosis complex (TSC) - via siRNA knockdown of
tuberin, a TSC complex constituent containing GTPase activity [73, 226, 227]. We
examined the effects of mTORC1 on NRVM contraction rhythm by video recording of
the contractions in culture. Figure 3.2 outlines the timeline for the in vitro experimental
protocol.
All the animal experimental protocol was reviewed and approved by UTHSC
Animal Welfare Committee, Institutional Animal Care and Use Committee of Baylor
College of Medicine, or both. All animal surgeries were performed by Dr. Corey
Reynolds from BCM mouse phenotyping core lab.
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Figure 3.1. Three different sets of mice were utilized for the in vivo experiments. Sham mice had EKG
recordings obtained at 1 week and 3 weeks post-surgery. Half of the TAC mice had baseline EKG recordings
at 1 week post-surgery, subsequent daily vehicle (DMSO) treatment for 2 weeks, and final EKG recordings at 3
week post-surgery. The other half of the TAC mice underwent the exact experimental protocol as the vehicle
treated group with the exception of daily 2mg/kg rapamycin treatment instead of vehicle.
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Figure 3.2. Three different sets of treatment were utilized for the in vitro experiments: Untransfected, scramble
siRNA transfected, and Tsc2 siRNA transfected. Untransfected NRVMs had the culture media replaced at the
same time as scramble or Tsc2 siRNA treated cultures. Cultures were transfected with scramble or Tsc2 siRNA
on day 3 for 6 hours and subsequently washed and replaced with serum-free culture media. RNA extraction
occurred on day 5 to assess knockdown effects prior to day 6 protein extraction and contraction recordings.

3.2.1 Pressure-overload model (transverse aortic constriction)
An animal model of pressure-overload hypertrophy and heart failure was induced
by a transverse aortic constriction (TAC). Adult animals (8-week old C57BL/6) will be
used in the surgical preparation. Prior to anesthesia each animal will receive a dosage of
buprenorphine (0.1-2.5 mg/kg SC). We purchased this agent through Center for
Comparative Medicine (Baylor College of Medicine) per animal. The animal was then
anesthetized using 2% isoflurane in 100% 02. The neck and chest areas were prepared
by shaving and removing hair, cleansing the skin with surgical soap followed by wiping
with 70% ethanol. This procedure was repeated three times. Prior to surgery, all
instruments were sterilized in a dry bead sterilizer. The anesthetized animal was placed
in a supine position and a 5mm section of the trachea was carefully exposed by mid-neck
incision and retraction of muscle tissue. This allowed visualization for insertion of the
endotracheal tube which was a polyethylene size 90 tubing beveled on the edge for ease
of entrance through the larynx. The tongue was carefully manipulated as the
endotracheal tube was inserted into the trachea with visibility through a dissecting
microscope, viewing the trachea and entrance of the endotracheal tube. Once the proper
position was confirmed, the endotracheal cannula was connected to a volume-cycled
rodent ventilator (CWE, Inc.) which runs on supplemental 100% oxygen with a tidal
volume approximately 0.15-0.25ml and a respiratory rate of 100-125 breaths per
minute. Once steady breathing was established, an incision was made through the
ventral chest skin to mid-thorax after which the thorax was opened to mid-sternum. This
partial thoracotomy was followed by retracting the sternal edges with a retractor (Fine
Science Tools). The thymus was then retracted to expose the transverse aorta. Between
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the right innominate and left carotid artery, an aortic constriction was placed by tying a
6-0 suture black braided non-absorbable silk suture) against a 3mm length of 27 gauge
needle. After two knots, the 27 gauge needle was promptly removed which yielded a
constriction of approximately 0.3mm as the outer diameter of the 27 gauge needle. This
produced a 60-80% aortic constriction. The outflow was then briefly (1-2s) pinched off
on the respirator to allow re-inflation of the lungs. The retractor was removed and the
ribs were drawn together and sutured using 5-0 Prolene (blue monofilament
polypropylene suture). Once the chest was closed, the outflow was briefly pinched off
again to ensure proper breathing. The skin was then closed using 5-0 non-absorbable
monofilament sutures, which will be removed within 10 days post-surgery. Once all
sutures were in place, anesthesia was stopped and the animal was allowed to recover and
removed from the ventilator. The animal was monitored closely for any abnormal signs
of pain or labored breathing before being returned to the animal room. In case of any
signs of pain, the animal received another dosage of buprenorphine (0.1-2.5 mg/kg SC)
every 6-12 hours when needed. The degree of constriction was evaluated with a Doppler
flow study a week after the procedure on the Vevo ultrasound machine.

3.2.2 Mouse EKG monitor and analysis
The mouse was anesthetized with 2% isoflurane mixed with 100% oxygen. Once
sedation was obtained, the paws of the mouse were placed on the heated mouse monitor
pad (Indus Instruments) in a supine position and the feet were taped to the EKG leads.
A rectal probe was inserted for core body temperature monitoring during the procedure.
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EKG rhythms were then recorded from the mouse for offline analysis with Adobe
Photoshop (version 11.0, San Jose, CA, USA).
For each EKG recording, P-, Q-, R-, S-, and T-waves are identified on a cardiac
cycle. The following three parameters that assess the conduction system of the heart are
measured: (1) Time between start of the P-wave to start of the Q-wave (P-R interval); (2)
start of the Q-wave to end of the S-wave (QRS interval); and (3) start of the Q-wave to
end of the T-wave (Q-T interval). The same measurements are made for a total of 3
cardiac cycles per recording and repeated 2-3 times per each condition and animal. See
figure 3.3 for illustration of the EKG waveforms and parameters measured.

Figure 3.3. An example of each of the three parameters
measured for each cardiac cycle from the animal EKG
recordings. Reproduced with permission from Wagner, G.,
Marriott's Practical Electrocardiography (Wagner) Series.
11th edition 2007, Lippincott Williams & Wilkins [7].
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3.2.3. Isolation of adult mouse cardiomyocytes
Two to three mice from the Sham/TAC experiment were used for isolation, and
all solutions used for the procedure were sterile filtered. This protocol was adapted from
the method used in Dr. Heinrich Taegtmeyer’s lab at The University of Texas Health
Science Center at Houston [228].
The animals were anesthetized with avertin. Once anesthetized, the mouse was
rinsed with 70% ethanol followed by exposure of the abdominal cavity. The abdominal
aorta was visualized and injected with 0.1mL of 1000U heparin. Immediately, the chest
cavity was exposed and all organs in the chest cavity were removed quickly and placed
in ice-cold PBS containing no calcium or magnesium. Excise the heart cleanly from
other tissues but leaving the ascending aorta attached. The ascending aorta was
cannulated using a flat-tipped 22 gauge cathether attached to a sterile syringe containing
ice-cold perfusion buffer [120.4mM NaCl, 14.7mM Kcl, 0.6mM KH2PO4, 0.6mM
Na2HPO4, 1.2mM MgSO4-7H2O, 10mM Na-HEPES, 4.6mM NaHCO3, 30mM taurine,
10mM BDM, 5.5mM glucose in ddH2O and adjusted to pH 7.35 with HCl/NaOH] and
fastened with a micro clip. Some perfusion buffer was injected through the catheter and
into the aorta to ensure the success of the cannulation. Once cannulated, surgical knot
was tied with a suture around the micro clip, micro clip was removed, and the catheter
transferred to the primed Langendorff-style retrograde perfusion system containing
calcium-free and collagenase-free perfusion buffer at 370C. The heart was perfused at a
flow rate of 4mL/minute throughout. Initially, the heart was perfused with the calciumfree and collagenase-free perfusion buffer for 3 minutes followed by 15mL calcium-free
digestion buffer [perfusion buffer with 2.4mg/mL collagenase type II (Worthington)].
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Finally, it is perfused with digestion buffer containing collagenase type II and 40µM
CaCl2 for an additional 6-8 minutes until the heart appears pale. This indicates a
successful digestion of the extracellular matrix.
After completion of the digestion process, the heart was removed from the
perfusion apparatus and transferred to a 60mm2 dish containing 5mL stopping buffer
[4.5mL perfusion buffer containing 100µM CaCl2, and 0.5mL FBS]. The catheter was
removed with the suture and heart was cut into small pieces in the stopping buffer. The
pieces were further dispersed by mechanical trituration with a transfer pipette. The
digested suspension was filtered through a 100µm-cell strainer into a 50mL conical,
transferred to a 15mL conical, and centrifuged at 300rpm at 4oC for 5 minutes. The
supernatant was immediately removed, and cell pellet was resuspended and fixed in
100% ice-cold ethanol. The fixed cells were kept in 100% ethanol and stored in -20oC
until further processing.

3.2.4. Isolation of neonatal rat ventricular cardiomyocytes
1-2 days old neonatal Sprague-Dawley rats (Texas Animal Specialities, Humble,
TX) were used to isolate neonatal rat ventricular cardiomyocytes. The isolation was
performed under sterile conditions in the tissue culture hood and all solutions were
sterile filtered in the hood. This protocol was adapted from the method used in Dr.
Heinrich Taegtmeyer and Dr. Diane Bick’s lab at The University of Texas Health
Science Center at Houston [228].
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The neonatal rats were rinsed with 70% ethanol three times. They were
decapitated, chest cavity exposed quickly and heart removed and placed in warmed 1x
ADS buffer [6.8g NaCl, 0.4g KCl, 1.5g NaH2PO4, 1g glucose, 0.1g MgSO4, 4.76g
HEPES, pH to 7.38 with HCl/NaOH, and brought up to 1 L with ddH2O]. Hearts were
rinsed once more with fresh 1x ADS when all hearts have been collected, then cut into
quarters with fine forceps to minimize tissue destruction. The cut tissues were
transferred to a 25mm2 culture flask containing 9mL of digestion buffer [0.6mg/mL
pancreatin (Sigma P-3292-25g) and 73U/mL collagenase type II (Worthington) in 1x
ADS] for a maximum of 15 hearts. Hearts were incubated in the flask for 20 minutes at
370C while shaking at 140rpm. Supernatant from this first digestion was discarded and
replaced with 9mL fresh digestion buffer for a total of four replacements. At the end of
the final digestion, a transfer pipette was used to gently triturate the remaining
undigested heart tissues in warm 1x ADS. Supernatant from all except for the first
digestion was collected, centrifuged for 5 minutes at 300g at room temperature and the
resultant supernatant discarded and pellet suspended in warmed 2mL fetal bovine serum
(Gibco). The resuspensions were pooled together and kept in incubator at 370C and 5%
CO2 until all digestion steps were completed.
The resuspensions were centrifuged for 5 minutes at 300g, supernatant discarded,
and the pellet was resuspended in warm 1x ADS at 1mL/heart harvested. The
resuspension were pre-plated in 6-well Nunc plates (Thermo Fisher Scientific) at 2mL
per well and kept in incubator for 2-5 hours to decrease the number of fibroblasts in the
final cardiomyocyte culture. The media from each well was collected without disturbing
the bottom layer and centrifuged for 5 minutes at 300g. The resulting supernatant was
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discarded and pellet was resuspended in complete media [500mL DMEM, 50mL BCS,
5mL of 100U/mL penicillin/streptomycin] at 1mL/heart harvested. Cells were counted
with Trypan Blue solution and plated at 1 million cell/well in a 6-well Primaria plate
(Fisher/Corning Life Sciences) or 1 x 105 cells per fibronectin-coated glass-bottom MatTek plate (MatTek Corporation).

3.2.5. Tissue and cell protein extraction and quantification
Two to three hearts from each treatment group outlined in 3.2 were snap frozen
in liquid nitrogen. Protein was isolated from snap-frozen heart tissues using sucrose
lysis buffer (1:4 weight to volume) containing 25mM sucrose, 1mM EDTA, 10mM Tris
HCl, 1mM PMSF (a protease inhibitor), and phosphatase inhibitor cocktail. Tissues
were pulverized in liquid-nitrogen chilled mortar and pestle then homogenized in a
dounce homogenizer on ice. Lysates were centrifuged at 4˚C for 13,000g for 15 minutes
and supernatant recovered.
Cells were washed in ice-cold 1x PBS twice, then scraped and collected in the
presence of ice-cold cell lysis buffer (5mM HEPES pH 7.4, 0.1mM EDTA pH 8.0,
0.1mM MgCl2, 0.1mM DTT, 1% Triton-X, 150mM NaCl, 1 Mini-Tab protease inhibitor
(Roche) per 10mL of lysis buffer, and 100µL of each phosphatase inhibitor cocktails 2
and 3 (Sigma) per 10mL of lysis buffer. Lysate was triturated 10-15 times on ice
through a 1mL 27.5 gauge syringe, then underwent 3 rapid freeze/thaw cycles with dry
ice in ethanol and 37oC water bath. The lysate was then sonicated on ice for 3 seconds
then centrifuged at 13,000g for 10 minutes at 4oC, and the supernatant was recovered.
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The protein concentration from each tissue/cell sample was quantified using
colorimetric Bradford Protein Assay (BioRad). A series of known BSA protein
concentrations were diluted to generate a standard curve (1-10 µg/µL). Protein samples
were diluted 5- to 10-fold and each diluted sample at two distinct amounts (2 µL and 5
µL) were added to 200 µL of Bradford reagent in a 96-well plate. The absorbance was
read on a microplate reader and each sample protein concentration was determined based
on the standard curve.

3.2.6. Immunoblot assay
0.1mM DTT and 4x loading dye were added to equal quantities of protein lysates
from 3.2.5 and heated at 70oC for 15 minutes. Protein lysates were then separated by
SDS-PAGE and transferred onto a PVDF membrane (Bio-Rad) using XCell II Blot
Module (Invitrogen). Membrane was washed with 1x TBST (0.1% tween-20) and
blocked with 5% nonfat milk in 1x TBST for an hour at room temperature to block nonspecific binding on the membrane. Membrane was incubated at 4oC in primary antibody
solution (5% milk or BSA in TBST) overnight. Primary antibody was then washed off
and incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour at
room temperature. Protein of interest was visualized using SuperSignal West Pico
Chemiluminescent Substrate kit (Pierce). Primary antibodies used were: tuberin (1:500;
Cell Signaling), phospho-S6 (1:500; Cell Signaling), S6 (1:500; Cell Signaling), panankyrin-B [229], ankyrin-G [142], ankyrin-R (1:500; Aviva System Biology), NCX1
(1:500; Swant), and GAPDH (1:20,000; Fitzgerald).
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3.2.7. Fluorescent immunocytochemistry
Cells isolated and cultured from 3.2.4 were washed twice with ice-cold 1x PBS
and fixed in 2% paraformaldehyde for 15 minutes at room temperature and cells
collected from 3.2.3 were washed in ice-cold phosphate-buffered saline (pH 7.4) 3 times.
Cells were then blocked with 5% normal goat serum and 0.075% TritonX-100 for 30
minutes at room temperature then incubated in primary antibodies overnight at 4°C. The
primary antibodies used were: tuberin (1:500; Cell Signaling), phospho-S6 (1:500; Cell
Signaling), pan-ankyrin-B [229], ankyrin-G [142], ankryin-R (1:500; Bethyl
Laboratories), Myomesin (1:500; Developmental Studies Hybridoma Bank/University of
Iowa), α-actinin (1:1000; Sigma). Secondary antibodies used were goat anti-rabbit
conjugated to Alexa Fluor 488 and goat anti-mouse conjugated to Alexa Fluor 568
(1:500, LifeTechnologies). Hoechst 33258 (1:1000, LifeTechnologies) was used for
nuclear staining after removal of the secondary antibody. ProLong® Gold Antifade
reagent (LifeTechnologies) was used for mounting coverslips. Images were obtained
with a Nikon A1 confocal microscope (Nikon, Melville, NY) equipped with 60X oil,
numerical aperture 1.4 objective lens.

3.2.8. NRVM RNA interference experiments
The siRNA duplexes targeting rat TSC2 and non-targeting siRNA control
(scramble) were purchased from Sigma. The siRNA was diluted in Tris-EDTA buffer
[10mM Tris, 1mM EDTA, pH to 7.0 with HCl/NaOH] to a stock concentration of 25µM.
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Prior to transfection, amount of siRNA calculated to have a final concentration of
100nM was mixed with Opti-MEM (Thermo Fisher Scientific). Separately,
DharmaFECT® (Dharmacon GE) [4µL per 2mL of culture media] was mixed with OptiMEM. After 5 minutes of incubation, the two are mixed together and allowed 15-20
minutes of incubation in room temperature prior to application to serum-free DMEM.
The NRVMs were transfected for 6 hours with 100nM of each siRNA, then media was
changed to fresh serum-free DMEM. Media change was the same for untransfected
controls. Experiments with transfected NRVMs were performed 48 hours later for
quantitative real-time PCR and 72 hours later for immunoblotting and cell contraction
recordings. The sequence of siRNA is as follows:

TSC2 siRNA sequence 1 starts on target 1092
sense: 5’-GAGAUUGUUCUGUCCAUAA[dT][dT]-3’
anti-sense: 5’-UUAUGGACAGAACAAUCUC[dT][dT]-3’
TSC2 siRNA sequence 2 starts on target 3271
sense: 5’-GAAAUAAGCUGGUCACUGU[dT][dT]-3’
anti-sense: 5’-ACAGUGACCAGCUUAUUUC[dT][dT]-3’
Scramble siRNA sequence
sense: 5’-GCUCCCAGCUCGUCUAUGU[dT][dT]-3’
anti-sense: 5’-ACAUAGACGAGCUGGGAGC[dT][dT]-3’
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3.2.9. Measurements of mRNA expression
Total RNA was extracted from NRVM with PerfectPure™ RNA Cell and Tissue
kit (5 Prime). cDNA synthesis from 500µg of total RNA was performed using
SuperScript III reverse transcriptase (LifeTechnologies) with random hexamers.
Transcript expression levels of TSC2 and GAPDH were measured in triplicate by
quantitative real-time (qt)-PCR using SYBR Green Dye (Bio-Rad). Transcript levels of
TSC2 were adjusted to the expression of GAPDH. The sequence of PCR primer
targeting junction of TSC2 exons 23/24 is as follows; 5’GACTAGACAG/CGTGAGATGG (slash indicates junction of exon 23 and 24)-3’ and
3’-GCTAGCTGTAGCAGAGATGTG-5’ for TSC2; targeting junction of GAPDH exons
6/7: 5’-CATCACTGCCACTCAGAAGAC-3’ and 3’-CATACTTGGC/AGGTTTCTCC
(slash indicates junction of exon 6 and 7) – 5’

3.2.10. NRVM syncytium contraction recording and analysis
A Mat-Tek plate with NRVMs was placed in a warm humidified chamber on a
flat stage of a light microscope (Micromaster; Fisher) with 10X magnification eyepiece
and 20X objective lens. A cell phone camera with 10 megapixel resolution (HTC One
M8) was mounted on the microscope using Snapzoom Universal Digiscoping Adapter
(Snapzoom). Once a NRVM syncytium was located visually, the contractions were
recorded for 2 to 2.5 minutes. The same recording method was used for recording of the
syncytia following stimulation with 1µM epinephrine.
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Using Video Spot Tracker (VST) program (http://cismm.cs.unc.edu/downloads)
and using the tracking method as described by Fassina et. al. [230], we placed a marker
on the contracting syncytium for each video recording in the program. By starting the
video, the program tracked the marker displacement frame by frame (30 frames per
second) and registered the spatial-temporal coordinates x, y, (expressed in pixels), and t
(expression in frame number that converts to second) of the marker. The coordinates are
plotted in Excel (Microsoft) and each peak corresponds to an active syncytial contraction.
We then assessed the rhythmicity of the syncytial contractions by randomly picking a
consecutive 30-second interval then measuring the time between contractions. Figure
3.4 is an example of the spatial-temporal pattern of marker displacement. The time
interval between contractions is plotted on GraphPad (GraphPad Software) as box-andwhisker plots.
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Figure 3.4. Example of marker displacement tracking. The peaks and troughs are identified as
contractions and relaxations, respectively. The interval between peaks is used to measure the time
between contractions. The 3 red double arrows in this figure are used as illustration for how the time
between contractions are measured. X-axis, time (seconds); y-axis, location of the marker (pixels);
blue line, marker displacement.

3.3 Results
3.3.1. Electrical remodeling in response to chronic load-induced hemodynamic
stress in vivo
We hemodynamically stressed the heart with increased load via transverse aortic
constriction (TAC) to induce mTORC1 activation as evidenced by the increased
phosphorylation of the ribosomal protein S6. Daily treatment with rapamcyin, a known
mTORC1 inhibitor, reduced the phosphorylation of S6 to baseline in the TAC group
(Figure 3.5A).
To determine the effects of chronic mTORC1 activation on the electrical
property in the heart, we obtained EKG for sham, TAC with vehicle treatment, and TAC
with rapamycin treatment groups 1 week (recovery period with no drug administered)
and 3 weeks (with drug treatment) post-surgery. We focused on three EKG parameters
including P-R interval, Q-T interval, and QRS duration. P-R interval measures the
conduction time of depolarization from sinus atrial (SA) node in the atria through the
atrioventricular (AV) node to the ventricles. Q-T interval measures the time between
ventricular depolarization and repolarization. QRS duration measures ventricular
depolarization time. There was not a statistically significant change in P-R interval and
Q-T interval between sham and TAC groups at 1 week post-surgery. However, we
observed a slight yet statistically significant increase in the QRS duration in the TAC
mice (Sham 15.90±0.51 ms, TAC Vehicle 19.59±1.44 ms, and TAC Rapa 18.55±0.87
ms. *p<0.05 between Sham and either TAC groups) (Figure 3.5B).
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At 3 week post surgery, P-R interval increased to an average of 42ms in TAC
treated with vehicle but normalized to 35ms with rapamycin treatment. The increased
duration confirms the findings by Zhang C et. al.[75] and represents a significant firstdegree heart block. Q-T interval decreased in both TAC groups treated with vehicle or
daily administration of rapamycin at 2mg/kg/day. QRS duration was similar between all
groups at the end of the experiment (Figure 3.5C). Thus, sustained mTORC1 activity
partially affected the electrical property of the myocardium. Specifically, the conduction
between the atria and the ventricle was delayed. Decreased Q-T interval in TAC with or
without rapamycin demonstrated the contributions of mTORC1-independent pathways
in electrical remodeling of the hemodynamically stressed heart.
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Figure 3.5. mTORC1 activity and electrical remodeling in hearts subjected to high
workload in vivo. Treatment with rapamycin rescues the conduction from atria to
ventricles. A, Representative Western blots demonstrated an increase in S6
phosphorylation 3 week after TAC surgery and the phosphorylation returns to baseline
with rapamycin treatment. B, Graph showing the three measured EKG parameters (P-R
interval, Q-T interval, and QRS duration) at the end of 1 week recovery after TAC
surgery. No drug treatment is yet administered at this time. No difference is seen in P-R
interval and Q-T interval between groups. However, QRS duration increases slightly in
the TAC groups (Sham 15.90±0.51 ms, TAC Vehicle 19.59±1.44 ms, and TAC Rapa
18.55±0.87 ms). C, Graph showing the three measured EKG parameters 3 weeks after
TAC surgery and with either vehicle or rapamycin treatment. P-R interval increases
significantly in the TAC Vehicle group, but returns to baseline with rapamycin treatment
(Sham, 35.68±1.47 ms, TAC Vehicle 41.37±2.5 ms, TAC Rapa 35.05±1.76 ms). Q-T
interval remains decreased in both TAC Vehicle and TAC Rapa groups suggests
mTORC1-independent processes may play a role in electrical remodeling (Sham
67.46±3.13 ms, TAC Vehicle 54.83±2.40 ms, TAC Rapamycin 54.16±3.65 ms).
*p<0.05 vs sham, #p<0.05 vs TAC Rapa. n = 6 for each group. TAC, transverse aortic
constriction; Rapa, rapamycin.

3.3.2. Ankyrin proteins expression changes in response to chronic load-induced
hemodynamic stress and mTORC1 inhibition
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Ankyrin proteins (ankyrin-B, -G, and –R) are adapter proteins pivotal in the
regulation of normal cellular physiology. A wide spectrum of arrhythmias (e.g. sinus
node disease, atrial fibrillation, and polymorphic ventricular tachycardia) have been
directly linked with loss-of-function mutations in the adapter protein ankyrin-B (ANK2)
[3, 5, 229].

Another specific type of arrhythmia characterized by S-T segment

elevations, atrial fibrillation, and sudden cardiac death known as Brugada syndrome has
been linked with disrupted interaction with ankyrin-G (ANK3) [142, 231]. Finally,
although not yet linked to any arrhythmia phenotype, ankyrin-R (ANK1) has been shown
to play an important role in calcium regulation - central to the integrity of the excitationcontraction coupling that establishes the normal rhythm and contraction of the
myocardium - via establishment and maintenance of normal sarco-endoplasmic
reticulum (SR) structure essential for normal functioning of sarco-endoplasmic reticulum
calcium ATPase 2a (SERCA2a) [232-235]. To date, there is limited data in regulation
of ankyrin-B [216], and no evidence yet exists for either ankyrin-G or ankyrin-R,
expression in the stressed heart.

Mechanisms that link structural and electrical

remodeling in the stressed heart are also lacking.
mTORC1 signaling has been identified as a central regulator of cardiac
hypertrophic growth [190, 192, 193] and modulates the expression of the calcium
handling protein SERCA2a [236]. However, mTORC1 activity has not been shown to
directly affect the function or the expression of sodium-calcium exchanger (NCX1) [237,
238], another essential calcium regulator, despite increased NCX1 expression in the
stressed heart [239, 240]. Yet, it was reported that NCX1 current decreases in an animal
model of pressure-overload cardiac hypertrophy [221].
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NCX1 proper membrane localization and function requires direct interaction with
adapter protein ankyrin-B [2, 133].

Reduced ankyrin-B expression reduces NCX1

function and localization to the transverse-tubule [4, 132]. Hence we assessed whether
mTORC1 affects NCX1 function and localization via regulation of ankyrin-B.
Consistent with the published data, NCX1 expression increased in our
hemodynamically stressed hearts and decreased when the hypertrophic process was
attenuated [221, 239, 241]. Using the same set of heart samples, we evaluated the
effects of mTORC1 activity on ankyrin-B expression. When mTORC1 activity was
unopposed, in the TAC Vehicle group, ankyrin-B expression was significantly decreased
compared with the sham control.

However, attenuation of mTORC1 activity with

rapamycin administration partially restored ankyrin-B expression (Figure 3.6A).
We also assessed the effects of mTORC1 activity on the subcellular localization
of ankyrin-B using isolated cardiomyocytes from the stressed heart. In addition to
overall generalized decreased expression, ankyrin-B localization also appeared to be
slightly dispersed in the TAC Vehicle group compared to the sham control. Treatment
with rapamycin (TAC Rapa group) not only restored ankyrin-B expression but also
restricted the dispersion and the subcellular level (Figure 3.6B).
Other important factors in the regulation of calcium homeostasis are sarcoendoplasmic reticulum calcium ATPase (SERCA2a) expression and function and its
proper localization at the sarcoplasmic reticulum (SR).

Although alterations in

SERCA2a function and expression may not be the initial cause of cardiomyopathy, the
contributions to the consequent development of arrhythmia in the hypertrophic heart are
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well-documented [219, 220, 242].

More recently, it has been shown that SERCA

expression, proper localization, and function are regulated by the adapter protein
ankyrin-R in striated muscle [232, 233]. Given that mTORC1 modulation alters levels
of SERCA2a expression in the heart [23, 44, 236], we evaluated whether mTORC1
affects SERCA2a expression by regulating ankyrin-R expression.
When we mechanically triggered mTORC1 activation in vivo by pressure
overloading the heart (TAC), our results showed that ankyrin-R expression clearly
decreased similar to findings in SERCA2a. However, whereas mTORC1 inhibition with
rapamycin in the stressed heart somewhat normalized SERCA2a expression, we did not
observe any change between rapamycin or vehicle treated TAC mice. This pointed to
the possibility of ankyrin-R regulation by mechanisms independent of mTORC1
signaling (Figure 3.6A).
In addition to the calcium regulatory function of NCX1, intercellular electrical
conduction to facilitate the transfer of current from one cardiomyocyte to another at the
intercalated discs is another important mechanism in establishing normal cardiac rhythm.
Key components of the intercalated disc include the gap junction protein connexin43
(Cx43), voltage-gated sodium channel (Nav1.5), and desmosomal protein plakophilin-2
(PKP2), and all three exhibit decreased expressions in cardiomyopathies involving
arrhythmias [23, 243, 244]. Central to this molecular complex involving these three
proteins is ankyrin-G that interacts, targets, and maintains these proteins at the
intercalated disc [142, 231, 245]. We asked how ankyrin-G expression changes in the
hemodynamically stressed heart.

80

Using our TAC model, our results indicated that ankyrin-G expression is
markedly decreased in pressure overloaded hearts.

Regression of the cardiac

hypertrophic process and inhibition of mTORC1 with rapamycin treatment did not
attenuate the effects of pressure overload and normalize the expression of ankyrin-G
(Fig 3.6A). Similar to ankyrin-R, this suggests the possibility of other mechanicallytriggered pathways other than mTORC1 that is responsible for regulating the expression
of ankyrin-G.
Collectively, our results suggest that mTORC1-responsive and mTORC1independent factors contribute to arrhythmogenesis in the hypertrophied hearts. Among
the three ankyrin proteins each with its unique set of interacting proteins, ankyrin-B
appears to be the only one regulated by mTORC1 whereas ankyrin-R and ankyrin-G are
mechano-sensitive but not mTORC1-specific. This idea is in line with our observations
of the EKG changes in TAC Vehicle and TAC Rapa mice. We observed normalization
of the P-R interval in the pressure-overload hearts with rapamycin treatment but it had
no effect on the Q-T interval (Figure 3.5B and 5C).
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Figure 3.6. Effects of in vivo pressure overload on ankyrin-B, -G, and –R. A, Representative
Western blots showing decreased ankyrin-B, -G, and –R expression in response to transverse
aortic constriction. Treatment with rapamycin partially restored the level of ankyrin-B but had
not effect on levels of ankyrin-G and –R. NCX1, one of the interacting partners of ankyrin-B,
had increased expression in response to pressure overload and normalized with rapamycin
treatment. B, Fluorescent immunocytochemistry of individually isolated adult mouse
cardiomyocytes from sham control, TAC mice treated with DMSO vehicle, and TAC mice treated
with rapamycin. In sham control, majority of the ankyrin-B population is concentrated at the Mline demonstrated by its localization in between the Z-line marker α-actinin whereas the minor
population is localized at the Z-line. In contrast, the relative intensity of ankyrin-B decreases at
the M-line and is not observed at the Z-line in TAC mice treated with DMSO vehicle.
Furthermore, ankyrin-B population at the M-line shows some degree of dispersion. Rapamycin
treatment reversed the expression and dispersion effects. Insets are shown to the right of the
corresponding images. Green, ankyrin-B; red, α-actinin; blue, Hoechst. TAC, transverse aortic
constriction; Rapa, rapamycin.
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3.3.3 Effects of in vitro mTORC1 activation on ankyrin-B expression
The induced biomechanical stress with transverse aortic constriction directly
activates numerous intracellular signaling pathways other than mTORC1 as well as
paracrine and autocrine signaling. These include, but are not exclusive to, mitogenactivated protein kinase (MAPK) pathway, angiotensin II signaling, endothelin-I, and
calcium/calmodulin-dependent kinase (CaMKII) [16, 82]. Hence, we wondered whether
the findings observed in vivo with ankyrin-B and mTORC1 correlate with increased
mTORC1 activity in vitro.
One strategy to elicit the regulatory mechanism between mTORC1 and ankyrinB is by selectively activating mTORC1 without directly affecting other signaling
pathways. mTORC1 becomes activated when its cellular negative regulator tuberous
sclerosis complex (TSC) is disrupted [226, 246]. TSC is a heterodimer composed of the
proteins hamartin (Tsc1) and tuberin (Tsc2), and deletion of tuberin has been
demonstrated to lead to overt mTORC1 activation [73, 98, 99].
We used siRNA against Tsc2 to activate mTORC1 in primary neonatal rat
ventricular myocyte cultures (NRVM) and studied the effects on ankyrin-B expression.
NRVMs transfected with scramble siRNA served as controls. QT-PCR of extracts of
NRVMs showed approximately 50% reduction in TSC2 transcripts with either TSC2 (1)
or TSC2 (2) siRNA transfected compared to the untransfected or the scramble siRNA
transfected (Figure 3.7A). Western blots showed a similar decrease in levels of tuberin
for NRVMs transfected with TSC2 (1) or TSC2 (2) siRNA compared to either of the
controls.
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As expected, mTORC1 becomes more active when the TSC complex is disrupted
by the knockdown of tuberin as measured by levels of phosphorylated ribosomal protein
S6 - a well-characterized downstream target of mTORC1 [69, 247]. And similar to the
results we obtained from the TAC mouse hearts in vivo, selective mTORC1 activation in
vitro reduced levels of ankyrin-B expression (Figure 3.7B). This further suggests that
mTORC1 activity regulates ankyrin-B.

A

B
Scramble
Untransfected
(2) siRNA
TSC2TSC2
(1) siRNA

Tsc2
pS6
S6
pan Ankyrin-B
GAPDH

Figure 3.7. Selective mTORC1 activation reduces ankyrin-B exression in vitro. A, TSC2
transcripts are reduced in NRVM cultures transfected with either siRNA sequences against TSC2.
TSC2 transcripts are not affected in either the untransfected or cultures transfected with scramble
siRNA. B, Tuberin protein is reduced in NRVM cultures transfected with either siRNA sequences
targeting TSC2 and is not affected in the untransfected or scramble siRNA control transfected
cultures. Ribosomal protein S6, a mTORC1 target, is phosphorylated demonstrating increased
mTORC1 activity when tuberin is knocked down. Ankyrin-B expression decreases when mTORC1
is active.
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3.3.4 In vitro mTORC1 activation alters ankyrin-B subcellular expression
siRNA targeting TSC2 to activate mTORC1 in vitro obviated the use of
mechanical force to activate mTORC1 as in the TAC hearts. Individually isolated
cardiomyocytes from pressure-overloaded hearts showed decreased ankyrin-B
expression and dispersion (Figure 3.6B). We now assessed the whether similar changes
can be recapitulated using the in vitro method.
Because the NRVM isolation procedure was not completely selective for
cardiomyocytes as some cardiac fibroblasts continued to remain in culture, we
performed fluorescent immunocytochemistry staining for Tsc2 to ensure that Tsc2 was
removed from the cardiomyocytes. We observed that Tsc2 staining was either absent or
significantly decreased in majority of the cardiomyocytes transfected with TSC2 siRNA
(Figure 3.8A). This finding also corroborated our results in figure 3.7.
Using the same technique, we assayed for the subcellular localization of ankyrinB.

Similar to the cardiomyocytes from TAC hearts, ankyrin-B expression in the

NRVMs transfected with TSC2 siRNA was decreased dramatically but displayed no
dispersion at the M-line. Interestingly, while the TAC cardiomyocytes demonstrated an
overall decrease in ankyrin-B expression at both the M-line and the transverse-tubule,
the TSC2 siRNA treated NRVMs appeared to have an increase in ankyrin-B expression
at the transverse-tubule (Figure 3.8B).
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Figure 3.8. Selective mTORC1 activation changes ankyrin-B expression differently at different
subcellular domains in vitro. Fluorescent immunocytochemistry of neonatal rat ventricular myocytes
(NRVM) transfected with siRNA targeting TSC2, scramble siRNA control, or untransfected.
Myomesin is used as a marker for the sarcomeric M-line and to differentiate NRVMs from fibroblasts
in staining. A, Tsc2 (tuberin) expression is either absent or dramatically decreased in the NRVMs
transfected with TSC2 siRNA compared to either of the control. Green, Tsc2 (tuberin); red, myomesin
(M-line marker); blue, Hoechst. B, Ankyrin-B expression at the M-line is decreased in the TSC2
siRNA transfected NRVMs and no dispersion is observed. However, ankyrin-B intensity at the
transverse-tubule (midway between two M-lines) is increased relative to the M-line population and the
transverse-tubule population of either of the controls. Insets are shown to the right of the corresponding
images. Green, ankyrin-B; red, myomesin; blue, Hoechst.
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3.3.5 Physiologic consequences of in vitro mTORC1 activation
Our in vivo study with the hemodynamically stressed hearts demonstrated
increased mTORC1 activity and abnormal EKG changes (Figure 3.5), we evaluated the
functional consequences of mTORC1 activation on cardiomyocyte contraction rhythms.
We tracked the contraction patterns of the NRVMs transfected with TSC2 siRNA and
compared them against the untransfected and scramble siRNA transfected controls. In
the absence of any exogenous stimulation, NRVM transfected with TSC2 siRNA in
general contracted slower and had a higher variability in time interval between
consecutive contractions. The box and whisker plot for TSC2 siRNA demonstrated an
increased and a wider spread in the timing between contractions relative to the
untransfected and scramble siRNA controls (Figure 3.9).
When stimulated with exogenous β-receptor agonist that increases the rate of
contraction by increasing the cycling rate of intracellular calcium, we observed an
overall increase in contraction rate as shown by the decrease in time between
contractions for all three groups. However, administration of epinephrine to the TSC2
siRNA group further enhanced the contraction time variability.

This suggests an

underlying calcium handling dysfunction when mTORC1 is overactive and that it is
further exacerbated by the pharmacologic stress with epinephrine application (Figure
3.9).

89

Figure 3.9. mTORC1 activation leads to arrhythmic contractions of NRVMs in vitro.
Contractions of untransfected, scramble siRNA transfected control, and TSC2 siRNA
transfected are recorded, and time between contractions was measured. Smaller time
between consecutive contractions equates to faster contraction rate and vice versa.
TSC2 siRNA transfected NRVMs tend to have a slower and a wider range of contraction
rates compared with either of the controls. When pharmacologically stressed by
epinephrine, all three groups tend to have similar contraction rates although TSC2
siRNA + Epi group displayed an even wider range of contraction rates. n = 5-7 NRVM
syncytia per group and 30 seconds of recording was analyzed per n.
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3.4 Discussion
A prominent mechanism of death in heart failure patients is arrhythmia leading to
inadequate delivery of oxygen and nutrient to vital tissues. Mortality rate for patients
with advanced heart failure is as high as 50% per year [14]. However, despite the
advances in preserving cardiac function in heart failure, existing anti-arrhythmic
therapeutics remain ineffective largely because the understanding of the mechanism
linking structural heart disease and electrical abnormalities in the failing heart remains
inadequate.
In the hypertrophic heart, expression and function changes in ion channels and
transporters have been documented in an animal study conducted by Zhang C et. al.[75]
They demonstrated electrical changes and inducible malignant arrhythmias at the tissue
level secondary to pressure-overload cardiac hypertrophy. At the same time, when
angiotensin II type 1 receptor was pharmacologically inhibited in the pressure-loaded
hearts, many of the changes in the electrophysiology parameters were attenuated
suggesting that underlying signaling changes associated with heart failure not only
affects structural remodeling, but may also affect electrical remodeling [75]. However,
the mechanism by which electrical properties of the heart is affected by pro-hypertrophic
signaling pathways remains to be elucidated.
A well-characterized cellular hypertrophic signaling pathway that underlies the
development of pressure-overload cardiac hypertrophy is the mammalian target of
rapamycin complex 1 (mTORC1) signaling. Genetic studies and mechanically stressed
hearts with activated mTORC1 recapitulated many signaling, structural, functional, and
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electrical abnormalities observed in hypertrophic cardiomyopathy [23, 24, 193, 248].
Most importantly, calcium cycling, important for establishment of normal contractility
and excitation-contraction coupling in cardiomyocytes, was dysregulated in these animal
models. Conversely, when mTORC1 activity was inhibited with either rapamycin or
metformin, many of the pathologic remodeling, especially abnormal calcium handling,
were either attenuated or reversed [192, 236, 249].
Major calcium handling proteins in cardiomyocytes include sarcoplasmicreticulum calcium ATPase (SERCA2a), SERCA2a-accesory protein phospholamban,
and sodium-calcium exchanger (NCX1). SERCA2a actively transports cytosolic
calcium ions into sarcoplasmic reticulum during the relaxation phase of a heartbeat
allowing for repolarization and phospholamban modulates levels of SERCA2a activity.
On the other hand, NCX1 extrudes the remaining cytosolic calcium to the extracellular
space using sodium gradient as the driving force. In cardiomyopathy, changes in
expression and activity of the calcium handling proteins results in altered calcium
cycling - a pathologic hallmark of heart failure - that leads to defects in excitationcontraction coupling and reduced contractility [250]. Whereas SERCA2a and
phospholamban have marked reduction in expression [23, 236], NCX1 shows increased
expression that is likely an adaptive response to compensate for SERCA2a
downregulation [251-253]. Interestingly, studies have shown that although NCX1
expression is increased in the stressed heart, the overall NCX1 current actually decreases,
suggesting another level of regulation for NCX1 activity in the hypertrophic heart [221,
254].
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Normal functioning of NCX1 requires precise localization and retention at the
transverse-tubule [255, 256]. The molecular mechanism required for the targeting and
maintenance of NCX1 at this specialized cardiomyocyte membrane domain was recently
identified to be an adaptor protein, ankyrin-B. Ankyrin-B binds, coordinates, anchors,
and is required for the post-translational stability of NCX1 at the transverse-tubule to the
underlying cytoskeleton [2, 133, 257]. Cardiomyocytes deficient in ankyrin-B show
decreased NCX1 expression and exhibit abnormal spontaneous contractions and calcium
dynamics. Animal hearts deficient in ankyrin-B exhibit abnormal electrocardiogram
recordings at baseline (increased P-R interval, QRS duration, QT interval, and
intermittent R-R interval variability) and develop fatal polymorphic ventricular
tachycardia with adrenergic stimulation by concomitant exercise and epinephrine
stimulation [4, 5]. Lastly, expressions of ankyrin-B and its interacting partner are
concurrently reduced in cardiomyopathy [216].
Even though ankyrin-B expression is decreased in heart failure and decreased
ankyrin-B expression is clearly linked to various cardiac arrhythmias that are present in
end-stage heart failure, pathway underlying ankyrin-B regulation in heart disease has not
been explored. Coupling the increased mTORC1 activity commonly observed in
hypertrophied hearts with changes in ankyrin-B expression, our findings provide data
suggesting that ankyrin-B is regulated by mTORC1. Specifically, we demonstrate that
TAC hearts have increased mTORC1 activity and significantly decreased overall
ankyrin-B expression, but inhibition of mTORC1 returns ankyrin-B expression to
baseline levels. Additionally, fluorescent immunocytochemistry demonstrates
dispersion of the remaining ankyrin-B suggestive of an underlying cytoskeletal
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organization in the pressure-overloaded cardiomyocytes. Furthermore, physiologic
consequences of mTORC1 activity modulation is reflected by the electrocardiogram
recordings and saw that P-R interval, a measure of conduction between the atria and the
ventricles, increases in TAC hearts but returns to baseline with rapamycin treatment.
However, it should be noted that Q-T interval, a measure of rate of ventricular
repolarization, remains unchanged in TAC hearts with or without treatment, suggestive
of mTORC1-independent factors that remodels the electrical properties of the heart.
The same observations in expression changes and physiology are observed in our
in vitro system. The only exception in the NRVM is increased ankyrin-B expression at
the transverse-tubule. This difference could be contributed to a lack of a mechanical
force on the cultured cardiomyocytes that does not perturb the structural integrity of the
transverse-tubule [235, 258-260]. On the other hand, the mechanical force applied to the
intact heart likely contributes to the lack of expression changes for both ankyrin-G and
ankyrin-R - localized at the intercalated disc and sarcoplasmic reticulum respectively –
in TAC hearts treated with vehicle or rapamycin.
Even though the in vitro ankyrin-B fluorescent immunocytochemistry finding
was different from cardiomyocytes isolated from TAC hearts, it is nevertheless
interesting as one subpopulation decreases in expression while another increases with
increased mTORC1 activity. This begs the possibility of whether there exists different
isoforms of ankyrin-B that are differentially regulated. On closer observation,
immunoblot from both TAC hearts and cultured cardiomyocytes shows ankyrin-B
population with different molecular weights. This issue will be explored in greater detail
in the following chapter.
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This is the first demonstration of a hypertrophic cellular signaling pathway
directly affecting the electrical remodeling of the myocardium by regulating the
anchoring protein that targets and maintains the proteins that make up the excitable
domains in the heart (Figure 3.10). But additional studies will be necessary to unravel
the mechanisms that differentially regulate the ankyrin-B subpopulations. For instance,
are there direct protein-protein interactions between the signaling proteins along the
mTORC1 pathway and ankyrin-B? Is mTORC1-regulated autophagy the common
mechanism that underlies decreased SERCA2a expression and ankyrin-B population at
the M-line? Is there a transporting mechanism that shifts ankyrin-B localization from
one subcellular domain to another? Is the change in ankyrin-B expression affecting
functions of NCX1? All these questions will need to be adequately addressed to clearly
define the role of ankyrin-B in cardiovascular health and disease. We will first start by
addressing the different ankyrin-B populations and their interactions with NCX in the
following chapter.

Figure 3.10. Proposed model for mTORC1 regulation of two subpopulations of ankyrin-B.
Increased mTORC1 activities appears to decrease the ankyrin-B population at the M-line although
there appears to be an increase expression of the ankyrin-B population at the SR/T-tubule.
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4.1 Introduction
Excitation-contraction coupling requires correct subcellular distribution of ion
channels and transporters in cardiomyocytes. Ankyrin-B is an adaptor protein that
facilitates recruitment and retention of membrane proteins to subcellular domains in
cardiomyocytes such as the transverse tubule and M-line of the sarcomere. Mutations
that disrupt interaction with ankyrin-B have been linked to a variety of cardiac
arrhythmias including type 4 long QT syndrome, sick sinus syndrome, and atrial
fibrillation [4, 229, 261].
In 1991, the cDNA for ankyrin-B 220kD was constructed by combining
overlapping but partial cDNAs identified through an expression library screen using an
antibody to ankyrin-R [147]. Since then, it has been assumed that this coding sequence
represents the dominant ankyrin-B isoform in most tissues including the heart.
Unfortunately, this assumption is not consistent with the common observation that
tissues frequently express numerous alternative isoforms of ankyrin genes [1, 138-141,
262, 263].
Alternative splicing of ankyrin genes is an important process because it most
likely confers specific functions to particular isoforms. In fact, the current paradigm that
the heart only expresses ankyrin-B 220kD is confounded by the observation that
ankyrin-B interacts with a variety of ion channels and transporters that lack similarity in
function and subcellular distribution. We hypothesize that the heart expresses a diverse
population of ankyrin-B isoforms that are tailored through alternative splicing to impart
functional specificity and distinct subcellular distribution. We previously demonstrated
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that the heart expresses over 25 unique iterations of ANK2 transcripts, but a limitation of
that study was that we only evaluated partial mRNA transcripts [1].
Here, we describe the identification and characterization of two ankyrin-B
isoforms AnkB-188 and AnkB-212 that were isolated by long-range reverse
transcriptase-PCR from human ventricular mRNA. Atrial and ventricular tissues from
mouse, rat, and human hearts express ANK2 transcripts corresponding to these isoforms
as determined by quantitative real-time PCR. We demonstrate that both isoforms bind to
the sodium calcium exchanger (NCX) in an in vitro binding assay, but only AnkB-188
increases NCX membrane expression and current. Furthermore, siRNA knockdown of
AnkB-188 in neonatal cardiomyocytes decreases NCX expression and localization at
transverse-tubules. We generated an isoform-specific antibody to AnkB-212 and
demonstrate that this isoform is selectively expressed in heart and skeletal muscle.
Moreover, endogenous AnkB-212 localizes to the M-line in adult and neonatal
cardiomyocytes. Only AnkB-212 binds to obscurin, a large scaffolding protein
implicated in M-line formation and maintenance, and this interaction regulates AnkB212 targeting to the M-line. Moreover, siRNA treatment to AnkB-212 significantly
reduces the expression of endogenous ankyrin-B at the M-line, but has no effect on NCX
localization at the T-tubules. In summary, our data provide the first description of two
ankyrin-B isoforms that display unique functions and subcellular distributions in
cardiomyocytes.
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4.2 Materials and Methods
4.2.1 Animals
Mice used in these studies include adult and neonatal wild-type (C57BL/6) and
ankyrin-B (C57BL/6) heterozygous and homozygous null animals. Neonatal SpragueDawley rats used in these studies were ordered from Texas Animal Specialties (Humble,
TX). Studies were conducted in accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institute of Health following protocols
that were reviewed and approved by the University of Texas Health Science Center at
Houston Animal Welfare Committee.

4.2.2 Human tissue samples
Ventricular and atrial tissues from healthy donor hearts not suitable for
transplantation were obtained through the Iowa Donors Network and the National
Disease Research Interchange. Age and sex were the only identifying information
acquired from tissue providers and the Iowa Human Subjects Committee determined that
informed consent was not required. This investigation conforms to the principles
outlined in the Declaration of Helsinki.

4.2.3 Isolation and cloning of full-length ANK2 transcripts from human ventricular
mRNAs
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RNA was isolated from ventricular tissue using a Qiagen RNeasy mini-kit and
500 ng of RNA was reverse-transcribed with a poly dT primer using SuperScript III
reverse transcriptase (LifeTechnologies). cDNAs corresponding to AnkB-188 and
AnkB-212 were PCR-amplified using the primer sets (atgaccaccatgttgcaaaag,
cttttaattattgatccatcctc) and (atgaccaccatgttgcaaaag, cttttcaaaagctgcatcttc). PCR products
were subcloned into pcDH1-MCS lenti-viral expression plasmid (System Biosciences).
The complete amino acid sequences for each isoform are shown here:
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4.2.4 Quantitative real-time (qt)-PCR analysis of ANK2 transcripts
Exon-exon boundary spanning primers were designed to the unique splice
junctions encoding the C-terminal domains of AnkB-188 kD (exon junction 45 to 51)
and AnkB-212 kD (exon junction 50 to 51). Primers were optimized based on
nucleotide sequence and annealing temperatures such that primer efficiencies were
between 90 – 110%. cDNAs were generated from ventricular and atrial mRNA that was
isolated from three human and three mouse hearts. Relative expression of ANK2
transcripts was measured in triplicate by qt-PCR using SYBR Green dye (Bio-Rad) and
experiments were replicated three times. Individual Ct values were normalized to the
average of the Ct values of ANK2 transcripts with exon junction 31 to 32 (which encodes
the minimal spectrin-binding domain).
The following table 4.1 contains the ANK2 qt-PCR primer sequences:
Primer set

5’ primer

3’ primer

Size
(bp)

Tm
(C°)

HuE31/32
HuE45/51
HuE50/51

GCATGGATGAAG/tactggatag

ctgctcagtacacctccttc

151

64

Primer
eff.
(%)
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CAGCTTTTGAAAAG/gacaac
aatgag
GGATCAATAATTAAAAG/g
acaacaatgag

caagtcctccttgcagaaa
tg
caagtcctccttgcagaaa
tg

180

62.5

90

183

57
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MuE31/32
MuE45/51
MuE50/51

CATGGATGAAG/tgctggacag

cactgtgctgctcagtact
c
CGCTTTTCAAAAG/gacaacaat gaaggagttgctggagat
gcg
ctc
GATCAATAATTAAGAG/gac gaaggagttgctggagat
aacaatgcg
ctc

158

67

90

157

59
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160

62

90
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Ra-E12/13 GGTTTTACTCCACTGCACA
TTG
Ra-E31/32 CATGGATGAAG/tgctggacag

GTTAGTGACAT
192
CTGGAGAGGC
gacagcttgcacctgtgat 178
ac
Ra-E50/51 GATCAATAATTAAGAG/gac gaaggagttgctggagat 159
aacaatgag
ctc
Hu: human; Mu: mouse; Ra: rat; Tm: optimal annealing temperature

64.5
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64.5
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57
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4.2.5 AnkB-212 antibody generation
93 amino acids encoded by ANK2 exons 50 and 51 and unique to AnkB-212
were subcloned in triplicate into pET-15b (Novagen), over-expressed in
BL21(DE3)pLysS competent cells (Promega), and purified over a nickel column.
Polyclonal antibody production was contracted to Pocono Rabbit Farm and Laboratory
(Canadensis, PA).

4.2.6 Tissue immunoblot assay
Heart, skeletal muscle, brain, lung, and liver lysates were isolated from neonatal
wild-type and ankyrin-B null mice. Human atrial and ventricular heart lysates were
obtained from donor hearts. Protein lysates were separated by SDS-PAGE, transferred to
nitrocellulose membrane (Whatman), incubated with primary antibody at 4°C overnight,
and visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Primary antibodies used were: pan-ankyrin-B [229], AnkB-212 specific antibody
(1:3000), and pan-actin-5 (1:10,000; Thermo Scientific).
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4.2.7 Cellular fractionation immunoblot assay
HeLa-T7 cells stably expressing NCX lentivirally transduced with GFP, AnkB188-GFP, or AnkB-212-GFP were washed with cold PBS, lysed in 200µL of
homogenization buffer (10mM Tris pH 7.5, 5mM MgCl2, 1mM EGTA, 0.003mg
aprotinin, 0.1mM Na3VO4, 0.033mg leupeptin, and 1mM DTT), and homogenized with
1mL-syringe and 23G1¼ needle with repeated strokes. The homogenate was
centrifuged 1500 x g for 10 minutes at 4°C and the supernatant was removed for
ultracentrifugation at 100,000 x g for 40 minutes at 4°C. The resulting supernatant
(cytosolic fraction) was placed in a new tube, and the pellet (membrane fraction) was
washed and resuspended in homogenization buffer by sonication for 1 min at 4°C.
Protein contents for both fractions were measured and same protein quantities were
separated by SDS-PAGE and immunobloted with the following primary antibodies:
NCX (1:250, Swant, Switzerland), GFP (1:500, Santa Cruz), and pan-actin-5 (1:10,000;
Thermo Scientific).

4.2.8 Isolation of neonatal mouse hearts and cultures of neonatal rat ventricular
cardiomyocytes
Neonatal mouse cardiomyocytes were isolated from newborn mouse pups (P0)
and NRVM were isolated from 1-2 day old Sprague-Dawley rat hearts as previously
described with a minor modification [228]. In accordance with the animal protocol
approved by the Animal Welfare Committee at University of Texas Health Science
Center at Houston, neonatal rat pups were euthanized by decapitation. Briefly, hearts
were exposed, excised, minced, and digested through a series of agitations in buffer
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containing collagenase type II (Worthington, Collagenase type II 305U/mg) and
pancreatin (Sigma). Cells from each digestion were collected and pooled, and pre-plated
on Nunc plates (Thermo Fisher Scientific) to reduce fibroblasts and enrich for
cardiomyocytes. Cells were then collected and plated on either Primaria plates (Corning)
or fibronectin-coated glass-bottom MatTek plates (MatTek Corporation). Media was
changed 24-hours after plating and experiments started 2 days after plating to ensure
homogenous cultures. Following 3 days in culture, cardiomyocytes were transfected
with either siRNA or lenti-viral constructs of GFP-tagged full-length AnkB-188 or
AnkB-212. Cells were harvested for RNA or protein lysates or were and imaged 4 days
later by confocal microscopy.

4.2.9 siRNA construct and NRVM transfections
NRVMs were transfected with siRNAs at a final concentration of 50 nM with
DharmaFECT (Dharmacon GE) targeting rat AnkB-188, AnkB-212, and non-targeting
siRNA control (scramble). The NRVMs were transfected for 6 hours, then media was
changed to serum-free DMEM. Experiments were performed 48 hours later for
quantitative real-time PCR and 72 hours later for immunoblot analysis and cell
contraction recordings. The following table 4.2 contains the siRNA sequences targeting
rat Ank2:
Target Oligo Name

Sequence (5’-3’)

E12

B188-siRNA sequence #2 sense

CUGCCUUCAUGGGCCACUU[dT][dT]

B188-siRNA sequence #2 anti-

AAGUGGCCCAUGAAGGCAG[dT][dT]
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sense
E17

E48

E49

B188-siRNA sequence #1 sense

CCAUGUUGCUGCUCAUUAU[dT][dT]

B188-siRNA sequence #1 antisense

AUAAUGAGCAGCAACAUGG[dT][dT]

B212-siRNA sequence #1 sense

CAGCUAUUCCAAAGUGAUA[dT][dT]

B212-siRNA sequence #1 antisense

UAUCACUUUGGAAUAGCUG[dT][dT]

B212-siRNA sequence #2 sense

GUUUCAGGCGGAACCAGUA[dT][dT]

B212-siRNA sequence #2 antisense

UACUGGUUCCGCCUGAAAC[dT][dT]-

Scramble sense

GCUCCCAGCUCGUCUAUGU[dT][dT]

Scramble anti-sense

ACAUAGACGAGCUGGGAGC[dT][dT]

4.2.10 Isolation of individual adult mouse cardiomyocytes
Adult mouse cardiomyocytes were isolated as described previously (Baskin KK
and Taegtmeyer H. Circ Res 2011). In accordance with the animal protocol approved by
the Animal Welfare Committee at University of Texas Health Science Center at Houston,
3 month-old mice were anesthetized with intraperitoneal injection of tribromoethanolAvertin (Sigma T48402) at 250 mg/kg in 1X PBS and euthanized by removing the heart.
Hearts from wild type or ankyrin-B+/- mice were placed in ice-cold saline and the aorta
was cannulated. Hearts were first perfused with warm perfusion buffer for a few
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minutes, followed by perfusion with digestion buffer containing collagenase
(Worthington, Collagenase type II 305U/mg). Once digested, hearts were minced and
triturated, then centrifuged at 300 rpm x 5 minutes at 4°C. Supernatant was removed and
cells were immediately fixed in ice-cold 100% ethanol, and kept in -20°C until use.

4.2.11 Fluorescent immunocytochemistry and image quantification
Cells were washed in ice-cold phosphate-buffered saline (PBS, pH 7.4) 3x. Cells
were then blocked with 5% normal goat serum and 0.075% TritonX-100 for 30 minutes
at room temperature then incubated in primary antibodies overnight at 4°C. Primary
antibodies used were: ankyrin-B [229], ankyrinB-212 (1:300), α-actinin (1:1000, Sigma),
myomesin (1:500, Developmental Studies Hybridoma Bank, University of Iowa),
MyBPC3 (1:250, Santa Cruz), GFP (1:250, UC Davis/NIH NeuroMab Facility).
Secondary antibodies used were goat anti-rabbit conjugated to Alexa Fluor 488 and goat
anti-mouse conjugated to Alexa Fluor 568 (1:500, LifeTechnologies). Hoechst 33258
(1:1000, LifeTechnologies) was used for nuclear staining after removal of the secondary
antibody. Images were obtained with a Nikon A1 confocal microscope (Nikon, Melville,
NY) equipped with 100X oil, numerical aperture 1.4 objective. Fluorescence intensities
for ankyrin-B populations and sarcomeric markers were analyzed with ImageJ (version
1.47, NIH, Bethesda, MD) and Excel (Microsoft, Bellevue, WA). Intensities were
obtained by the mean pixel intensity of the magnified image.

4.2.12 Binding studies
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AnkB-188-GFP and AnkB-212-GFP were expressed in HeLa-T7 cells and
purified using an affinity-purified GFP Ig coupled to protein A-agarose beads as
previously described [133] and incubated with in-vitro translated 35S-radiolabeled
fragments of the sodium-calcium exchanger (Asp-253 to Lys-615, NM_021097) or the
C-terminal domain of human obscurin (Leu-6148 to Asn-6460, NM_052843) (TnT T7Coupled Reticulate Lysate System, Promega). Binding reactions occurred in 500µL
binding buffer (50mM Tris pH 7.4, 1mM EDTA, 1mM EGTA, 150mM NaCl, 0.1%
TritonX-100) at 4oC overnight. Reactions were washed in wash buffer (binding buffer
with 500 mM NaCl and 1% TritonX-100), pelleted, re-suspended in SDS-sample buffer,
separated by SDS-PAGE, and visualized with autoradiography film (HyBlot CL,
Denville Scientific).

4.2.13 Patch-clamp recording
Whole-cell patch-clamp recordings were performed using an Axopatch 200B
amplifier (Molecular Devices, CA) at room temperature (22–24 °C) on the stage of an
inverted phase-contrast microscope equipped with an appropriate filter set for green
fluorescence protein visualization. Pipettes pulled from borosilicate glass (BF 150-8610; Sutter Instrument Company, Novato, CA) with a Sutter P-97 pipette puller had
resistances of 2–4 MΩ when filled with pipette solution containing (mM) 120 CsCl, 20
NaCl, 5 Na2ATP, 3 CaCl2, 1 MgCl2, 10 HEPES, and 10 EGTA with pH 7.3 and
315 mOsm l−1 in osmolarity. The extracellular solution for whole-cell recording
contains (mM) 140 NaCl, 5

CsCl, 2 CaCl2, 1 MgCl2, 10 mM glucose, and 5 mM
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HEPES (the pH was adjusted to 7.4 with NaOH, and the osmolarity was adjusted to
340 mOsm l−1 with sucrose). The whole-cell membrane currents were recorded using
a voltage ramp (from +80 to -100 mV at 100 mV/s) following 100-ms step
depolarization to +80 mV from a holding potential of -40 mV. Data were acquired and
analyzed using pClamp 10 software (Molecular Devices, CA). Currents were filtered at
2 kHz and digitized at 10 kHz with Digidata 1440A acquisition system (Molecular
Devices, CA). Membrane capacitance was directly read from the membrane test function
of pClamp 10. Current density was obtained by dividing the current amplitude by cell
capacitance.

4.2.14 Recording and analysis of NRVM contraction rates
Contracting NRVM syncytium was located on light microscope (Micromaster;
Fisher) with 10X magnification eyepiece and 20X objective lens. A camera with 10
megapixel resolution (HTC One M8) was mounted on the microscope using Snapzoom
Universal Digiscoping Adapter (Snapzoom). Contractions were recorded for 2 to 2.5
minutes. The same recording method was used following stimulation with 1µM
epinephrine.
Using Video Spot Tracker (VST) program (http://cismm.cs.unc.edu/downloads)
and the tracking method described by Fassina L et. al. [230], we placed a marker on the
contracting syncytium and the program tracked the marker displacement frame by frame
(30 frames per second) registering the spatial-temporal coordinates x, y, (expressed in
pixels), and t (expression in frame number that converts to second). Coordinates were
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plotted in Excel (Microsoft) with each peak corresponding to an active syncytial
contraction. We assessed rhythmicity of the syncytial contractions by randomly picking
a consecutive 30-second interval and measuring the time between contractions. The
average contraction time for each video was calculated and the time difference between
each contraction and the average was plotted on GraphPad Prism 6 (GraphPad Software)
using box-and-whisker plots.

4.2.15 Statistical analysis
P-values were determined for single comparisons using unpaired Student’s t-test
(two-tailed). The NRVM contraction data was assessed for normality and processed to
calculate the mean and the standard deviation separately for each syncytial recording.
To standardize the dispersion of the time difference between each contraction and the
average contraction time for each respective syncytium, the coefficient of variation for
each recording was calculated. The coefficients of variation across the groups were
compared using the Kruskal-Wallis test with post-hoc Wilcoxon rank-sum test. A Pvalue of less than 0.05 was considered statistically significant. Values are expressed as
means ± SE except for the box-and-whisker plot for contractile rhythm variability where
the box contains interquartile range covering 25-75% of the readings and the whiskers
contains 90% of the readings.
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4.3 Results
4.3.1 Identification and cardiac expression of ankyrin-B isoforms
The biggest challenge to isolating tissue-specific ankyrin cDNAs is that ankyrin
genes are long and complex containing over 50 exons that are alternatively spliced
resulting in mRNA transcripts over 5000 bases in length. To identify full-length ANK2
cDNAs encoding ankyrin-B isoforms expressed in human heart, we performed longrange PCR on reverse transcribed mRNA isolated from human hearts. We identified
two novel ankyrin-B isoforms AnkB-188 and AnkB-212, which are labeled based on
their predicted molecular weights (Figure 4.1A). In contrast to ankyrin-B 220kD, which
starts with exon 1, both isoforms start with exon 1’ [1]. Both isoforms display similar
alternative splicing patterns including excision of exons 7, 30, and 40. Unique
alternative splicing to AnkB-188 includes excision of exons 24, 28, 38, and 46-50.
Remarkably, exons 46-50 encode the majority of the C-terminal regulatory domain
including the binding site for the large scaffolding protein obscurin [136]. Unique
alternative splicing to AnkB-212 includes excision of exons 12-13 and 17. Previously,
we have mapped the NCX binding site to the three ANK repeats encoded by exons 1517 [133] suggesting that AnkB-212 does not interact with NCX. In addition, the cDNA
for AnkB-212 includes exon 50 that shifts the open reading frame by plus one such that
exon 51 encodes a unique stretch of 62 amino acids terminating with the residues QEAK.
In contrast, the amino acid sequences for both ankyrin-B 220kD and AnkB-188
terminate with residues DNNE (see materials and methods 4.2.3 for the complete
sequences). Missense mutations associated with ankyrin-B dysfunction and cardiac
arrhythmias have been mapped to the spectrin-binding and C-terminal regulatory
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domains of both isoforms (Figure 4.1B). Interestingly, the mutation E1425G resides in
exon 38 and this exon is not present in the AnkB-188 isoform. E1425G has been well
studied and linked to a variety of arrhythmias including type 4 long QT syndrome, sick
sinus syndrome, and atrial fibrillation [2-5, 261].

Figure 4.1. Exon composition and protein domains of ankyrin-B isoforms AnkB-188
and AnkB-212. A, Exon organization and functional domains of ankyrin-B 220kD,
AnkB-188, and AnkB-212. Individual ANK repeats are indicated by dotted gray
squares and dipeptides linking ANK repeats are labeled. The ZU5A, ZU5B and UPA
domains are identified in the SBD. Binding sites for sodium/calcium exchanger
(NCX) and obscurin (Obs) are shaded in gray. B, Ten missense mutations associated
with cardiac arrhythmias are mapped to both isoforms [1-6]. MBD: membranebinding domain, SBD: spectrin-binding domain, DD: death domain, CTD: C-terminal
regulatory domain.
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To validate and measure the expression of these isoforms in heart mRNA, we
designed exon-exon boundary spanning primers that specifically amplify partial
transcripts based on unique exon junctions in each isoform. For example, to detect
partial mRNAs encoding AnkB-188 we designed a primer set to the unique exon
junction of exons 45 to 51. This exon-exon boundary spanning primer anneals to the
terminal 14 nucleotides of exon 45 (CAGCTTTTGAAAAG) and the initial 12
nucleotides of exon 51 (GACAACAATGAG). We validated that a PCR product is only
amplified using a full-length exon-exon boundary spanning primer (Figure 4.2A, lane 3).
In contrast, no PCR products are amplified using half the exon-exon boundary spanning
primer (Figure 4.2A, lanes 1 & 2). To amplify partial transcripts of AnkB-212, we
designed a primer set to amplify the junction of exons 50 to 51. All primer sets were
optimized based on nucleotide sequences and annealing temperatures such that primer
efficiencies are within 90 – 110% (see materials and methods 4.2.4).
Using these exon-exon boundary spanning primers, we performed qt-PCR to
measure the relative mRNA expression of AnkB-188 and AnkB-212 in ventricular and
atrial tissues isolated from both human and mouse hearts (Figure 4.2B and C). Relative
expression of each isoform was normalized to expression of exon junction 31/32. These
exons encode the minimal spectrin-binding domain and presumably this domain is
expressed in the majority of ankyrin-B isoforms. Both isoforms are expressed in atrial
and ventricular tissues. Interestingly, each primer set demonstrated a similar expression
pattern between human and mouse. Both human and mouse hearts express less mRNA
for AnkB-188 (45/51) than AnkB-212 (50/51). While the trends are the same in human
and mouse hearts, the magnitude of difference between the paired junctions (45/51 vs.
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50/51) is not the same. For example, junction 50/51 is ~3
~3-fold
fold greater than junction
45/51 in mouse, but only ~1.5
~1.5-fold
fold greater in human. We speculate that variations
var
in
tissue extraction and preservation most likely account for these differences. Taken
together, these findings demonstrate that mouse and human hearts express ANK2
transcripts with unique exon junctions present in AnkB
AnkB-188 and AnkB-212.
212.

Figure 4.2. Relative mRNA expression of AnkB
AnkB-188 and AnkB-212
212 in human and
mouse cardiac tissues. A, Exon
Exon-exon
exon boundary spanning primers were used to PCR
amplify alternative splice junctions unique to each isoform (AnkB
(AnkB-188:
188: junction 45/51,
AnkB-212: junction 50/51).
0/51). B
B, Relative mRNA expression of alternative splice
junctions in AnkB-188
188 and AnkB
AnkB-212
212 was measured in cardiac tissues from three
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human hearts. Expression of each splice junction was normalized to the expression of
exon junction 31/32 (presumably expressed in all ANK2 transcripts and set to 100%). C,
Relative mRNA expression of alternative splice junctions in AnkB-188 and AnkB-212
was measured in cardiac tissues from three mouse hearts. For B & C, samples were
repeated in triplicate (n=3) and experiments were repeated three times

4.3.2 AnkB-188 and AnkB-212 binding to NCX
In the heart, many different functions have been ascribed to ankyrin-B including
the recruitment and retention of various membrane proteins including dystrophin [264],
sodium potassium ATPase (NKA) [2, 4], IP3 receptor [2, 4, 265], and NCX [4, 133]. We
previously demonstrated that ANK repeats 16-18 in the membrane-binding domain of
ankyrin-B encodes the binding site for NCX [133]. Considering AnkB-212 lacks exon
17 that encodes ANK repeat 18, we anticipated that NCX would not bind to this isoform
(Figure 4.3A).
To assess whether the AnkB isoforms display different NCX binding, we
performed an in vitro binding assay with radiolabelled NCX fragment and full-length
AnkB-188 or AnkB-212 (Figure 4.3B). GFP-tagged AnkB isoforms were transiently
expressed in HeLa-T7 cells and immunoprecipitated from lysate using a GFP antibody.
Interestingly, both isoforms equally bound NCX suggesting that the absence of ANK
repeat 18 had no effect on NCX binding in this in vitro paradigm.
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Figure 4.3. Both AnkB-188 and AnkB-212 bind NCX. A, Exons encoding the
membrane-binding domains of AnkB-188 and AnkB-212. The NCX binding site maps
to ANK2 exons 15-17. (B) 35S-labelled, in vitro translated NCX fragment binds to both
AnkB isoforms. Experiments were repeated three times. Coomassie Blue Stain
demonstrates equal expression of both isoforms.

4.3.3 AnkB-188 increases NCX membrane expression and current
To examine the effect of each isoform on NCX function, we measured the NCX
current in HeLa-T7 cells stably expressing NCX and transiently expressing either GFPtagged AnkB isoform. Similar expression of each isoform was demonstrated by
immunoblot analysis of the GFP-tag, and individual GFP-positive cells were measured
for NCX current (Figure 4.4A). While a basal NCX current was also detected in the
stable cell lines, only the transient expression of AnkB-188 enhanced this current
compared to cells expressing GFP alone or AnkB-212 (Figure 4.4B). HeLa-T7 cells
express an endogenous isoform of ankyrin-B as detected by immunoblot (data not
shown), which most likely accounts for the basal NCX current in the stable cell lines.
Qt-PCR analysis demonstrated that NCX mRNA expression was equivalent in all
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transfection conditions, indicating that neither ankyrin isoform increases NCX mRNA
expression (Figure 4.4E).
To investigate the molecular basis for increased NCX current mediated by AnkB188, we measured the expression of NCX in cytosolic and membrane fractions of cells
transiently expressing GFP alone, AnkB-188, or AnkB-212 by immunoblot analysis
(Figure 4.4C). We found that membrane expression of NCX was 2-fold greater in cells
expressing AnkB-188 compared to cells expressing GFP alone or AnkB-212 as
determined by densitometry analysis of immunoblots from three independent
experiments (Figure 4.4D). Taken together, these data suggest that cells expressing
AnkB-188 display enhanced NCX current because this isoform increases NCX
expression in the plasma membrane.
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Figure 4.4. AnkB-188, but not AnkB-212, increases NCX current and membrane
expression. A, Detection of the GFP-tag on isoforms by immunoblot and
immunofluorescence in HeLa-T7 cells that stably express NCX. Scale bar is 5 µm. B,
NCX voltage-current curves of HeLa-T7 cells transiently expressing GFP, AnkB-188, or
AnkB-212 (n=29 for GFP and AnkB-188, n=27 for AnkB-212, *P<0.05). C, NCX
expression is increased in the membrane fraction of HeLa-T7 cells expressing AnkB-188.
Equal protein loading was demonstrated by immunoblot to pan-actin, while membrane
enrichment was demonstrated by immunoblot to caveolin-1. Experiments were
replicated three times. D, Densitometry of NCX membrane expression from C. E, QtPCR of NCX mRNA expression in untransfected HeLa cells and HeLa cells transiently
expressing GFP, B188-GFP, or B212-GFP.

4.3.4 AnkB-212 is selectively expressed in heart and skeletal muscle
In the initial characterization of ankyrin-B, a polyclonal antibody was generated
against the death and C-terminal domains (Figure 4.5A). We have previously
demonstrated that the C-terminal regulatory domain is subject to complex alternative
splicing presumably resulting in numerous alternative ankyrin-B isoforms [1]. Using
this pan-AnkB antibody, we demonstrate that multiple AnkB isoforms are expressed in
adult mouse heart and in mouse neonatal tissue including heart, skeletal muscle, brain,
lung, and liver (Figure 4.5A). In contrast, no isoforms are detected in the same tissues
isolated from neonatal AnkB null (-/-) mice. Using the same antibody, multiple ankyrinB isoforms are also detected in atrial and ventricular tissues isolated from adult human
heart.
One of the challenges in characterizing alternative isoforms is identifying a
unique stretch of amino acids that could be used to generate an isoform-specific antibody.
Fortunately, the coding sequence for AnkB-212 includes exon 50, which shifts the open
reading frame plus one such that exon 51 encodes a unique stretch of 62 amino acids
(Figure 4.5B). Numerous expressed sequence tags (>10) from human cDNAs contain
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this unique coding sequence including DB499390.1, DA768553.1, and DA364599.1. To
generate an isoform-specific antibody to AnkB-212, we made a bacterially expressed
and purified His-tag fusion protein of the 93 amino acids encoded by exons 50 and 51.
Rabbit anti-serum was used to detect AnkB-212 expression in AnkB wild-type (+/+) and
null (-/-) tissues including heart, skeletal muscle, brain, lung, and liver (Figure 4.5B).
Interestingly, AnkB-212 is expressed in wild-type adult and neonatal mouse heart as
well as skeletal muscle. However, it is not expressed in brain, lung, or liver from wildtype neonates. AnkB-212 was also detected in human atrial and ventricular tissues.
These findings suggest that expression of AnkB-212 is restricted to striated muscle.
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Figure 4.5. Expression of pan-AnkB and AnkB-212 in various tissues. A, The antibody to
pan-AnkB was generated against the death and C-terminal domains encoded by exons 4145, 47-48 and 51. Expression of multiple AnkB isoforms was detected in neonatal mouse
heart, skeletal muscle, brain, lung, and liver of wild-type (+/+) and adult mouse heart. B,
The antibody to AnkB-212 was generated against amino acids encoded by exons 50 and
51. Only one isoform of AnkB-212 was detected in heart and skeletal muscle of wild-type
neonates and adult mouse heart. Pan-actin immunoblot demonstrates equal protein
loading. For A & B, experiments were replicated three times.

4.3.5 Endogenous AnkB-212 is expressed at the cardiomyocyte M-line
Within cardiomyocytes, ankyrin-B is expressed at the sarcomeric M-line and the
sarcoplasmic reticulum/transverse-tubule junctions, which generally co-localize with
components of the sarcomeric Z-line. Using the pan-AnkB antibody, we demonstrate
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the expression of these two ankyrin-B subpopulations at the Z- and M-lines in isolated
adult cardiomyocytes (Figure 4.6A and C). We measured the relative fluorescence
intensity of this signal and found that the less abundant ankyrin-B population colocalizes with the resident Z-line marker protein α-actinin, while the more abundant
population co-localizes with myomesin, a M-line resident protein. Interestingly, AnkB212 is only detected at the M-line of adult cardiomyocytes (Figure 4.6B and D).
Specifically, AnkB-212 co-localizes with myomesin, but not with α-actinin. Similar
results were found in experiments using cardiomyocytes isolated from ankyrin-B
heterozygous hearts (Figure 4.7). These findings suggest that the M-line population of
ankyrin-B is partially comprised of the AnkB-212 isoform.
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Figure 4.6. AnkB and AnkB-212 endogenous localizations in adult cardiomyocytes. A and C, Two
subpopulations of ankyrin-B are detected using the pan-AnkB antibody. The less abundant population
(white arrow heads) co-localizes with the Z-line marker α-actinin while the more abundant population
(white arrows) co-localizes with the M-line marker myomesin. Relative fluorescence intensities of the
insets were measured and graphed. B and D, Only one population of AnkB-212kD (white arrows) is
detected and co-localizes with the M-line marker myomesin
and not the Z-line marker α-actinin. For all
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antibody conditions, 6-8 myocytes per condition were imaged. Scale bar = 2 µm

Figure 4.7. Expression of pan-AnkB and AnkB-212 in isolated AnkB+/- adult cardiomyocytes. A and
C, Two subpopulations of ankyrin-B are expressed in AnkB+/- cardiomyocytes. The less abundant
population (white arrowheads) co-localizes with α-actinin at the Z-line while the more abundant
population (white arrows) co-localizes with myomesin at the M-line. B and D, There is one
population of AnkB-212 (white arrows) that co-localizes with myomesin, but not with α-actinin. For
all antibody conditions, 6-8 myocytes per condition were imaged. Scale bar = 2 µm

4.3.6 Exogenous AnkB-212 is targeted to the M-line via an interaction with
obscurin
To investigate the molecular basis of AnkB-212 targeting and retention at the
sarcomeric M-line, we evaluated the isoforms for binding to obscurin, an 800kD
structural protein that has been implicated in M-line formation and alignment [234, 266,
267]. Two ankyrin-binding sites reside in the C-terminal domain (CTD) of obscurin
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[268]. We previously demonstrated that the ankyrin-B C-terminal domain contains two
obscurin-binding sites encoded by ANK2 exons 46 and 47 [136]. Interestingly, the Cterminal domain of AnkB-188 lacks exons 46 through 50, while the same domain in
AnkB-212 contains these exons (Figure 4.8A). We performed an in vitro binding assay
in which the obscurin CTD was in vitro translated and radiolabelled with 35S methionine,
then incubated with GFP-tagged AnkB-188 or AnkB-212, which was over-expressed
and purified from HeLa-T7 cells. Obscurin only bound to AnkB-212, and not to AnkB188 (Figure 4.8B).

Figure 4.8. AnkB-212, but not AnkB-188, binds to obscurin. A, Exons coding
the C-terminal regulatory domains of AnkB-188 and AnkB-212. ANK2 exons 46
and 47 encode two obscurin binding domains. B, In vitro translated obscurin
CTD binds GFP-tagged AnkB-212. C, GFP immunoblot demonstrates similar
expression of ankyrin isoforms. Experiments were replicated twice. OBD,
obscurin binding domains.
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Because we lack an antibody specific to AnkB-188, we evaluated the colocalization of each isoform to three sarcomeric proteins: α-actinin (Z-line), myosinbinding protein C (A-band), and myomesin (M-line) to assess whether AnkB-188 and
AnkB-212 display differential subcellular localization in cardiomyocytes. GFP-tagged
ankyrin isoforms were expressed in rat neonatal cardiomyocytes by lenti-virus and
images were acquired by confocal microscopy. AnkB-188 expression was diffusely
cytosolic and lacked sarcomeric localization (Figure 4.9A). In contrast, AnkB-212
distinctly co-localizes with myomesin and is flanked by myosin-binding protein C
suggesting that its localization does not extend beyond the M-line (Figure 4.9B).
Removal of exon 46, which encodes the first obscurin-binding site, from the CTD of
AnkB-212 disrupts AnkB-212’s interaction with obscurin and abrogates the M-line
localization (Figure 4.10). Taken together, these data suggest that AnkB-212 is targeted
to the M-line via its interaction with obscurin.
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Figure 4.9. AnkB-212 is
targeted to the M-line of
cardiomyocytes. Double
labeling of A, GFP-tagged
AnkB-188 or B, GFPtagged AnkB-212 with Zline marker α-actinin, Aband marker MyBP-C, and
M-line marker myomesin
in neonatal rat
cardiomyocytes. AnkB212, but not AnkB-188,
colocalizes with
myomesin at the M-line.
For all antibody
conditions, 6-8 myocytes
were imaged. MyBP-C,
myosin binding protein C.
Scale bar = 2µm.

128

Figure 4.10. AnkB-212 CTD ∆E46 lacks obscurin-binding and M-line targeting. A,
Diagram of two tagged (flag and GFP) constructs of AnkB-212 CTD that lack exon 46, the
first obscurin binding site in ANK2. B, A GST-fusion protein of obscurin CTD (containing
the ankyrin-binding sites) does not precipitate AnkB-212 CTD ∆E46. C, GFP-tagged AnkB212 CTD ∆E46 does not co-localize with myomesin in virally transduced cardiomyocytes.
Scale bar = 2µM.

4.3.7 AnkB-188 knockdown decreases the expression and proper subcellular
localization of NCX
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To identify potential functions associated with either ankyrin-B isoform in rat
neonatal cardiomyocytes, we used siRNAs to selectively knockdown each isoform.
SiRNAs were designed to unique exons in each isoform (Figure 4.11A). We used qtPCR transcript analysis to evaluate the efficacy and specificity of the siRNAs against its
intended isoform (Figure 11B, gray bars) versus the other isoform (Figure 4.11B, black
bars). SiRNAs that displayed preferential knockdown of each isoform were used in
subsequent assays. Immunoblot analysis was performed to confirm siRNA-mediated
knockdown of each isoform. Using the pan-AnkB antibody, two high molecular weight
isoforms are clearly resolved and siRNAs to AnkB-188 reduce the expression of the
smaller isoform although expression of the larger isoform also decreases but to lesser
extent (Figure 4.11C). The isoform-specific antibody to AnkB-212 demonstrates a
marked reduction in the expression of this isoform following siRNA treatment (Figure
4.11C).
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Figure 4.11. AnkB-188
188 knockdown decreases the expression of NCX. A
A, Isoform-specific
Isoform
siRNAs were designed to exons unique to AnkB
AnkB-188 and AnkB-212. B, Knockdown of isoform
mRNA was assessed by qt-PCR
PCR using primer sets unique to each is
isoform
oform (black arrows). Qt-PCR
Qt
values were normalized to GAPDH mRNA expression and expressed as a percentage of isoform
expression in untransfected cardiomyocytes, which was set to 100%. Gray bars represent isoform
mRNA expression targeted by the siRNAs. Black bars represent mRNA expression of controls
and the other isoform. C, Immunoblot analysis of AnkB
AnkB-188, AnkB-212,
212, and NCX in control and
siRNA-treated
treated cardiomyocytes. Pan
Pan-actin
actin immunoblot demonstrates equal protein loading.
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Previous studies have demonstrated that ankyrin-B is important for the
expression and proper subcellular targeting of NCX [2, 4, 133]. Considering AnkB-188
increases NCX membrane expression and current in HeLa-T7 cells (Figure 4.4 B, C, and
D), we evaluated siRNA-mediated knockdown of each isoform on the expression and
localization of NCX in neonatal rat cardiomyocytes. While NCX protein expression is
slightly reduced following AnkB-212 knockdown, AnkB-188 knockdown results in a
more significant reduction in NCX protein expression (Figure 4.11C). In untransfected
cardiomyocytes, NCX predominantly co-localizes with α-actinin at the Z-line (Figure
4.12D) while two populations of ankyrin-B are detected at the M- and Z-lines (Figure
4.12A and B). AnkB-212 knockdown dramatically reduces ankyrin-B expression in
cardiomyocytes, but interestingly NCX maintains its striated patterning over the Z-lines
(Figure 4.12A and D). In contrast, the Z-line striated patterning of NCX is markedly
reduced in cardiomyocytes following AnkB-188 knockdown (Figure 4.12C and D)
suggesting that this isoform is important for NCX subcellular localization in
cardiomyocytes.
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Figure 4.12. AnkB-188 knockdown decreases NCX Z-line localization. A, Endogenous AnkB212 co-localizes with the M-line marker myomesin. AnkB-212 siRNA treatment reduces
AnkB-212 expression at the M-line. B, Both the M-line and Z-line populations of ankyrin-B
are visualized in the untransfected and scramble controls. AnkB-188 siRNA treatment
diminishes the AnkB subpopulation at the Z-line. C, NCX localization is diminished by AnkB188 siRNA. (D) NCX expression at the Z-line (α-actinin) is not affected by either scramble or
AnkB-212 siRNA treatment. In contrast, AnkB-188 siRNA treatment dramatically reduces the
expression and striated patterning of NCX.
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4.3.8 AnkB-188 and AnkB-212 knockdown causes different arrhythmic contraction
patterns
Ankyrin-B haploinsufficiency results in decreased NCX membrane expression,
altered calcium dynamics, and decreased contractions in ventricular cardiomyocytes [3,
4, 133]. Considering the numerous cardiac arrhythmias associated with ankyrin-B
dysfunction, we evaluated the effect of isoform-specific knockdown on cardiomyocyte
contractile rhythms. Both untransfected and scramble siRNA-treated cardiomyocytes
display a pattern of uniformly timed contractions (Figure 4.13A). In contrast,
cardiomyocytes with knockdown of AnkB-188 display patterns of arrhythmic
contractions. Surprisingly, cardiomyocytes with knockdown of AnkB-212, which has no
effect on NCX membrane expression or localization, also exhibits patterns of arrhythmic
contractions (Figure 4.13A). The same patterns are observed following epinephrine
treatment (Figure 4.13B).
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Figure 4.13. AnkB-188 and AnkB-212 knockdown precipitates different contraction
irregularities. A, The left panel presents representative contraction rhythms of untransfected
and transfected cardiomyocytes. The right panel presents the summary data. Box-andwhisker plots represent the difference in time between individual contractions and the
average contraction time over a 30-second interval. B, The left panel presents
representative contraction rhythms in control and transfected (scramble, B188-siRNA,
B212-siRNA) cardiomyocytes following epinephrine stimulation (1 µM). The right panel
presents the summary data for each condition. Box-and-whisker plots represent the
difference in time between individual contractions and the average contraction time over a
30-second interval. Sample size for unstimulated NRVM is untransfected: 6, scramble: 7,
B188-siRNA: 7, and B212-siRNA: 5. Sample size for NRVM stimulated with epinephrine
is untransfected: 5, scramble: 5, B188-siRNA: 7, B212-siRNA: 5. #p>0.05 and *p<0.05
when compared to the untransfected control.
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4.4 Discussion
Normal heart function requires the proper functioning of proteins at unique
membrane and sarcomeric domains in cardiomyocytes such as the costamere,
intercalated disc, and T-tubules. As an adaptor protein, ankyrin targets and maintains
distinctive networks of membrane and signaling proteins at these domains by tethering
them to the underlying cytoskeletal network. The alternative splicing of an ankyrin gene
regulates the modular nature of ankyrin isoforms such that they can serve as a common
interface between β-spectrin and unique cohorts of proteins that define functionally
distinct subcellular domains.
In earlier studies that initially described ankyrin genes, there were many
references to alternative isoforms. Some of these isoforms displayed tissue specific
expression, while other isoforms demonstrated unique subcellular distribution. For
example, while ankyrin-G expression is relatively ubiquitous throughout tissues, a brainspecific isoform is targeted to the neuronal axon initial segment by a ~6000 bp exon
[137, 138]. Likewise, an alternative start site in the ankyrin-R gene gives rise to a
truncated muscle-specific isoform with a novel transmembrane domain that sequesters it
to the membrane of the sarcoplasmic reticulum [262, 269, 270].
In the initial characterization of the ankyrin-B gene, two isoforms (440kD and
220kD) were detected in the brain [146, 147]. The cDNA for the 220kD isoform was
synthesized by combining seven partial, but overlapping cDNA clones that were
identified in an expression library screen [147]. The only difference between these
cDNAs is that a ~6000 bp exon is included in the cDNA of the brain-specific 440kD
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isoform. With time, it became tacitly assumed that the 220kD isoform represented the
predominant isoform expressed in other tissues.
This study is the first to describe two novel ankyrin-B isoforms identified by
long-range PCR of reverse transcribed mRNA isolated from human ventricular tissue.
We demonstrate the expression of mRNA and protein of these isoforms in human, rat,
and mouse hearts. In addition, we can discriminate between the two isoforms based on
their function and subcellular distribution in cardiomyocytes. Specifically, overexpression of AnkB-188 in HeLa-T7 cells increases NCX membrane expression and
current, while siRNA-mediated knockdown of this isoform decreases NCX expression
and subcellular localization at Z-lines in neonatal cardiomyocytes. Using an isoformspecific antibody, we demonstrate that expression of AnkB-212 is restricted to striated
muscle and distinctly expressed at the M-line in cardiomyocytes. Moreover, the M-line
targeting of AnkB-212 is regulated by its interaction with the large scaffolding protein
obscurin. In contrast to AnkB-188, the preferential knockdown of AnkB-212 in neonatal
cardiomyocytes does not alter the Z-line striated patterning of NCX. Interestingly,
knockdown of either isoform results in arrhythmic contractions. The function of AnkB212 at the M-line and whether these isoforms share areas of functional overlap remain
unanswered questions but are important lines of inquiry for future experiments. The
summary of the experiments and results is shown below (Table 4.3).
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Table 4.3. Summary of the experiments and findings. The last two rows are experiments
involving the use of isoform specific siRNA.
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Figure 4.14. Summary model of the subcellular domain localizations of the two fulllength ankyrin-B isoforms. AnkB-188 localizes to the transverse tubule with NCX.
AnkB-212 localizes to the sarcomeric M-line by interacting with ankyrin-binding
domains (ABD) of obscurin.

One unresolved question in the ankyrin field is what regulates ankyrin specificity
for particular membrane proteins. Ankyrin-B 220kD has been shown to interact with a
diverse array of proteins including the sodium calcium exchanger (NCX), sodium
potassium ATPase (NKA), inositol 1,4,5-triphosphate receptor (IP3R), ATP-sensitive
inward-rectifying potassium channel subunit (Kir6.2), dystrophin, and obscurin [2, 133,
136, 264, 265, 271-273]. Our data supports the hypothesis that alternative splicing
tailors ankyrin proteins such that they are specific for particular membrane or
scaffolding proteins. We anticipate that the heart expresses additional ankyrin-B
isoforms that have yet to be identified.
The expression of different function-specific ankyrin-B isoforms in heart would
provide a fitting explanation for the diversity of arrhythmias associated with ankyrin-B
dysfunction. In fact, the designation of ankyrin-B syndrome has been adopted to
incorporate the various arrhythmias associated with ankyrin-B dysfunction, which
partially include bradycardia, idiopathic ventricular fibrillation, catecholaminergic
polymorphic ventricular tachycardia, and atrial fibrillation [3-5, 229]. Past efforts to
understand the molecular basis of dysfunction stemming from these mutations have been
performed in the context of ankyrin-B 220kD. While these studies have provided insight
into ankyrin-B function, it is important to re-evaluate ankyrin-B syndrome in the context
of the newly identified ankyrin-B isoforms. For example, previous studies have
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demonstrated that the arrhythmia-associated AnkB missense mutation E1425G decreases
NCX membrane expression in ventricular cardiomyocytes. Our data demonstrates that
NCX membrane expression is regulated by AnkB-188, which lacks exon 38 and would
not express the E1425G missense mutation. We anticipate future experiments
characterizing these isoforms will provide a more complete picture of ankyrin-B
function in normal hearts and how missense mutations in different ankyrin-B isoforms
result in various atrial, nodal, and ventricular arrhythmias.
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CHAPTER 5: CONCLUDING CHAPTER
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5.1 Summary of results and perspectives
On the surface, it may appear that the heart simply beats. In reality, it is an
extremely dynamic organ subjected to complex signaling and metabolic regulations. In
establishing and maintaining a normal beat-to-beat rhythm in response to various
stressors, the heart remodels functionally, electrically, and metabolically. Central to all
these changes is the immediate and prolonged intracellular signaling modifications: the
mammalian/mechanistic target of rapamycin.
Like the heart, another organ subjected to such complex signaling and metabolic
regulation is the brain. Although the brain does not perform mechanical work, its main
function is to communicate via excitation and conduction. Instead of beat-to-beat
contractions, the brain utilizes and dedicates most of its energy to the active transport of
ions to restore membrane potentials for its unceasing activities [274]. However, when
the normal excitation-conduction becomes dysregulated, the abnormal neuronal firings
manifests physically as seizures. A classic seizure disorder is the neurodevelopmental
disease tuberous sclerosis complex where up to 95% of the patients exhibit medically
refractory epilepsy [275, 276].
A well-characterized brain-specific mouse model of TSC, the Tsc2flox/ko;hGFAPCre [98], exhibits intractable seizures that result in death at around weaning age (median
survival at postnatal day 23). Additionally, many aspects of the TSC neuropathology
were recapitulated including defects in neuronal migration, cortical lamination,
subcortical organization, myelination, and maturation [98, 99]. Interestingly, the seizure
disorder and the histologic pathologies observed in this mouse model were alleviated
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with the treatment of rapamycin, an allosteric inhibitor of mTORC1 [277, 278].
Furthermore, as long as the animal is maintained on a regular treatment with rapamycin,
no seizure activity is observed. This is in stark contrast to the cessation of rapamycin
treatment where 100% of the animals have seizures that result in death. Taken
altogether, this suggests the high degree of mTORC1 involvement in maintaining the
ionic homeostasis of the neurons and its role in general seizure disorders.
Unlike the brain where abnormal electrical activities result in seizures, the
abnormal electrical activities in the heart - whose primary function is to beat regularly –
is manifested as arrhythmia, or irregular contractions. Whereas there is a readily
available genetic model of brain-specific dysregulated mTORC1, no such model yet
exists for the heart. Instead, it was discovered that increased hemodynamic load by
constricting the transverse or the descending abdominal aorta can trigger increased
mTORC1 activity in addition to other cellular growth pathways such as the MAP-kinase
and angiotensin pathways in the heart [16, 75, 192, 193, 279]. Prolonged exposure to
hemodynamic stress in the animals results in abnormal electrical activities in the heart at
baseline that appears to have slowed conduction – increased P-wave duration and PR
interval as measured by electrocardiogram. The labile electrical nature of the stressed
heart is made evident when frank ventricular fibrillation can easily be induced by fast
external pacing [75].
In the preceding chapters I demonstrated changes in electrical conductance in the
heart in as early as 1-week of aortic constriction. But the heart, being a dynamic organ,
remodels itself continuously such that the electrical changes observed acutely are
different from the chronically stressed heart. As expected, overactivity of mTORC1 in
145

the stressed heart is abated by rapamycin administration that also attenuates the
hypertrophic and fibrotic (structural), functional, and metabolic remodeling secondary to
pressure overload [190, 192, 193].
Like the neurons, the heart must repolarize after every depolarization in order to
initiate the next depolarization wave.

The time between depolarization and

repolarization is termed Q-T interval. Calcium removal processes are paramount during
the repolarization period, and the two major players involved are the sarco/endoplasmic
reticulum calcium ATPase (SERCA2a) and sodium-calcium exchanger (NCX1).
SERCA2a is responsible for sequestering approximately 90% of the cytosolic calcium
ions and NCX1 contributes around 7% in small animals and 70% and 25% in humans,
respectively [280].

SERCA2a expression decreases in the stressed heart but is

normalized with rapamycin treatment [23, 192, 219, 281]. In contrast, NCX1 expression
is increased in the stressed heart and rapamycin does not alter its expression, surface
localization, or transporter activity [221, 237]. Contrary to the expected, NCX1 current
is decreased in the stressed heart despite the increased expression and surface
localization [221]. The heart may adapt to the decreased NCX1 activity by reducing Ltype calcium current and shortening action potential to further limit calcium similar to
the NCX knockout mouse model [282-284](. This may in part explain our finding that
despite the regression of structural, functional, metabolic, and most of the electrical
changes in the hemodynamically stressed heart with mTORC1 inhibition, the Q-T
interval remains shortened and seems unresponsive to rapamycin treatment.
Even though NCX1 seemingly only contributes to a small percentage of the
calcium removal process during repolarization, it has a profound impact on the
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maintenance of a normal cardiac rhythm. In animal models where NCX1 stability is
affected by a loss-of-function mutation in the adaptor protein ankyrin-B, the main
targeting and interacting partner of NCX1 in the heart, high degree of heart rate
variability, rhythm variability, and lethal arrhythmias with adrenergic stimulation have
been reported. At the cellular level, calcium transients are irregular and both slow and
fast pacing induced unsolicited action potentials [2, 4, 5, 133].

Thus, when we

interrogate ankyrin-B expression in the stressed heart, we observe a change in ankyrin-B
expression that could account for the decreased NCX1 current despite the increased
NCX1 expression and secondarily lead to arrhythmias. Similar findings are found in our
in vitro system when we genetically activated mTORC1 by knocking down Tsc2. This
also marks the first study where the adaptor protein ankryin-B is shown to be regulated
by the mTORC1 pathway.
Although ankyrin-B expression was altered with dysregulated mTORC1 activity
both in vivo by hemodynamic stress and in vitro by genetic ablation, it should be noted
that ankyrin-B expression was reduced ubiquitously in the stressed heart whereas the
mTORC1-specific activation in vitro saw a reduction in expression at the cardiac M-line
and a dramatic upregulation at the SR/T-tubule, the subcellular domain where NCX1
resides. The discrepancy between the in vivo and in vitro systems brings up several
interesting issues: 1.) what other cell signaling pathway(s) is/are able to regulate
ankyrin-B expression, 2.) what mechanism is responsible for the degradation of ankyrinB at the M-line secondary to mTORC1 activity, and 3.) what specific regulatory
mechanisms govern which ankyrin-B isoform expression.
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Increased mTORC1 activity generally increases protein synthesis, but the
reduction of protein expressions has also been observed. For example, SERCA2a and αmyosin heavy chain both have documented reduced expressions in the hemodynamically
stressed heart that are reversible with rapamycin, but the reductions are at least in part
associated with transcriptional changes [23, 192, 219, 281]. On the other hand, ankyrinB mRNA transcript level remains the same in the stressed heart suggesting that
mTORC1-regulation of ankyrin-B (at least the M-line population) is a post-translational
event. It was reported recently that chronic mTORC1 activation leads to endoplasmic
reticulum stress in the heart [190], and given the relationship between endoplasmic
reticulum stress and mechanisms of autophagy, it is possible that ankyrin-B is degraded
via autophagic processes [285, 286]. In addition to autophagy, it is also possible that the
calpain system contributes to the ankyrin-B degradation [216] although the specificity
for the M-line versus the SR/T-tubule population remains to be elucidated.
In the preceding chapters, we present compelling evidence for the existence of
multiple ankyrin-B isoforms and the different subcellular localizations of two full-length
ankyrin-B isoforms – AnkB-188 and AnkB-212. Given that AnkB-188 interacts with
the SR/T-tubule resident protein NCX1 and that knockdown of AnkB-188 decreases
NCX1 expression, AnkB-188 likely accounts for the changes in NCX1 function in the
stressed heart although this is yet to be determined because of the absence of
transcriptional changes and the lack of an AnkB-188-specific antibody. What is more
surprising to us is that ankyrin-B population at the M-line, of which AnkB-212 is a part
of, is important, and perhaps even more so than AnkB-188, for maintaining regular
cardiac rhythm. In both the in vitro models where either Tsc2 or AnkB-212 is targeted
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by siRNA knockdown, the expression of the ankyrin-B population at the SR/T-tubule
either increases or remains the same. However, both demonstrate a dramatic decrease in
ankyrin-B expression at the cardiac M-line and significant irregular contraction patterns.
Although AnkB-212 interacts with the M-line organizer obscurin, the molecular
function(s) of AnkB-212 remains to be determined and represents an interesting and
imperative direction for future investigation of the mechanisms of cardiac hypertrophic
changes and arrhythmias. Finally, there are many other ankyrin-B isoforms that have yet
to be identified and characterized. It will be interesting to see how each functions and
contributes to maintenance of normal cardiac rhythm.
While this thesis explores the relationship between mTORC1 signaling, ankyrins,
and electrical properties of the heart, it brings forth another interesting area for further
investigation: seizure disorders associated with TSC. In the nervous system, multiple
isoforms of all three ankyrin genes have been identified and characterized and their
proper localization and function are critical to the formation and maintenance of
excitable subcellular domains in neurons.

It was recently identified that seizure

activities affects the expressions of the adaptor protein ankyrin-G at the axon initial
segment, the site where information is integrated and the action potential is generated,
and its interacting partner voltage-gated sodium channel (Nav 1.6) [128]. We showed
that dysregulated mTORC1 causes electrical remodeling in the heart and that the M-line
ankyrin-B population expression is subjected to regulation by mTORC1.

The

Tsc2flox/ko;hGFAP-Cre has a pronounced dysregulated mTORC1 activity, cortical
disorganization, and severe myelination defect in addition to a lethal tonic-clonic seizure
phenotype. It will be intriguing to see how the expression and localization of different
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ankyrin proteins are affected in Tsc2flox/ko;hGFAP-Cre mice (Tsc2-hGFAP) which may
potentially shed light on the mechanistic relationship between cell signaling and aberrant
electrical activities in the central nervous system of the TSC patients.
While there are still many questions and interesting areas of investigation, it is
evident that mTORC1 activity is at least in part responsible for structural, functional,
metabolic, and electrical remodeling processes in the heart and that proper ankyrin
function and localizations are central for maintaining the normal electrical properties of
the heart. This thesis provides evidence that supports the idea that mTORC1 regulation
of ankyrin-B serves as the link between the hypertrophic response and arrhythmogenesis
in the stressed heart. The results I present in this thesis have wide-ranging implications
for heart diseases and central nervous system disorders, and uncovering the relationship
between mTORC1 activity and ankyrin regulation could potentially lead to novel
therapeutics.

5.2 Future experiments
There remain many questions to be addressed. First, how is the trafficking of
AnkB-188 handled and how does NCX1 get transported to the SR/T-tubule to be
anchored by AnkB-188? A related question is what are the interacting partners of
AnkB-212 such that its knockdown mediates arrhythmias? Second, what mechanism
directs mTORC1 downregulation/upregulation of ankyrin-B expression in the heart?
Third, how do the expressions of different ankyrin proteins change in the Tsc2-deficient
neurons and do different ankyrin proteins play a role in the neuropathology of TSC?
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The first two inquiries can be addressed by exogenously expressing GFP-tagged
full-length AnkB-188 and RFP-tagged NCX in the neonatal rat ventricular
cardiomyocytes starting immediately after isolation. The timepoint is important as the
sarcomeric structures are disturbed during the isolation procedure and will start to reorganize right after plating. At this time, we can perform live cell imaging on the
transfected NRVMs to monitor trafficking of AnkB-188 and NCX to the developing
transverse tubules.

The results of this study will differentiate whether AnkB-188

interacts with NCX first and then is co-transported to the SR/T-tubule. Alternatively,
separate intracellular transport machinery may exist for both AnkB-188 and NCX1 and
they may subsequently interact at the SR/T-tubule. Also, rate of protein turnover must
be balanced by the rate of protein synthesis.

Previously NCX half-life has been

determined to be around 27.2 hours in wild type cardiomyocytes [133], so future
experiments should determine mechanisms of transport and retention at the SR/T-tubule
for both AnkB-188 and NCX1. Similarly, to address the molecular transport of AnkB212, we will use GFP-tagged AnkB-212 and assess its transport from the Golgi network
to the M-line where it interacts with the M-line organizer protein obscurin.
Separately, to identify the unique interacting partners of each isoform, we will
precipitate macromolecular complexes associated with each of the two ankyrin-B
isoforms for mass spectrometry analysis. One of the most interesting and challenging
questions from our study in Chapter 4 is identifying the mechanism(s) responsible for
the abnormal contractions rhythms of the cardiomyocytes with decreased levels of
AnkB-212.

We may begin addressing this question by identifying the interacting

partners of AnkB-212.
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Although it has previously been demonstrated that calpain may be a mechanism
for ankyrin-B degradation in the heart [216], given our findings with decreased ankyrinB expression at the M-line following induced mTORC1 activation, we cannot discount
the fact that prolonged mTORC1 activation may induce autophagy from imbalance
between protein synthesis and degradation [285].

To address this issue, we will

investigate the role of autophagy in ankyrin-B regulation by inhibiting autophagy with
bafilomycin or chloroquine in models of mTORC1 overactivity.

If inhibition of

autophagy restores ankyrin-B expression at the M-line, it would highly suggest
mTORC1 regulates ankyrin-B expression at the M-line by increasing autophagic flux.
Alternatively, another key degradation pathway in the heart is the ubiquitin-proteasome
pathway [228].
Finally, virtually nothing is known regarding mTORC1-mediated regulation of
ankyrin proteins in the central nervous system. Fortunately, there is a well-characterized
TSC mouse model with overactive mTORC1 [98, 99]. Preliminary experiment will
assess expression of all three different ankyrin proteins, voltage-gated sodium and
potassium channels (known interacting partners of ankyrin-G) in brain lysates of the
Tsc2-hGFAP at embryonic day 15.5 (3 days after genetic mTORC1 activation), at birth,
and at postnatal day 21 (weaning age when the mice are nearing 50% mortality). The
results will be compared side-by-side with the mice treated with the combined
rapamycin protocol.
Ankyrin proteins, especially ankyrin-G, have been shown to be important for
establishing axo-dendritic polarity and axon initial segment (AIS) [287, 288]. Tsc2hGFAP mice have increased dendritic sprouting, neuronal migration and cortical
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lamination defects.

Therefore, another experiment will assess the establishment of

neuronal polarity from the neurite stage, dendritic arborization, axon initial segment
(AIS), and nodes of Ranvier formations in primary cortical neurons from Tsc2-hGFAP
mice by immunocytochemistry at different timepoints. It will be important to note the
clustering of the ankyrin proteins such as ankyrin-G at the AIS and nodes of Raniver and
ankyrin-B clustering at the developing axon and at the dendrites as migration and
cortical lamination defects may be secondary to a loss or delayed axo-dendritic
specification.
Lastly, since all Tsc2-hGFAP mice exhibit seizures and if mTORC1-mediated
dysregulated ankyrin protein expression mediates abnormal action potential conductance,
the necessary experiments are 1.) exogenously express the decreased or knockdown the
increased ankyrin in the Tsc2-hGFAP primary neurons, 2.) re-assess the expression and
localization of the respective interacting partners such as voltage-gated ion channels at
the appropriate subcellular domains by immunocytochemistry, and 3.) record the
intrinsic electrical activities in the neurons and assess the synaptic strength. Coupling
these findings with mTORC1 inhibition with rapamycin or torin1 (a potent in vitro
mTOR inhibitor) will establish mTORC1-mediated ankyrin expression/localization
changes as a mechanism for the abnormal electrical activities and neuropathologies in
TSC.
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A.1 Introduction
Increases in the rates of energy substrate metabolism are the first responders to
hemodynamic stress in the heart (Goodwin GW, Taylor CS, Taegtmeyer H. JBC 1998).
When subjected to a sustained increase in pressure, hearts remodel both metabolically
and structurally. Metabolically, hearts increase their reliance on carbohydrates for
energy provision (Goodwin GW, Taylor CS, Taegtmeyer H. JBC 1998; Bishop S and
Altschuld R. Am J Physiol 1970). Structurally, hearts hypertrophy (Dorn GW II, Force
T. JCI 2005). In independent studies we have previously demonstrated that the
footprints of metabolic remodeling precede structural remodeling of the heart in
hypertension and that activation of the insulin signaling pathway downstream of Akt
requires hexose-6-phosphate (Taegtmeyer H and Overturf ML. Hypertension 1988;
Sharma S et. al. Cardiovasc Res 2007). We now asked: Could the metabolic remodeling
process also regulate signaling pathways of structural remodeling in the heart?
Remodeling is to some extent driven by the mammalian target of rapamycin
(mTOR), a regulator of myocardial protein synthesis that is downstream of Akt in the
insulin signaling pathway. mTOR kinase nucleates 2 major protein complexes – mTOR
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Under stressed conditions,
mTORC1 activity in the heart is inhibited by the tuberous sclerosis complex (TSC),
composed of hamartin (TSC1) and tuberin (TSC2). Phosphorylation of a number of
serine and threonine residues on TSC2 relieves TSC’s inhibition on mTORC1 (Huang J
and Manning BD. Biochem J 2008; Inoki K et. al. Nat Cell Biol 2002). Activated
mTORC1 triggers protein synthesis and cardiac growth by phosphorylating p70S6
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kinase (p70S6K) and eIF-4E binding protein 1 (4E-BP1) to promote ribosomal
biogenesis and CAP-dependent protein translation, respectively.
It is already known that mTORC1 plays a critical role in promoting cardiac
growth in response to increased workload (Shioi T et. al. Circ 2003) and that mTORC1
is activated by nutrients and growth factors (Proud CG. Eur J Biochem 2002). Whether
inotropic mTORC1 activation is regulated by changes in energy substrate metabolism
that occur in response to increased workload is unknown, however. We therefore
investigated the functional and structural consequences of glucose-mediated mTOR
signaling in the stressed heart and discovered that it is both deleterious and preventable.

A.2 Materials and Methods
To determine whether enhanced glucose uptake regulates mTOR activation at
increased workload, we first tested the hypothesis ex vivo. The hearts were obtained
from 4 groups of animals: (1) rats pretreated with vehicle for 7 days before ex
vivo perfusion with noncarbohydrate substrates; (2) rats pretreated with vehicle for 7
days before ex vivo perfusion with glucose; (3) rats pretreated with mTOR inhibitor
rapamycin for 7 days before ex vivo perfusion with NCS; (4) rats pretreated with the
mTOR inhibitor rapamycin for 7 days before ex vivo perfusion with glucose. TABLE
A.1 lists the perfusion protocols. Each of the experimental groups was then evaluated in
normal workload conditions for 60 minutes or for 30 minutes at normal workload
followed by increased workload conditions for another 30 minutes. Hearts were
freeze‐clamped at the end of the protocol.
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Table A.1.Ex vivo perfusion protocols containing four different sets of rats used to study glucose regulated mTOR activation at
high workload. 1) untreated prior to perfusion; 2) received mTOR inhibitor rapamycin (PO, 4 mg/kg/day) for 7 days prior to
perfusion (or vehicle control); 3) received metformin (IP, 250 mg/kg/day or 500 mg/kg/day) for 7 days prior to perfusion (or
vehicle control). 4) hearts was perfused with metformin (10 mM, 7.5 mM, 5 mM) added directly to the buffer. No significant
differences in cardiac power were found between all perfusion groups under normal workload. *Animals were pretreated with
rapamycin.

A.2.1. Rationale for animal models used and overall strategy
The structural and functional response to increased workload has been
extensively studied in the murine transverse aortic constriction (TAC) model (Rockman
et. al. PNAS 1991). How the metabolic response to increased workload regulates these
changes has yet to be investigated. To systematically answer this question, we used 3
models. First, we used the isolated working rat heart ex vivo to elucidate the mechanisms
for the observed in vivo phenomena. The isolated working rat heart permitted a dynamic
minute‐by‐minute assessment of metabolism and function and allowed for assessment of
intracellular metabolites and activation of relevant signaling pathways at the end of the
perfusion. The ex vivo isolated working heart model was also chosen because it gave us
complete control over workload, substrate concentration, and hormone supply. Second,
we optimized in vivo 2‐deoxy, 2[18F]fluorodeoxy‐glucose positron emission tomography
(FDG‐PET) and magnetic resonance imaging (MRI) to simultaneously image changes in
metabolism, function, and structure in mice subjected to TAC for up to 4 weeks. In this
model we established that metabolic remodeling (enhanced glucose uptake) and
contractile dysfunction precede structural remodeling (growth and dilation of the left
ventricle). In addition, a set of mice underwent in vivo aortic banding for molecular and
metabolite analyses. Third, we analyzed left ventricular tissue from failing human heart
muscle before and after mechanical unloading with a left ventricular assist device to
correlate our findings to the failing human heart.
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A.2.2. Experimental groups
The experimental groups and conditions are listed in TABLE A.1. The animals
received standard laboratory chow and water ad libitum. A subset of rats received either
rapamycin (4 mg/kg per day) or vehicle control (propylene glycol) by oral gavage for 7
days before experimentation. A second subset received either metformin (250 or 500
mg/kg per day) or vehicle control (saline) intraperitoneally for 7 days before
experimentation. On day 7, animals were anesthetized with chloral hydrate (300 mg/kg)
and anticoagulated with heparin (200 U) immediately before their hearts were isolated
and perfused in the working mode as described previously (Taegtmeyer, Hems, Krebs.
Biochem J 1980). A third subset of untreated rats hearts were isolated and perfused with
metformin (10, 5, 1 mmol/L) added directly to the perfusion buffer.

A.2.3. Isolated working rat heart perfusions
To assess rates of myocardial glucose metabolism in response to increased
workload, male Sprague‐Dawley rats (387±11 g) were obtained from Harlan
Laboratories (Indianapolis, IN) and housed in the Animal Care Center of the University
of Texas Medical School at Houston under controlled conditions (23±1°C; 12‐hour
light/12‐hour dark cycle).
Briefly, hearts were perfused as working hearts (Taegtmeyer, Hems, Krebs.
Biochem J 1980) in the presence or absence of glucose (5 mmol/L) plus 0.05 µCi/L
[2‐3H]‐glucose to measure rates of glucose uptake and 20 µCi/L [U‐14C]‐glucose to
measure rates of glucose oxidation. In the absence of glucose, sodium propionate (2
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mmol/L) plus lithium acetoacetate (5 mmol/L) were used as a noncarbohydrate substrate
(NCS) control. Together these substrates fuel the Krebs cycle without generating any
upstream metabolites (Russell, Mommessin, Taegtmeyer. Am J Physiol 1995) and
sustain cardiac work in the absence of glucose and in the presence of nonmetabolizable
glucose analogues (Doenst, Taegtmeyer. J Nucl Med 2000). Hearts perfused with NCS
were first perfused substrate‐free for 15 minutes to deplete endogenous glycogen stores
(Goodwin, Taegtmeyer JBC 1998). Under steady‐state conditions, hearts were perfused
at a normal (physiological) workload (afterload set to 100 cm H2O) for 60 minutes
(protocol A). Hearts subjected to a high workload were perfused for 30 minutes at
normal workload followed by 30 minutes of perfusion at increased workload (afterload
raised to 140 cm H2O plus 1 µmol/L epinephrine bitartrate added to the perfusate;
protocol B). Left atrial pressure was 15 cm H2O in each perfusion protocol. At 60
minutes the beating hearts were freeze‐clamped with aluminum tongs cooled in liquid
nitrogen. A portion of frozen heart tissue was weighed and dried to constant weight. The
remainder was stored at −80°C for further analyses.

A.2.4 Cardiac power, oxygen consumption, metabolic rates, metabolite
concentrations
In ex vivo isolated working hearts, coronary and aortic flows were recorded every
5 minutes, and aortic pressures were recorded continuously with a 3F Millar pressure
transducer (Millar Instruments, Houston, TX) in sidearm to the aortic cannula linked to a
physiologic recorder (Gould Model 2400S, Gould Instruments, Cleveland, OH). Cardiac
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power (in milliwatts) was calculated as the product of cardiac output (coronary plus
aortic flow, m3/s) and mean aortic pressure (in pascals).
Myocardial oxygen consumption and rates of glucose uptake and oxidation were
determined as previously described (Goodwin, Taegtmeyer. JBC 1998; Katz, Dunn.
Biochemistry 1967). ATP, ADP, and AMP levels were quantified in freeze‐clamped
hearts as described previously (Taegtmeyer. JMCC 1985). Glucose 6‐phosphate levels
were measured by spectrophotometric enzymatic analysis using glucose 6‐phosphate
dehydrogenase coupled to NADPH production with extinction at 340 nm (Bergmeyer
HU. Methods of Enzymatic Analysis 1974).

A.2.5. PET and MRI imaging
Male C57BL/6 mice (8 to 9 weeks of age) obtained from Charles River
Laboratories (Raleigh, NC) were subjected to sham operation or transverse aortic
constriction to induce pressure‐overload hypertrophy by methods previously described
(Liao, Takashima. Circ Res 2003). All mice were housed in a 12‐hour light/12‐hour
dark cycle and given standard laboratory chow and water ad libitum. Prior to imaging,
animals were fasted overnight with access to water. All experiments were performed in
compliance with the Guide for the Care and Use of Laboratory Animals, published by
the National Institutes of Health, and were conducted under protocols approved by the
Animal Care and Use Committee at the University of Virginia.
Left ventricular pressure measurements were performed using a Mikro‐tip
Catheter Transducer (Model SPR‐671, size 1.4F; Millar Instruments Inc, Houston, TX)
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connected to Millar and PowerLab hardware and ADI Software (AD Instruments Inc,
Colorado Springs, CO). Animals were anesthetized with 3% isoflurane and maintained
at 1% to 2% while the catheter was placed in the right carotid artery under
stereomagnification and advanced through the aorta so that the tip was positioned in the
left ventricle. Heart rate and cardiac pressure were continuously monitored throughout.
Body temperature was maintained at 37°C with a warming blanket.
FDG‐PET and MRI were sequentially performed in anesthetized animals. PET
imaging was performed in a Focus 120 micro PET scanner (Siemens Molecular Imaging
Inc, Knoxville, TN) to assess changes in metabolism. The protocol was initiated by
injecting 150 to 200 µL of 18.5‐37 MBq FDG solution intravenously over a period of 1
minute. Myocardial glucose uptake was assessed using FDG (IBA Molecular, Sterling,
VA) at baseline, 1 day, 2 weeks, and 4 weeks after surgery. The net FDG influx constant,
Ki (mL/min per gram), was measured over a period of 4 weeks (Locke, Berr, Kundu.
Mol Imaging Biol 2011). Determination of Ki is considered a robust index of glucose
transport and phosphorylation (Nguyen, Mossberg, Taegtmeyer. Am J Physiol
1990). Therefore, our present work focused on determination of Ki with partial volume
and attenuation corrections in vivo. Throughout the procedure, heart rate, respiration,
and body temperature were recorded with a physiological recorder (model 1025L; SA
Instruments, Inc, Stony Brook, NY), and the ECG was monitored (Blue Sensor, Ambu
Inc, Glen Burnie, MD). All the signals were sent to a single SA Instruments software
interface, which was configured to trigger data acquisition based on the ECG. The SAI
1025L was also used to maintain the animal's core body temperature at 37°C.
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Mice were also imaged using a 7T Bruker‐Siemens Clinscan MRI system for
structural and functional analyses of the heart. After once again being anesthetized, each
mouse was placed prone inside the radiofrequency coil, and the ECG leads were
connected to an ECG monitoring module (SA Instruments, Inc, Stony Brook, NY). An
ECG‐triggered 2‐dimensional cine gradient echo pulse sequence was used (Berr, Roy,
French. Magn Reson Med 2005), with a slice thickness of 1 mm and a zero‐filled,
in‐plane resolution of 100×100 µm2. During each session, the entire left ventricle (LV)
was imaged with 6 to 7 contiguous short‐axis slices. The MR images were analyzed
using the ARGUS software package (Siemens Medical Systems, Erlangen, Germany) for
left ventricular end‐systolic volume, left ventricular end‐diastolic volume, and left
ventricular ejection fraction was computed from the traced borders. Epicardial contours
were also traced at the end‐diastolic and end‐systolic phases to compute LV mass
(Vinnakota, Bassingthwaighte. Am J Physiol Heart Circ Physiol 2004). This was
divided by the body weight to obtain the heart weight to body weight (HW/BW) ratios.

A.2.6. Transgenic mice overexpressing cardiac‐‐specific isoform of SERCA2a
Transgenic mice overexpressing rat SERCA2a (TG) in heart were produced as
described before (He, Giordano, Dillmann. JCI 1997). Ascending aortic constriction
was performed in both TG and age‐matched wild‐type mice to induce pressure‐overload
left ventricular hypertrophy (Pinz, Tian, Ingwall. JBC 2011). Mice were studied 8
weeks after surgery. Cardiac function was assessed by M‐mode echocardiography.
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Subsequently, hearts were freeze‐clamped and stored at the temperature of liquid
N2 before extraction at a later time. Sham‐operated mice were used as controls.

A.2.7. Tissues from failing human hearts
Cardiac tissue samples were obtained from 11 nondiabetic patients with idiopathic
dilated cardiomyopathy (10 were male) referred to the Texas Heart Institute for heart
transplantation and placed on left ventricular assist device (LVAD) support for a mean
duration of 254±63 days. Tissue from the left ventricular apex was obtained during
LVAD implantation and again during LVAD explantation (each patient went on to
transplantation). Tissue samples were immediately frozen in liquid nitrogen and stored at
−80°C for metabolic and molecular analyses at a later time. TABLE A.2 provides
further detail on the patients assessed in this study. The protocol was approved by the
Committee for the Protection of Human Subjects of St. Luke's Episcopal Hospital in
Houston, Texas, and of the University of Texas Medical School at Houston.
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Gender
Ethnicity
Mean age
Mean LVEDD before
LVAD
Mean LVEDD after LVAD
Mean EF before LVAD

10 males, 1 female
5 Caucasian, 5 African-American, 1 Hispanic
48±4 years (range, 19-67)
75.33±4.40 mm
55.67+±3.22 mm
21±3%

Table A.2. Clinical Data: Samples from Failing Human Hearts. LVEDD, left ventricular
end-diastolic dimension; LVAD, left-ventricular assist device; EF, ejection fraction

A.2.8. Western Blot Analyses
Protein was extracted from frozen heart tissue after homogenization (Polytron,
Brinkman Instruments), and Western blot analyses were performed as previously
described (Razeghi, Sharma, Taegtmeyer. Circ 2003). Antibodies for PI3K, Akt 1/2,
TSC2, mTOR, RAPTOR, p70S6K1, 4EBP1, AMP kinase (AMPK), acetyl CoA
carboxylase (ACC), phospho‐PI3K p85 (Tyr458), phospho‐Akt1/2 (Ser473),
phospho‐TSC2 (Ser939), phospho‐TSC2 (Ser1387), phospho‐mTOR (Ser2448),
phospho‐p70S6K (Thr389), phospho‐4EBP1 (Thr70), phospho‐AMPKinase (Thr172),
phospho‐ACC (Ser79), and phospho‐RAPTOR (Ser792) were obtained from Cell
Signaling (Beverly, MA). GAPDH was used to normalize for protein loading (Research
Diagnostics, Flanders, NJ). Densitometry was performed with ImageJ program provided
by the NIH. For clarity, densitometry values (mean±SEM) are presented for all blots
collectively following the figures.

A.2.9. RNA Extraction and qRTPCR
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For transcriptional analysis, total RNA was extracted with TRI Reagent
(Molecular Research Center, Cincinnati, OH) and treated for genomic DNA
contamination with DNA‐free (Applied Biosystems/Ambion, Austin, TX). RNA
concentration was measured with a NanoDrop 1000 Spectrophotometer (Thermo
Scientific, Wilmington DE). Absolute quantification of transcripts was based on known
amounts of synthetic DNA standard (Integrated DNA Technologies, Coralville, IA).

A.3 Results

A.3.1. mTORC1 Activation and Impaired Cardiac Power With Increased
Workload
Irrespective of the substrate present in the perfusate, increased workload alone
induced phosphorylation of PI3K, and Akt at both Thr308 and Ser473 (Figure A.1A).
However, strong phosphorylation of TSC2, mTOR, p70S6K, and 4EBP1 was observed
only in the presence of glucose at high workload. Rapamycin pretreatment of the rats
for 1 week inhibited phosphorylation of Akt at both Thr308 and Ser473, TSC2,
mTORC1, p70S6K, and 4EBP1. mTORC1 signaling was not activated in hearts
perfused either at normal workload with glucose or at increased workload in the absence
of glucose.
To determine the functional consequence of mTORC1 activation, we measured
cardiac power in hearts from vehicle‐treated and rapamycin‐treated rats perfused with
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glucose or non-carbohydrate substrate (NCS) (Figure 1B). At normal workload, there
was no significant difference in mean cardiac power between the experimental groups.
When subjected to increased workload, all perfused hearts demonstrated an increase in
cardiac power relative to their normal workload values. However, in the
vehicle‐pretreated group, hearts perfused with glucose as the only substrate did not
increase their cardiac power to the same extent as the other 2 groups. Because this
differential effect of glucose on cardiac power was mitigated by pretreatment with
rapamycin, the difference is most likely mTORC1 dependent.

Normal Workload

A

High Workload (Hemodynamically Stressed)
NCS

Glucose
RAPAMYCIN

(Tyr 458) P PI3K
PI3K
(Thr 308) P Akt
(Ser 473) P Akt
Akt 1/2
(Ser 939) P TSC2
TSC2
(Ser 2448) P mTOR
mTOR
(Thr 389) P p70S6K
p70S6K
(Ser 65) P 4EBP1
4EBP1
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B
epinepherine (1 uM) +
increase afterload

*
* * *

Figure A.1. At high workload, glucose activates mTORC1 and impairs cardiac power
in perfused rat hearts. Pretreatment of animals with rapamycin inhibits mTORC1 and
rescues contractile function. A, Representative Western blots of the mTORC1 signaling
pathway in hearts freeze‐clamped at the end of perfusion. High workload resulted in
phosphorylation of PI3K and Akt in all hearts. However, phosphorylation of TSC2,
mTOR, and p70S6K at high workload occurred only in the presence of glucose.
Pretreating rats for 7 days with rapamycin (4 mg/kg per day) before perfusion of the
heart resulted in decreased phosphorylation of Akt, TSC2, mTOR, and its downstream
targets. B, At normal workload there was no difference in cardiac power among the 3
groups. At high workload the presence of the glucose substrate decreased cardiac power
in hearts from vehicle‐treated rats. Pretreatment of rats with rapamycin for 7 days
rescued cardiac performance in glucose‐perfused hearts. Data shown are mean±SEM;
n=5 to 7 for each group. *p<0.05 (Mann–Whitney rank sum test) for hearts from
vehicle‐treated rats perfused with glucose in comparison with hearts from vehicle‐treated
rats perfused with NCS and those from rats pretreated with rapamycin and perfused with
glucose at high workload. mTOR indicates mammalian target of rapamycin; TSC2,
tuberin; NCS, noncarbohydrate substrate.
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A.3.2. Oxygen Utilization and Mitochondrial Efficiency Were Not Affected By
Increased Workload or Rapamycin Treatment
To evaluate whether the differences in cardiac power were the result of changes
in efficiency, we also measured oxygen consumption in groups at comparable workloads.
There was no difference in oxygen consumption (Figure A.2A) or efficiency (Figure
A.2B) between groups at comparable workloads.

Figure A.2. Pretreatment
with rapamycin has no effect
on cardiac efficiency in rat
hearts perfused with glucose
at high workload. A,
Myocardial oxygen
consumption (MVO2) at low
and high workloads did not
differ in hearts perfused with
noncarbohydrate substrate
(NCS) and in hearts from rats
pretreated with vehicle or with
rapamycin and perfused with
glucose. B, Cardiac efficiency,
as calculated by dividing
cardiac power by MVO2, was
also unchanged. The dot plots
show individual
measurements for each heart
at 2 different workloads.
Comparison within each
group and between groups
showed no significant
difference (p>0.05).
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We also measured UCP3. Both mRNA (Figure A.3A) and protein (Figure A.3B)
levels of UCP3 were unchanged with rapamycin treatment or increased workload,
suggesting that mitochondrial efficiency was also unchanged with rapamycin
pretreatment (2 to 3 repeated measures for each animal). We also noted that under all
experimental conditions the adenine nucleotide levels (ATP, ADP, and AMP) did not
differ significantly despite differences in mTORC1 activity and contractile function
(data not presented). This is in keeping with our earlier observation that the levels of
ATP, ADP, and AMP as well as total adenine nucleotides do not change with increased
workload of the perfused heart (Taegtmeyer. JMCC 1985).
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Figure A.3. Uncoupling protein 3 (UCP3) mRNA and protein levels are not associated
with G6P‐mediated mammalian target of rapamycin (mTOR) activation. A, Transcript
analysis of UCP3 gene expression in isolated working rat hearts. The dot plots show
median values for n=2 to 3 rat hearts with 2 to 3 repeats per animal. P>0.05 for all
comparisons based on Friedman test on repeated measurements of all hearts in each
group compared with hearts perfused with noncarbohydrate substrate (NCS) at a normal
workload. Neither workload nor glucose in the perfusate nor pretreatment of mice with
rapamycin changed UCP3 mRNA expression at the end of perfusion. B, Compared with
hearts perfused with NCS at a normal workload, neither workload, glucose, nor
rapamycin pretreatment changed UCP3 protein levels

A.3.3. Glucose 6‐‐Phosphate (G6P) and mTOR Activation
To elucidate possible mechanisms of glucose‐mediated mTORC1 activation,
rates of glucose uptake and oxidation were simultaneously quantitated in ex vivo hearts.
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At normal workload, rates of glucose uptake (4.2±0.7 µmol/min per gram dry
weight) matched rates of glucose oxidation (3.9±0.7 µmol/min per gram dry weight).
However, when the workload was increased, rates of glucose uptake (11.5±0.8 µmol/min
per gram dry weight) exceeded rates of glucose oxidation (9.5±0.6 µmol/min per gram
dry weight) by >10%. Rapamcyin pretreatment reduced rates of glucose uptake and
rates of glucose, correcting the mismatch between glucose uptake and oxidation (Figure
A.4A). Lactate production, an indirect measure of glycolytic activity, was unchanged in
both groups (data not shown).
Because mTORC1 activation was associated with a suggested mismatch between
glucose uptake and oxidation, we investigated whether the accumulation of glucose or
one of its metabolites was associated with mTORC1 activation. G6P levels were 4‐fold
higher on average in hearts subjected to an acute increase in workload (4.8±1.0 nmol/mg
protein) compared with hearts perfused at normal workload (1.3±0.2 nmol/mg protein).
Rapamycin pretreatment severely reduced the tissue content of G6P (0.36±0.1 nmol/mg
protein) in hearts perfused with glucose at increased workload (Figure A.4B). In
contrast, levels of other glycolytic intermediates were unchanged at high workload (data
not shown).
To assess whether hexose‐6‐phosphate accumulation leads to load‐induced
mTORC1 activation, we next perfused 2 groups of hearts with either of the 2 glucose
analogues: 3‐O‐methylglucose (which is transported in and out of the cardiomyocyte,
but not metabolized), or 2‐deoxyglucose (which is taken up by the cardiomyocyte,
phosphorylated, and trapped as a G6P analogue and not further degraded) (Doenst and
Taegtmeyer. J Nucl Med 2000). 2‐Deoxyglucose, but not 3‐O‐methylglucose, increased
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To assess whether hexose 6-phosphate accumulates and activates mTORC1 in a

physiologic setting, we perfused hearts with a “physiological” mix of substrates (a

combination of glucose, NCS, and the long‐chain fatty acid oleate) at both normal and

high workloads to mimic more closely the metabolic milieu of hearts in vivo. Indeed,
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to high workload, rates of glucose uptake exceed rates of glucose oxidation, hexose 6‐phosphate accumulates,
A, Rates of glucose uptake exceeded rates of glucose oxidation in hearts from rats pretreated with either vehicle
sed at normal and high workloads. Pretreating rats with rapamycin significantly reduced rates of both glucose
ight). Data shown are mean±SEM; n=5 to 6 per group. *p=0.07 with Mann–Whitney rank sum test. B, Glucose
ls in freeze‐clamped hearts. Subjecting hearts to high workload ex vivo induced a 4‐fold increase in average G6P
served when rats were pretreated with rapamycin. Dot plots show G6P levels for each heart. Kruskal–Wallis test
. C, To test the hypothesis that hexose‐6‐phosphate (and no other glucose metabolite) activates mTOR, we also
S plus 2‐deoxyglucose or 3‐O‐methylglucose. Representative Western blots of Akt, TSC2, mTOR and p70S6K
earts perfused with glucose (5 mmol/L) or NCS plus the glucose analogues 2‐deoxyglucose (2DG; 5 mmol/L), or
MG; 5 mmol/L) at either normal or high workload are shown. Glucose or 2DG, but not 3OMG, increased
2, mTOR, and p70S6K at high workload. mTOR indicates mammalian target of rapamycin; TSC2, tuberin; NCS,
te

phosphorylation of TSC2, mTOR, and its downstream targets in hearts perfused at high

workload (Figure A.4C). mTOR and its downstream targets were not phosphorylated in

hearts perfused with either glucose analogue at normal workload. These experiments

provided strong evidence that hexose phosphate levels are associated with mTORC1

activation in hearts subjected to increased workload.

although not quite statistically significant, hearts perfused with this “physiological” mix
of substrate at high workload displayed a 2.5‐fold increase on average in G6P levels
(Figure A.5A) and increased phosphorylation of both downstream targets of mTORC1,
p70S6K and 4EBP1 (Figure A.5B) compared with hearts perfused with NCS.
Phosphorylation of the mTORC1 targets are similar between hearts perfused with
physiologic substrates and glucose alone.

Figure A.5. In the presence of mixed substrates (glucose, NCS, and oleate), G6P levels
are increased and mTORC1 signaling is activated at high workload. A, G6P accumulates
in hearts perfused with glucose, oleate, and NCS. Dot plot shows G6P levels for each
heart at the end of perfusion at low or high workload; p=0.083 using Mann–Whitney test.
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B, Representative Western blots showing phosphorylation of mTORC1 targets p70S6K
and 4EBP1 in ex vivo working rat. Both glucose and mixed substrates in the perfusate
increased p70S6K and 4EBP1 phosphorylation. NCS indicates noncarbohydrate
substrate; mTOR, mammalian target of rapamycin; G6P, glucose 6‐phosphate.

A.3.4. G6P‐‐Dependent mTOR Activation and AMPK Downregulation
Next we investigated the effect of enzyme 5′‐AMP activated protein kinase
(AMPK), an enzyme with a dual role in signaling and metabolic regulation. AMPK is
upstream of TSC2 and mTORC1 and regulates fuel supply and substrate metabolism in
the heart. When phosphorylated at Thr172, AMPK phosphorylates and inhibits
acetyl‐CoA carboxylase (ACC), which is also used as a marker of AMPK activation.
AMPK also phosphorylates TSC2 (Ser1387) and RAPTOR (Ser792) to inhibit mTORC1.
Neither increased workload nor glucose alone was associated with a change in AMPK
phosphorylation (Figure 6A). However, perfusion at increased workload with glucose
resulted in downregulation of phospho‐AMPK (Thr172), phospho‐ACC (Ser79), and
phospho‐TSC2 (Ser1387). Pretreating animals with rapamycin prevented the
downregulation of AMPK, ACC, and TSC2 phosphorylation with increased workload
and glucose as the only substrate. RAPTOR (Ser792) phosphorylation was unchanged
with workload or rapamycin treatment (Figure A.6A).
To determine the functional consequences of AMPK activation, hearts from rats
pretreated with metformin (500 mg/kg per day for 7 days IP) to pharmacologically
activate AMPK underwent ex vivo working heart perfusions. Metformin restored cardiac
power by 26% in hearts perfused with glucose substrate at increased workload (Figure
A.6B); 2 time points were statistically significant (denoted by asterisks in the figure).
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To examine whether changes in glucose metabolism secondary to AMPK activation
were associated with the restoration of cardiac power, rates of glucose uptake and
oxidation were quantitated. Systemic metformin pretreatment did not change rates of
glucose uptake (11.7±1.1 µmol/min per gram dry weight) in perfused hearts subjected to
high workload, but it improved rates of glucose oxidation (11.0±0.7 µmol/min per gram
dry weight) (Figure A.6C) and blunted G6P accumulation (2.1±0.1 nmol/mg protein)
compared with vehicle‐pretreated animals (Figure A.6D). To further determine whether
AMPK mediates glucose‐dependent mTORC1 activation, animals were treated with the
AMPK activator metformin for 7 days (500 or 250 mg/kg per day IP) before perfusion
with glucose at high workload. Systemic treatment with metformin prevented AMPK
downregulation and inhibited mTOR activation in hearts perfused with glucose at high
workload (Figure A.6E). Metformin treatment had no effect on mTOR phosphorylation
or on cardiac power in hearts perfused at physiologic workload (data not shown). To
circumvent systemic or off‐target effects of metformin, we also perfused hearts of
untreated animals with buffer containing metformin. The perfusion of hearts with buffer
containing metformin demonstrated that metformin prevented AMPK downregulation
and inhibited mTORC1 activation in a dose‐dependent manner (Figure A.6E).
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Figure A.6. G6P‐dependent mTOR activation is associated with downregulation of
AMPK. A, Representative Western blots demonstrate reduction in phosphorylation of
AMPK (T172) and ACC (S79), its downstream target, in hearts perfused with glucose at
high workload. B, Contractile performance in the working heart perfused with glucose in
the presence and absence of metformin. Data shown are mean±SEM; n=5 to 7 for each
group. Metformin improves cardiac power at high workload. *P<0.05, #p=0.08, using
Mann–Whitney rank sum test. C, Rates of glucose uptake and oxidation by hearts from
animals receiving vehicle or metformin pretreatment for 7 days (vehicle treated,
metformin treated). Data shown are mean±SEM; n=5 to 6 per group. Metformin
treatment did not change rates of glucose uptake and oxidation at normal workload. At
high workload, pretreating animals with metformin corrected the mismatch between
rates of glucose uptake and oxidation. ‡p=0.021 using Mann–Whitney rank sum test. D,
G6P levels in hearts from rats receiving either vehicle or metformin for 7 days before
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perfusion of their hearts with glucose as the only substrate. Dot plots of G6P show
individual measurements for each heart at normal and high workloads. G6P
accumulation was reduced in stressed hearts perfused with glucose in hearts of animals
pretreated with metformin. Kruskal–Wallis test yielded an overall p=0.012. E,
Representative Western blots demonstrating increased AMPK phosphorylation and
decreased p70S6K as well as 4EBP1 phosphorylation in hearts from animals pretreated
for 7 days with metformin (500 or 250 mg/kg) and perfused with glucose at high
workload or in hearts from untreated animals perfused with glucose plus metformin at
high workload. The concentrations of metformin in the perfusate were (a) 10 mmol/L, (b)
7.5 mmol/L, or (c) 5 mmol/L. mTOR indicates mammalian target of rapamycin; AMPK,
AMP kinase; ACC, acetyl‐CoA carboxylase; G6P, glucose 6‐phophate; MF, metformin.

A.3.5. Metabolic, Structural, and Signaling Remodeling in Response to Increased
Workload In Vivo
We wondered whether the findings observed ex vivo correlate with hearts
subjected to pressure overload in vivo. In mice subjected to aortic constrictions (TAC),
transverse end‐diastolic mid‐ventricular positron emission tomography (PET) images
indicated an increase in 2‐deoxy,2‐fluoro‐d‐glucose (FDG) uptake beginning 1 day after
transverse aortic constriction (TAC), which increased further and was sustained over 4
weeks (Figure A.7A). Sham‐operated animals showed no change in FDG uptake over
the same period. Quantitatively, a 5‐fold increase in the rate of myocardial FDG uptake,
Ki (mL/min per gram), a specific measurement of metabolic remodeling, was observed 1
day after TAC using a 3‐compartment model (Figure A.7B). The rate of FDG uptake
continued to increase (1.5‐ to 3.2‐fold) over time from 1 day to 4 weeks. Calculated
Ki at baseline (0.11±0.03) agreed well with the measured Ki (0.14±0.06) obtained from
arterial blood samples used for input function estimation. No significant difference in
Ki values was observed over 4 weeks in shams. In addition, we assessed G6P levels in
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these hearts 1 day and 2 weeks after TAC to corroborate the metabolic remodeling
observed with PET imaging. We observed a slight increase in G6P levels 1 day after
TAC, and the increase was more pronounced 2 weeks after TAC (Figure A.7C). To
determine the association between the increased G6P levels and mTORC1 activation in
vivo, we assessed G6P levels and mTORC1 signaling 1 day and 2 weeks after TAC.
Representative Western blots demonstrated an apparent increase in p70S6K and 4EBP1

phosphorylation at both time points (Figure A.7D).

Figure A.7. Metabolic remodeling and mTOR activation precede structural remodeling
in hearts subjected to high workload in vivo. A, Representative serial transverse,
end‐diastolic PET slices for TAC and sham‐operated mice 1 day, 2 weeks, and 4 weeks
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after surgery. One day after TAC, there was an increase in FDG uptake that increased
further over 4 weeks. B, Quantification of the rate of cardiac FDG uptake (Ki) of PET
images from all TAC (n=8) and sham‐operated (n=5) mice. Data shown are mean±SEM.
Ki in TAC mice demonstrated a 5‐fold increase in FDG uptake on day 1 and a 1.5‐ to
3.2‐fold increase from day 1 to 4 weeks. Sham‐operated mice showed no significant
change in FDG uptake over 4 weeks. Comparisons at different times within TAC group:
day 1 vs baseline (BSL), #p<0.05; 2 weeks vs BSL or day 1, **p<0.05; 4 weeks vs BSL,
day 1, or 2 weeks, *P<0.001. Comparisons between TAC and sham groups at the same
points, ^p<0.05. C, Tissue G6P levels in hearts after TAC or sham operation at baseline
and after 1 day and 2 weeks. Dot plots of G6P levels for each group; n=6 for TAC and
n=5 for sham. G6P levels were 2.3‐ and 4.6‐fold higher compared with sham‐operated
animals 1 day and 2 weeks after TAC, respectively. Kruskal–Wallis test yielded
overall p=0.0356. D, Representative Western blots demonstrated an increase in p70S6K
and 4EBP1 phosphorylation 1 day and 2 weeks after TAC. mTOR indicates mammalian
target of rapamycin; PET, positron emission tomography; TAC, transverse aortic
constriction; FDG, 2‐deoxy, 2[18F]fluorodeoxy‐glucose.

A.3.6. Structural and Functional Remodeling in Response to Increased Workload
In Vivo
Although significant change in metabolic remodeling was observed starting 1
day after TAC, there was no appreciable change at this early time in the heart weight to
body weight ratio (HW/BW; Figure 8A). On day 1 there was a small increase in wall
thickness. However, the increase in left ventricular pressure was accompanied by a
much greater increase in the rate of glucose uptake (Figure 7A) and a decrease in the
ejection fraction (Figure 8E). Thus, profound changes in cardiac metabolism were
accompanied by functional changes (decreased ejection fraction), whereas the structural
changes were small in the acute period. TABLE A.3 summarizes additional metabolic,
functional, and structural parameters measured 1 day after TAC.
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TABLE A.3. Comparison of baseline and day 1 values for different parameters among
TAC mice. P-values were obtained using the Wilcoxon signed rank test. Change (%)
indicates average change from baseline to day 1 in each of the measured corresponding
parameters; “n” indicates number of animals used in each of the measured corresponding
parameters; TAC, transverse aortic constriction; HW/BW, heart weight to body weight
ratio; LV, left ventricle.
To see whether functional and structural changes accompany metabolic and cell
signaling changes after TAC, end-diastolic wall thickness, end‐diastolic volume (EDV),
end‐systolic volume (ESV), and ejection fraction (EF) were followed for a period up to 4
weeks. 2 and 4 weeks after TAC, the HW/BW had increased by 1.4‐ and 1.7‐fold,
respectively (Figure A.8A). Similarly, end‐diastolic wall thickness increased
significantly (Figure A.8B). Increases in the ESV (Figure A.8C) and EDV (Figure A.8D)
and significant decreases in the EF (Figure A.8E) followed the metabolic changes seen 1
day after TAC. Both the ESV and EDV (Figure A.8C and D) progressively increased 2
and 4 weeks after TAC. Subsequently, the EF continued to decrease 1.4‐ and 1.6‐fold 2
and 4 weeks after TAC, respectively. No significant changes in HW/BW, wall thickness,
EDV, ESV, or EF were observed in sham‐operated animals over 4 weeks.
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Taken together, the in vivo imaging experiments support the hypothesis that
metabolic, signaling, and functional changes precede or accompany structural changes in
pressure overload‐induced left ventricular hypertrophy (LVH).
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Figure A.8. In vivo structural and functional changes accompany metabolic changes in response to
pressure overload. Data shown are mean±SEM; n=8 for TAC and n=5 for shams. A, Ratio of heart
weight (HW) measured using MRI and body weight (BW). HW/BW ratio remained unchanged 1 day
after TAC, but increased by 1.4‐ and 1.7‐fold between day 1 and 4 weeks, respectively. HW/BW showed
no significant change over 4 weeks in sham‐operated mice. B, End‐diastolic wall thickness measured in
vivo using MRI. Wall thickness was unchanged 1 day after TAC, but increased about 1.4‐fold between
day 1 and 4 weeks. Wall thickness showed no significant change over 4 weeks in sham‐operated mice.
End‐systolic volume (ESV; C), end‐diastolic volume (EDV; D), and resultant ejection fraction (EF; E)
assessed in vivo using MRI imaging. An increase in ESV and decline in EF occurred 1 day after TAC.
Sham‐operated mice exhibited no significant change in EDV, ESV, and EF over 4 weeks. Comparisons
at different times in the TAC group: day 1 vs baseline (BSL), #P<0.05; 2 weeks vs BSL or day 1,
**P<0.05; 4 weeks vs BSL or day 1, *P<0.01; BSL vs day 1, 2 weeks, and 4 weeks, †P<0.05.
Comparisons between TAC and sham groups at the same points, ^P<0.05. Two‐way repeated‐measures
ANOVA analyzed, and Holm‐Sidak post hoc test performed to obtain individual significance factors.
TAC indicates transverse aortic constriction.
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A.3.7. Failing Human Hearts Before and After Unloading With a Left Ventricular
Assist Device (LVAD)
Finally, we assessed whether the findings in rodent heart had any relevance in the
failing human hearts of patients with nonischemic idiopathic dilated cardiomyopathy
receiving a left ventricular assist device to unload the heart as bridge to transplant.
Changes in energy substrate metabolism have been observed in failing human hearts
(Razeghi, Taegtmeyer. Circ 2001; Razeghi, Taegtmeyer. Cardiology 2002). We noted
that G6P levels dramatically decreased after mechanical unloading (Figure A.9A), and to
investigate whether changes in cardiac glucose metabolism accompanied changes in
mTORC1 activation in the human hearts, we assessed the downstream targets of
mTORC1 activity by the phosphorylation status of p70S6K and 4EBP1.
Phosphorylation of p70S6K and 4EBP1 (Figure A.9B) decreased after mechanical
unloading with an LVAD, suggesting that tight coupling of glucose uptake and oxidation
with mechanical unloading led to decreased mTORC1 activity.
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Figure A.9. Mechanical unloading of failing human hearts results in reduced G6P
accumulation and reduced mTORC1 activation. A, Tissue G6P levels for individual
patients with idiopathic dilated cardiomyopathy before and after mechanical unloading;
n=11 paired samples, p<0.05 using paired t test. B, Representative Western blots of
p70S6K and 4EBP1 before and after mechanical unloading. Each “implant” refers to
time of LVAD implantation and “explant” refers to removal of post-LVAD heart at the
time of transplantation. Each adjacent “implant” and “explant” constitute 1 patient's
heart—4 total patients. G6P indicates glucose 6‐phosphate.
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A.4 Disucssion
We set out to test the hypothesis that a metabolic signal links hemodynamic
stress with activation of the mTOR pathway. Our main findings are summarized in
Figure A.10 and include the following points. (1) Doubling the workload of rat hearts
perfused ex vivo with glucose as the only substrate increases rates of myocardial glucose
uptake beyond the hearts' oxidative capacity, resulting in G6P accumulation, which
mediates load‐induced mTOR activation. (2) Load‐induced mTOR activation impairs
cardiac power and induces ER stress response in a glucose‐dependent manner.
Administration of rapamycin or metformin in vivo rescues cardiac power. (3) Correcting
the mistmatch between glucose uptake and oxidation in the stressed heart prevents G6P
accumulation and rescues contractile function in hearts subjected to pressure overload.
(4) In hearts subjected to increased workload, metabolic remodeling precedes structural
remodeling of the heart and accompanies load-induced contractile dysfunction. (5) In
the failing human heart, mechanical unloading decreases levels of G6P and reduces
mTORC1 activation.
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Figure A.10. Proposed mechanism by which G6P accumulation regulates load
load‐induced
induced
mTORC1 activation. The intersections of the metabolic pathway of glucose transport and
phosphorylation with the molecular signaling pathways addressed in the study are shown. We
propose that rapamycin (mTORC1
C1 inhibitor), metformin (AMPK activator
activator),
), or LVAD
(mechanical unloading) protect the heart from metabolic stress at high workload. G6P indicates
glucose‐6‐phosphate; mTORC1,, mammalian target of rapamycin complex 1;; AMPK, AMP
kinase; LVAD, left ventricular assist device; HK, hexokinase; TSC, or tuberous sclerosis
complex, is composed of TSC1 (hamartin) and TSC2 (tuberin)
(tuberin).

These findings deserve consideration in a broader context. Although the normal
heart preferentially oxidizes fatty acids, the increased energy requirements of hearts
subjected to high workload are met by the oxidation of carbohydrates (Goodwin GW,
Taylor CS, Taegtmeyer H. JBC 1998). The classic explanation for this phenomenon is
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based on the hypothesis that the heart oxidizes the most efficient substrate for a given
environment (Taegtmeyer H, Hems R, Krebs HA. Biochem J 1980). Aside from merely
providing energy for cell function, however, glucose metabolites also regulate gene
expressions in the liver, pancreatic β‐cells (Girard J, Ferre P, Foufelle F. Annu Rev Nutr
1997; Schuit FC et. al. Diabetes 2001), and heart (Young ME et. al. Gene Regul Syst Bio
2007). More recently, we have suggested that the glucose metabolite G6P mediates
activation of the transcription factor carbohydrate responsive binding protein (ChrebP)
(Li MV et. al. Biochem Biophys Res Commun 2010) and that G6P activates
insulin‐dependent mTOR signaling in the unstressed heart (Sharma S. et. al. Cardiovasc
Res 2007). We now provide evidence in 3 models (mouse, rat, and human heart) to
suggest that load‐induced mTOR activation and the ensuing ER stress are mediated by
G6P, as well.
Until now, no study has addressed whether cardiac substrate metabolism can
regulate “load‐induced” hypertrophy via the mTOR signaling pathway (Shioi T et. al.
Circ 2003; McMullen JR et. al. Circ 2004; Zhang D et. al. JCI 2010). Our findings in
the working heart ex vivo demonstrate that acute increases in workload require glucose
metabolism to activate mTOR, suggesting that “load‐induced” hypertrophic signaling
through mTORC1 is substrate specific. More to the point, we propose that mTORC1 is
activated by the metabolic signal G6P, which accumulates at increased workload when
rates of glucose uptake exceed the heart's oxidative capacity for glucose. The G6P
hypothesis is confirmed by the glucose analogue 2‐deoxyglucose, which is
phosphorylated to 2‐deoxyglucose 6‐phosphate and not metabolized further, resulting in
strong activation of mTOR (Figure A.4C). In contrast, the glucose analogue
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3‐O‐methylglucose, which is transported into the cell and not phosphorylated, exhibited
no effect on mTOR activation (Figure A.4C). We consider this evidence compelling and
in support of our hypothesis.
The metabolic findings require a discussion of mTOR activation by a metabolic
signal. In the unstimulated state, mTORC1 is inhibited by the heterodimer tuberous
sclerosis complex (TSC), composed of hamartin (TSC1) and tuberin (TSC2).
Differential phosphorylation states of TSC2 are necessary to dissociate the complex to
release its inhibition on mTORC1. We dissected the load‐ and substrate dependence of
mTORC1 signaling in the heart and determined that increased workload alone triggers
PI3K, Akt, and minimal Akt‐dependent phosphorylation of TSC2 at Ser939, regardless
of glucose. However, complete load‐induced mTORC1 activation requires
downregulation of AMPK‐dependent phosphorylation of TSC2 at Ser1387, which
occurs with G6P accumulation. Indeed, AMPK activation with metformin, both in vivo
and ex vivo, prevents G6P‐mediated mTOR activation at increased workload. In skeletal
muscle, high levels of glucose activate mTOR in an AMPK‐dependent manner by
modulating the redox state (Saha AK et. al. Diabetes 2010). In heart, the redox state
does not change with workload (Taegtmeyer H. JMCC 1985). However, like in skeletal
muscle, AMPK downregulation by glucose in the heart occurs independently of the
energy state, which is consistent with previous work both ex vivo (Taegtmeyer H. JMCC
1985) and in vivo (Balaban RS, Kontor HL, Katz LA, Briggs RW. Science 1986). In the
genetically modified ACSL1−/− mouse, in which cardiac glucose metabolism is
upregulated (like a heart subjected to increased workload), mTOR activation correlates
with G6P accumulation and AMPK downregulation independent of change in the
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AMP/ATP ratio (Ellis JM et. al. Mol Cell Biol 2011). Taken together, our study reveals
that load‐induced mTOR activation is mediated by changes in glucose metabolism.
Excessive glucose uptake by the heart has been associated with contractile
dysfunction and deemed glucotoxic by increasing flux through the hexosamine
biosynthetic pathway, dysregulating protein glycosylation, and producing reactive
oxygen species (Modesti A et. al. Diabetes 2005; Ren J and Davidoff AJ. Am J Physiol
1997). Genetically modified mice that take up excess glucose but also demonstrate
enhanced glycolytic flux are, however, protected from glucotoxicity (Taegtmeyer H,
McNulty P, and Young ME. Circ 2002; Liao R et. al. Circ 2002). We now propose that
intermediary glucose metabolite (G6P) accumulation itself may impose metabolic stress
on the heart and contribute to contractile dysfunction by activating mTORC1.
Rapamycin pretreatment also rescues G6P‐mediated ER stress and cardiac
dysfunction at increased workload. Rapamycin binds and disrupts the mTOR complexes.
We now discover that its indirect metabolic effects may mediate via its inhibition of
mTOR complexes. Prolonged rapamycin treatment inhibits mTORC2 assembly, which
prevents phosphorylation of Akt (Sarboassov DD et. al. Mol Cell 2006), a known
regulator of glucose uptake in the heart (Gong LN et. al. Mol Endocrinol
1997). Therefore, not surprisingly, we observed that rapamycin administration blunts
Akt phosphorylation and rates of glucose uptake at increased workload. In doing so,
rapamycin prevents the mismatch between glucose uptake and oxidation, depletes
intracardiac G6P, and inhibits mTOR complexes.
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Despite lowering rates of myocardial glucose uptake and oxidation to “unstressed”
levels, rapamycin treatment also improves cardiac power (Figures A.1 and A.4). From
an energetic perspective, this suggests that the increased energy requirements of hearts
subjected to high workload, which are met by the oxidation of carbohydrates, may
largely be responsible for fueling protein turnover and protein quality control (“internal
work”). Protein turnover utilizes roughly 15% to 20% of a cell's energy in the resting
state (Waterlow JC. Q J Exp Physiol 1984) and at least 3 times more energy during times
of growth (Laurent GJ and Millward DJ. Fed Proc 1980; Lane N and Martin W. Nature
2010). It is, therefore, tempting to speculate that the energy conserved by rapamycin's
inhibition of protein synthesis and the resulting ER stress improves cardiac efficiency
and contributes to its ability to reverse load‐induced cardiac dysfunction (Shioi T et. al.
Circ 2003; McMullen JR et. al. Circ 2004; Martin TM et. al. JCI 2011). Furthermore,
the improvement in cardiac power observed in rapamycin‐treated rats gives credence to
the hypothesis that the hypertrophic process may not be necessary to maintain systolic
function in hearts subjected to increased workload (Hill JA et. al. Circ 2000). Our
results offer a new perspective on the energy cost of protein synthesis and protein quality
control.
Metformin is known to improve cardiac function in murine models of heart
failure (Yin M et. al. Am J Physiol Heart Circ Physiol 2011; Gundewar S et. al. Circ Res
2009). When administered systemically, metformin also improves the oxidative
capacity of the heart, blunts G6P accumulation, and improves cardiac function.
Therefore, we propose that, like rapamycin, metformin metabolically protects hearts
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subjected to increased workload and, in doing so, may account for improving survival in
diabetic patients with heart failure (Aguilar D et. al. Circ Heart Fail 2011).
We now report that in hearts from a cohort of 11 nondiabetic patients with
idiopathic dilated cardiomyopathy and heart failure, mechanical unloading with an
LVAD reduces intracardiac G6P levels and decreases mTORC1 activation. We
observed a significant decrease in G6P accumulation after LVAD support. We have
previously observed decreased myocardial glycogen content in failing human hearts
after mechanical unloading (Razeghi P and Taegtmeyer H. Cardiovasc Res 2004), and
more recently, proteomic analysis has revealed upregulation of proteins involved in
glycolysis, energy, and oxidative metabolism in LVAD‐supported patients (de Weger
RA et. al. J Heart Lung Transplant 2011). Taken together, these studies support our
findings and suggest that mechanical unloading promotes recoupling of glucose uptake
and oxidation, and prevents intermediary metabolite accumulation. However, we wish to
emphasize that we relied on metabolic and/or pharmacologic interventions in our
experimental work. The results are therefore largely descriptive, and off‐target effects
cannot be discounted.
Finally, previous studies performed in rat models of progressive hypertrophy
used the tracer FDG analogue and semiquantitative measurements of myocardial FDG
standardized uptake value with partial volume corrections (Handa N et. al. Ann Nucl
Med 2007). We have shown quantitatively in vivo that enhanced glucose uptake in the
heart accompanies load‐induced contractile dysfunction before an increase in left
ventricular mass. When increased, workload was sustained for up to 4 weeks, and
increased wall thickness and HW/BW ratio directly correlated with increased FDG
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retention, suggesting that metabolic remodeling precedes and sustains structural
remodeling of the heart.
In summary, we have provided evidence in support of the concept that metabolic
remodeling precedes, triggers, and sustains structural remodeling of the heart.
Specifically, we propose that dysregulated glucose metabolism and subsequent G6P
accumulation mediate load‐induced mTOR activation and contractile dysfunction. Our
study highlights the general notion that intermediary metabolism is a rich source of
signals for cardiac growth and demonstrates the potential to reduce internal work and
improve cardiac efficiency by targeting the metabolic axis in load‐induced heart disease.
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